RayKnowChina Research Map
Shortlist

Open clinical trials in mainland China

1,699 open trials registered on ClinicalTrials.gov with at least one of 308 hospitals on this site as lead sponsor or study site, as registered on 8 Nov 2026. Filter by disease, city, phase and the registered age and sex.

Not a ranking or a recommendation. Whether someone can take part is decided by the study team. Trials registered only in China’s own registry (ChiCTR) are not included.

  1. Recruiting
    A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT05199688

    Age 2 years to 11 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  2. Recruiting
    Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.
    Phase
    Phase 2
    Started
    2026-02
    Registry
    NCT06059261

    Age 18 years to 65 years (registered criteria)

    Led by Chongqing University Cancer HospitalChongqing

  3. Recruiting
    Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial
    Phase
    Phase 1
    Started
    2026-03
    Registry
    NCT06326008

    Age 1 year to 18 years (registered criteria)

    Led by Beijing GoBroad HospitalBeijing

  4. Recruiting
    TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis
    Phase
    Phase 1/Phase 2
    Started
    2026-06
    Registry
    NCT06726577

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteSuzhou

  5. Recruiting
    Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study
    Phase
    N/A
    Started
    2026-01
    Registry
    NCT06794073

    Age 18 years to 80 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  6. Recruiting
    Hypofractionated Radiotherapy for Nasopharyngeal Carcinoma
    Phase
    N/A
    Started
    2026-02
    Registry
    NCT06796270

    Age 18 years to 75 years (registered criteria)

    Led by Hainan General Hospital / Hainan Medical University hospitalsHaikou

  7. Recruiting
    International Collaborative Study on AJCC/UICC TNM-10 for Nasopharyngeal Cancer
    Phase
    Not given
    Started
    2026-01
    Registry
    NCT07013461

    Age 18 years to Not stated (registered criteria)

    Led by The University of Hong Kong–Shenzhen HospitalShenzhen

  8. Recruiting
    Daoyin Technique for Improving Exercise Endurance in IPF
    Phase
    N/A
    Started
    2026-04
    Registry
    NCT07019714

    Age 40 years to 85 years (registered criteria)

    Led by Affiliated Hospital of Liaoning University of Traditional Chinese Medicine; 2 listed hospitals as study sitesBeijing, Shenyang, Zhengzhou

  9. Recruiting
    The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy
    Phase
    Not given
    Started
    2026-09
    Registry
    NCT07039474

    Age 18 years to 75 years (registered criteria)

    Led by Peking University First HospitalBeijing

  10. Recruiting
    Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Registry
    NCT07061938

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Chengdu, Shanghai, Wuhan

  11. Recruiting
    A Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radiation Therapy) Therapy and Hepatic Arterial Infusion Chemotherapy (Hepatic Artery Infusion Chemotherapy) for Potentially Resectable Intermediate and Advanced Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2026-08
    Registry
    NCT07070076

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Jinan UniversityGuangzhou

  12. Recruiting
    A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
    Phase
    Phase 2/Phase 3
    Started
    2026-03
    Registry
    NCT07221149

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Nanning, Shanghai

  13. Recruiting
    A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07221669

    Age 0 days to 42 days (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Zhengzhou

  14. Recruiting
    PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07235319

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 4 listed hospitals as study sitesChangsha, Fuzhou, Guangzhou, Hangzhou, Nanning

  15. Recruiting
    Single-port Robotic Radical Gastrectomy for Gastric Cancer
    Phase
    N/A
    Started
    2026-07
    Registry
    NCT07237126

    Age 18 years to 75 years (registered criteria)

    Led by Daping Hospital, Army Medical UniversityChongqing

  16. Recruiting
    Neoadjuvant Ivonescimab(AK112) Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-06
    Registry
    NCT07244978

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  17. Recruiting
    Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study
    Phase
    Phase 3
    Started
    2026-03
    Registry
    NCT07246330

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  18. Recruiting
    KSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
    Phase
    Phase 1
    Started
    2026-01
    Registry
    NCT07246707

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  19. Recruiting
    A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)
    Phase
    Phase 3
    Started
    2026-01
    Registry
    NCT07249632

    Age 12 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  20. Recruiting
    A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
    Phase
    Phase 1
    Started
    2026-03
    Registry
    NCT07255898

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteChengdu

  21. Recruiting
    A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-02
    Registry
    NCT07258511

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Nanjing, Nanning, Wenzhou, Wuhan, Xi'an

  22. Recruiting
    NIR-II Fluorescence-Guided Hepatectomy Using ICG-Cisplatin Nanoprobes for HCC
    Phase
    Early phase 1
    Started
    2026-01
    Registry
    NCT07295262

    Age 18 years to 75 years (registered criteria)

    Led by West China HospitalChengdu

  23. Recruiting
    Safety and Efficacy of Transarterial ICG Fluorescence-Guided Laparoscopic Anatomical Liver Resection
    Phase
    Not given
    Started
    2026-03
    Registry
    NCT07295275

    Age 18 years to 80 years (registered criteria)

    Led by West China Hospital; 2 listed hospitals as study sitesBeijing, Chengdu, Xuzhou

  24. Recruiting
    Diagnostic Accuracy of Folate-Targeted NIR-II Carbon Dots for Ex Vivo HCC Detection
    Phase
    Not given
    Started
    2026-01
    Registry
    NCT07295340

    Age 18 years to 80 years (registered criteria)

    Led by West China HospitalChengdu

  25. Recruiting
    Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07310173

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanjing

  26. Recruiting
    SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07311408

    Age 18 years to Not stated (registered criteria)

    Led by Liaoning Cancer Hospital & InstituteShenyang

  27. Recruiting
    A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-01
    Registry
    NCT07315750

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  28. Recruiting
    Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07318831

    Age 0 years to 18 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  29. Recruiting
    IASO206 in Patients With Relapsed/Refractory Multiple Myeloma
    Phase
    Early phase 1
    Started
    2026-01
    Registry
    NCT07322159

    Age 18 years to 75 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  30. Recruiting
    Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07324824

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  31. Recruiting
    LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07325539

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 1 listed hospital as study siteGuangzhou, Shenzhen

  32. Recruiting
    A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07328009

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  33. Recruiting
    MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC
    Phase
    Phase 2
    Started
    2026-06
    Registry
    NCT07331428

    Age 18 years to 70 years (registered criteria)

    Led by Fujian Cancer HospitalFuzhou

  34. Recruiting
    PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC
    Phase
    Phase 2
    Started
    2026-02
    Registry
    NCT07332247

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  35. Recruiting
    First in Human Study of SIM0610 in Solid Tumors
    Phase
    Phase 1
    Started
    2026-01
    Registry
    NCT07348211

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChongqing, Harbin, Shanghai, Shenyang

  36. Recruiting
    Remimazolam for Reducing Postoperative Delirium in Elderly Patients Undergoing Laparoscopic Gastrectomy
    Phase
    N/A
    Started
    2026-01
    Registry
    NCT07351474

    Age 65 years to 100 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  37. Recruiting
    A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2026-01
    Registry
    NCT07351669

    Age 18 years to 75 years (registered criteria)

    Led by Zhongda Hospital, Southeast UniversityNanjing

  38. Recruiting
    A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Registry
    NCT07354711

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  39. Recruiting
    A Study of SHR-2173 in Participants With Primary IgA Nephropathy
    Phase
    Phase 2
    Started
    2026-03
    Registry
    NCT07354932

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai

  40. Recruiting
    LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07362186

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  41. Recruiting
    Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2026-03
    Registry
    NCT07362979

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 3 listed hospitals as study sitesDongguan, Guangzhou, Shenzhen, Zhanjiang

  42. Recruiting
    A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.
    Phase
    Phase 1/Phase 2
    Started
    2026-02
    Registry
    NCT07375758

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  43. Recruiting
    IMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk Features
    Phase
    Not given
    Started
    2026-01
    Registry
    NCT07376603

    Age 18 years to 70 years (registered criteria)

    Led by Fujian Cancer HospitalFuzhou

  44. Recruiting
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Registry
    NCT07379047

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Wuhan, Zhengzhou

  45. Recruiting
    The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities
    Phase
    Phase 2
    Started
    2026-04
    Registry
    NCT07381634

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Wenzhou Medical UniversityWenzhou

  46. Recruiting
    SBRT Versus Surgical Resection for Small HCC
    Phase
    Phase 3
    Started
    2026-03
    Registry
    NCT07381660

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  47. Recruiting
    A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Registry
    NCT07385001

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu HospitalXi'an

  48. Recruiting
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07385703

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 64 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou

  49. Recruiting
    A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT07387549

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Guangzhou, Jinan, Nanchang, Shanghai, Tianjin, Zhengzhou

  50. Recruiting
    Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07390123

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Changchun, Changsha, Huangshan City, Linyi, Shanghai, Wuhu, Xi'an, Zhanjiang

  51. Recruiting
    A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2026-02
    Registry
    NCT07392320

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  52. Recruiting
    Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Registry
    NCT07392892

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesChengdu, Guangzhou, Shanghai, Wuhan

  53. Recruiting
    Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07400341

    Age 18 years to 65 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  54. Recruiting
    DeepComp for Prediction of Gastric Cancer Postoperative Complications (DeepComp-Prospective)
    Phase
    Not given
    Started
    2026-03
    Registry
    NCT07401173

    Age 18 years to 85 years (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  55. Recruiting
    Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)
    Phase
    Not given
    Started
    2026-02
    Registry
    NCT07401199

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShijiazhuang, Wuhan

  56. Recruiting
    Full-time RDI for ESD: Impact on Major Adverse Events and Procedure Time
    Phase
    N/A
    Started
    2026-03
    Registry
    NCT07401303

    Age 18 years to 75 years (registered criteria)

    Led by Xijing HospitalXi'an

  57. Recruiting
    Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCC
    Phase
    Phase 2
    Started
    2026-04
    Registry
    NCT07403136

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  58. Recruiting
    Safety of Robotic Surgery for GISTs at Special Anatomic Sites
    Phase
    N/A
    Started
    2026-02
    Registry
    NCT07405125

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  59. Recruiting
    A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Registry
    NCT07405151

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Hangzhou, Hefei, Jinan, Xiamen, Xuzhou, Zhengzhou

  60. Recruiting
    A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
    Phase
    Phase 1
    Started
    2026-02
    Registry
    NCT07409246

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Tianjin

  61. Recruiting
    MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07409454

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  62. Recruiting
    Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study
    Phase
    Phase 4
    Started
    2026-02
    Registry
    NCT07410039

    Age 18 years to 65 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  63. Recruiting
    Surgery vs. Watch-and-Wait Strategy in Partial & Complete Responders for Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2026-03
    Registry
    NCT07410715

    Age 18 years to 80 years (registered criteria)

    Led by West China HospitalChengdu

  64. Recruiting
    Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2026-04
    Registry
    NCT07413354

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  65. Recruiting
    Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)
    Phase
    N/A
    Started
    2026-03
    Registry
    NCT07413835

    Age 18 years to 80 years (registered criteria)

    Led by Affiliated Hospital of Xuzhou Medical UniversityXuzhou

  66. Recruiting
    A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT07416526

    Age 12 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  67. Recruiting
    A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07416604

    Age 12 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Tianjin

  68. Recruiting
    Adjuvant TACE in HCC With High-risk Recurrence Factors
    Phase
    Phase 3
    Started
    2026-02
    Registry
    NCT07417397

    Age 18 years to 70 years (registered criteria)

    Led by Guangxi Medical University Cancer HospitalNanning

  69. Recruiting
    Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder
    Phase
    Phase 3
    Started
    2026-01
    Registry
    NCT07420296

    Age 18 years to 80 years (registered criteria)

    Led by Tianjin Medical University General HospitalTianjin

  70. Recruiting
    A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC
    Phase
    Phase 2
    Started
    2026-03
    Registry
    NCT07422753

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  71. Recruiting
    Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia
    Phase
    Early phase 1
    Started
    2026-02
    Registry
    NCT07429461

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  72. Recruiting
    A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma.
    Phase
    Early phase 1
    Started
    2026-03
    Registry
    NCT07429721

    Age 18 years to Not stated (registered criteria)

    Led by Union HospitalWuhan

  73. Recruiting
    Digital Rehabilitation for Gastric Cancer Surgery After Neoadjuvant Therapy
    Phase
    N/A
    Started
    2026-03
    Registry
    NCT07441850

    Age 18 years to 70 years (registered criteria)

    Led by Beijing Friendship HospitalBeijing

  74. Recruiting
    A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam
    Phase
    Phase 3
    Started
    2026-09
    Registry
    NCT07444476

    Age 15 years to 60 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  75. Recruiting
    Biochemical Response and Clinical Outcomes in Patients With PBC
    Phase
    Not given
    Started
    2026-02
    Registry
    NCT07449793

    Age 18 years to 85 years (registered criteria)

    Led by Renji HospitalShanghai

  76. Recruiting
    A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-03
    Registry
    NCT07452198

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  77. Recruiting
    Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC
    Phase
    Phase 2
    Started
    2026-05
    Registry
    NCT07452601

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu HospitalXi'an

  78. Recruiting
    To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2026-04
    Registry
    NCT07454187

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHangzhou, Suzhou, Xi'an, Zhengzhou

  79. Recruiting
    Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC
    Phase
    Phase 2
    Started
    2026-03
    Registry
    NCT07457528

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  80. Recruiting
    Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC
    Phase
    Phase 3
    Started
    2026-03
    Registry
    NCT07459296

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of Guangxi Medical UniversityNanning

  81. Recruiting
    Adverse Effects of ATG/ALG Therapy in Aplastic Anemia
    Phase
    Not given
    Started
    2026-02
    Registry
    NCT07461116

    Age not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  82. Recruiting
    PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy
    Phase
    Phase 2
    Started
    2026-04
    Registry
    NCT07463248

    Age 18 years to 75 years (registered criteria)

    Led by West China HospitalChengdu

  83. Recruiting
    QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07463573

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  84. Recruiting
    SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer
    Phase
    Phase 2
    Started
    2026-04
    Registry
    NCT07464756

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  85. Recruiting
    Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.
    Phase
    Phase 3
    Started
    2026-09
    Registry
    NCT07465718

    Age 8 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Hangzhou

  86. Recruiting
    A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and Adults
    Phase
    Early phase 1
    Started
    2026-04
    Registry
    NCT07470073

    Age 12 years to 75 years (registered criteria)

    Led by Union HospitalWuhan

  87. Recruiting
    Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases
    Phase
    N/A
    Started
    2026-03
    Registry
    NCT07470151

    Age 18 years to 70 years (registered criteria)

    Led by Union HospitalWuhan

  88. Recruiting
    Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial
    Phase
    Phase 2
    Started
    2026-03
    Registry
    NCT07474324

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  89. Recruiting
    A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07475026

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  90. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

  91. Recruiting
    A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2026-04
    Registry
    NCT07478302

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesFuzhou, Nanning

  92. Recruiting
    MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
    Phase
    Phase 1/Phase 2
    Started
    2026-04
    Registry
    NCT07479485

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Nanjing, Tianjin, Zhengzhou

  93. Recruiting
    Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Registry
    NCT07479732

    Age 12 years to 65 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  94. Recruiting
    A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma
    Phase
    Phase 1/Phase 2
    Started
    2026-02
    Registry
    NCT07482059

    Age 18 years to 80 years (registered criteria)

    Led by West China HospitalChengdu

  95. Recruiting
    Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus
    Phase
    Phase 2
    Started
    2026-05
    Registry
    NCT07483359

    Age 18 years to 80 years (registered criteria)

    Led by First Hospital of China Medical UniversityShenyang

  96. Recruiting
    IBI343 in Combination Therapy for Advanced Malignant Solid Tumors
    Phase
    Phase 2
    Started
    2026-04
    Registry
    NCT07483554

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou

  97. Recruiting
    TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk
    Phase
    Phase 2
    Started
    2026-03
    Registry
    NCT07487662

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  98. Recruiting
    A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
    Phase
    Phase 2/Phase 3
    Started
    2026-03
    Registry
    NCT07490262

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  99. Recruiting
    A Phase I Study of SHR-3836 in Patients With Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-06
    Registry
    NCT07490613

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteSuzhou

  100. Recruiting
    A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07492615

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  101. Recruiting
    An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2026-03
    Registry
    NCT07493044

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  102. Recruiting
    A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma
    Phase
    Early phase 1
    Started
    2026-04
    Registry
    NCT07493135

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  103. Recruiting
    Intelligence System for Predicting Atezolizumab-Bevacizumab Response and Clinical Outcomes in Unresectable Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2026-03
    Registry
    NCT07495735

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Wenzhou Medical UniversityWenzhou

  104. Recruiting
    Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy
    Phase
    Phase 2
    Started
    2026-02
    Registry
    NCT07496190

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  105. Recruiting
    A Study of YKST02 in Participants With Primary IgA Nephropathy
    Phase
    Early phase 1
    Started
    2026-05
    Registry
    NCT07498673

    Age 18 years to 75 years (registered criteria)

    Led by Union HospitalWuhan

  106. Recruiting
    Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Registry
    NCT07500220

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

  107. Recruiting
    Efficacy and Safety Comparison Between Intensified Therapy and Conversion Therapy For Advanced HCC After Failure of First-line
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07501351

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  108. Recruiting
    Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Registry
    NCT07502287

    Age 12 months to 21 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

  109. Recruiting
    Large Language Models Assist in Tumor MDT
    Phase
    N/A
    Started
    2026-01
    Registry
    NCT07504367

    Age 25 years to 33 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  110. Recruiting
    Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07505186

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  111. Recruiting
    Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
    Phase
    Early phase 1
    Started
    2026-04
    Registry
    NCT07507201

    Age 3 years to Not stated (registered criteria)

    Led by Children's Hospital, Zhejiang University School of MedicineHangzhou

  112. Recruiting
    Predicting Response to Selinexor-Based Therapy in Relapsed/Refractory Multiple Myeloma: A Multicenter Prospective Study
    Phase
    Not given
    Started
    2026-01
    Registry
    NCT07514052

    Age 18 years to Not stated (registered criteria)

    Led by Shanxi Bethune HospitalTaiyuan

  113. Recruiting
    Dynamic Circulating Tumor DNA Monitoring to Guide Systemic Therapy in Gastric Cancer
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07517107

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  114. Recruiting
    A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT07518147

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  115. Recruiting
    A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT07518186

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Chengdu, Hangzhou, Nanchang, Nanjing, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an

  116. Recruiting
    Intensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCC
    Phase
    Phase 2
    Started
    2026-04
    Registry
    NCT07519486

    Age 18 years to 80 years (registered criteria)

    Led by West China HospitalChengdu

  117. Recruiting
    A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC
    Phase
    Phase 2
    Started
    2026-03
    Registry
    NCT07521852

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesFuzhou, Shanghai

  118. Recruiting
    Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT07522151

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  119. Recruiting
    Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Registry
    NCT07523529

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

  120. Recruiting
    Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Registry
    NCT07523555

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

  121. Recruiting
    Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)
    Phase
    Phase 1/Phase 2
    Started
    2026-04
    Registry
    NCT07525466

    Age 18 years to Not stated (registered criteria)

    Led by Beijing Tongren HospitalBeijing

  122. Recruiting
    AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer
    Phase
    Not given
    Started
    2026-04
    Registry
    NCT07525765

    Age 18 years to 90 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  123. Recruiting
    Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
    Phase
    Phase 1
    Started
    2026-04
    Registry
    NCT07526493

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  124. Recruiting
    Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07528183

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 3 listed hospitals as study sitesFuzhou, Guangzhou, Nanning, Wuhan

  125. Recruiting
    Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-03
    Registry
    NCT07529782

    Age Not stated to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Jinan, Suzhou, Tianjin

  126. Recruiting
    Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2026-04
    Registry
    NCT07536789

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  127. Recruiting
    Safety and Efficacy of Leucine-Restricted Diet Combined With Chemotherapy and Immunotherapy in Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07537348

    Age 18 years to 70 years (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  128. Recruiting
    Safety and Efficacy of Leucine-Restricted Diet Combined With Neoadjuvant Chemotherapy and Immunotherapy in Gastric Cancer
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07537361

    Age 18 years to 70 years (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  129. Recruiting
    AI-Assisted Staging and Treatment Decision-Making for Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2026-04
    Registry
    NCT07538882

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  130. Recruiting
    Safety of KN057 Prophylaxis in Patients With Haemophilia A or B
    Phase
    Phase 3
    Started
    2026-03
    Registry
    NCT07545395

    Age 12 years to 65 years; men only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  131. Recruiting
    A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
    Phase
    Phase 1/Phase 2
    Started
    2026-05
    Registry
    NCT07547553

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Bengbu, Changchun, Fuzhou, Guangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Tianjin, Zhengzhou

  132. Recruiting
    Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Registry
    NCT07551362

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

  133. Recruiting
    AI Model for Early Gastric Cancer Diagnosis Using Endoscopic Imaging
    Phase
    Not given
    Started
    2026-05
    Registry
    NCT07551466

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  134. Recruiting
    Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
    Phase
    N/A
    Started
    2026-06
    Registry
    NCT07552402

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Chengdu, Dalian, Fuzhou, Hangzhou, Nanning, Shanghai, Shijiazhuang, Suzhou, Wuhan, Yinchuan

  135. Recruiting
    A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)
    Phase
    Phase 2/Phase 3
    Started
    2026-06
    Registry
    NCT07554456

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  136. Recruiting
    A Phase I/II Clinical Study to Evaluate SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type I
    Phase
    Phase 1/Phase 2
    Started
    2026-07
    Registry
    NCT07554924

    Age Not stated to 180 days (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Hangzhou, Shanghai

  137. Recruiting
    Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07555938

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesGuangzhou, Hangzhou, Jinan, Kunming, Nanjing, Qingdao, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan

  138. Recruiting
    LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study
    Phase
    Phase 2
    Started
    2026-04
    Registry
    NCT07556640

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  139. Recruiting
    18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
    Phase
    N/A
    Started
    2026-04
    Registry
    NCT07557225

    Age 18 years to Not stated (registered criteria)

    Led by Peking University First HospitalBeijing

  140. Recruiting
    A Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR)
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07557446

    Age 12 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Changsha, Shanghai, Shenzhen, Suzhou

  141. Recruiting
    Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07559045

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Zunyi Medical UniversityZunyi

  142. Recruiting
    Topical Chlorhexidine Spray for the Prevention of Acute Radiation Dermatitis in Patients With Nasopharyngeal Carcinoma:
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07559877

    Age 18 years to 75 years (registered criteria)

    Led by Jiangxi Cancer HospitalNanchang

  143. Recruiting
    Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2026-03
    Registry
    NCT07560488

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  144. Recruiting
    Taurine for the Prevention and Treatment of Radiation-induced Oral Mucositis in Patients With Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2026-05
    Registry
    NCT07567742

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  145. Recruiting
    Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Registry
    NCT07575919

    Age 18 years to 85 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  146. Recruiting
    Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic Leukemia
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Registry
    NCT07575971

    Age 18 years to 85 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  147. Recruiting
    A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-01
    Registry
    NCT07579234

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  148. Recruiting
    A Novel Two-Tooth Clip for ESD and EFTR of GIST
    Phase
    N/A
    Started
    2026-04
    Registry
    NCT07581977

    Age 18 years to 85 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  149. Recruiting
    A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA Nephropathy
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07582133

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  150. Recruiting
    Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07584499

    Age 2 years to 18 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  151. Recruiting
    CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07585760

    Age 18 years to 80 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  152. Recruiting
    CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease
    Phase
    Early phase 1
    Started
    2026-05
    Registry
    NCT07586267

    Age 3 years to Not stated (registered criteria)

    Led by Children's Hospital, Zhejiang University School of MedicineHangzhou

  153. Recruiting
    A Novel Conditioning Regimen for Haplo-HSCT in Older Patients With SAA
    Phase
    Not given
    Started
    2026-06
    Registry
    NCT07586735

    Age 40 years to 60 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  154. Recruiting
    A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Registry
    NCT07589244

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  155. Recruiting
    68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma
    Phase
    Phase 1/Phase 2
    Started
    2026-06
    Registry
    NCT07590336

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  156. Recruiting
    HAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven)
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT07594340

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  157. Recruiting
    Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-05
    Registry
    NCT07595770

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  158. Recruiting
    Evaluation of Fecal Multi-target Biomarkers in the Screening of Digestive Tract Cancers
    Phase
    Not given
    Started
    2026-08
    Registry
    NCT07600125

    Age 18 years to Not stated (registered criteria)

    Led by Xijing Hospital; 3 listed hospitals as study sitesDalian, Qingdao, Wuxi, Xi'an

  159. Recruiting
    Efficacy and Safety of Nefecon on Prevention of Relapse of IgA Nephropathy
    Phase
    Phase 4
    Started
    2026-06
    Registry
    NCT07604311

    Age 18 years to 75 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  160. Recruiting
    Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases
    Phase
    Phase 2
    Started
    2026-05
    Registry
    NCT07614477

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Tianjin

  161. Recruiting
    Laparoscopic-endoscopic Surgery Assisted Sentinel Lymph Node Navigation Surgery for Early Gastric Cancer
    Phase
    N/A
    Started
    2026-05
    Registry
    NCT07615374

    Age not stated (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  162. Recruiting
    Phase I Study of FXS0683 in the Treatment of Blood Tumors
    Phase
    Phase 1
    Started
    2026-06
    Registry
    NCT07616089

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  163. Recruiting
    Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA
    Phase
    Phase 1
    Started
    2026-09
    Registry
    NCT07620275

    Age 18 years to 75 years (registered criteria)

    Led by Chinese PLA General Hospital; 2 listed hospitals as study sitesBeijing, Tianjin

  164. Recruiting
    HIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07621484

    Age 18 years to 75 years (registered criteria)

    Led by Changzheng HospitalShanghai

  165. Recruiting
    A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07622342

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangsha, Shanghai

  166. Recruiting
    A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07623798

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  167. Recruiting
    Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors
    Phase
    Phase 1
    Started
    2026-03
    Registry
    NCT07625423

    Age 18 years to 65 years (registered criteria)

    Led by West China HospitalChengdu

  168. Recruiting
    Efficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma(ESCC)
    Phase
    N/A
    Started
    2026-05
    Registry
    NCT07627347

    Age 18 years to 70 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  169. Recruiting
    Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07629817

    Age 18 years to 75 years (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  170. Recruiting
    Peripheral Blood Versus Bone Marrow Plus Peripheral Blood Grafts for Haploidentical Transplantation in Severe Aplastic Anemia
    Phase
    N/A
    Started
    2026-06
    Registry
    NCT07629947

    Age 18 years to 40 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  171. Recruiting
    Comparison of Double-tract and Tubular Gastric Anastomosis in Proximal Gastric Cancer
    Phase
    N/A
    Started
    2026-05
    Registry
    NCT07635836

    Age 18 years to 75 years (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  172. Recruiting
    A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).
    Phase
    Phase 2
    Started
    2026-05
    Registry
    NCT07638683

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  173. Recruiting
    Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07639138

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  174. Recruiting
    Two-component Radiology-guided Autonomous Cascade Engine (TRACE)
    Phase
    N/A
    Started
    2026-06
    Registry
    NCT07651644

    Age not stated (registered criteria)

    Led by Liaoning Cancer Hospital & InstituteShenyang

  175. Recruiting
    A Clinical Study of SHR-5421 in Patients With Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-07
    Registry
    NCT07652281

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  176. Recruiting
    CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07652905

    Age 18 years to 75 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  177. Recruiting
    TACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for HCC
    Phase
    Not given
    Started
    2026-07
    Registry
    NCT07658833

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  178. Recruiting
    GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders
    Phase
    Phase 1
    Started
    2026-06
    Registry
    NCT07660939

    Age 18 years to 80 years (registered criteria)

    Led by Peking University First HospitalBeijing

  179. Recruiting
    Individualized Primary Clinical Target Volume Based on Margin Expansion for Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2026-07
    Registry
    NCT07661771

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 6 listed hospitals as study sitesChangsha, Dongguan, Foshan, Guangzhou, Shenzhen, Zhongshan

  180. Recruiting
    Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
    Phase
    Not given
    Started
    2026-06
    Registry
    NCT07663253

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan University; 9 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Kunming, Nanning, Nantong, Shanghai, Wuhan, Xi'an, Zhengzhou

  181. Recruiting
    A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
    Phase
    Phase 3
    Started
    2026-07
    Registry
    NCT07673887

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  182. Recruiting
    GPC3-Targeted PET/CT in Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2026-05
    Registry
    NCT07677774

    Age 18 years to 90 years (registered criteria)

    Led by First Affiliated Hospital of Xiamen UniversityXiamen

  183. Recruiting
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    Phase
    Phase 3
    Started
    2026-09
    Registry
    NCT07687459

    Age 40 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou

  184. Recruiting
    Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07689851

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shenzhen, Taiyuan

  185. Recruiting
    PD-1 Inhibitors Combined With Local Therapy at Different Timings in Oligometastatic ESCC
    Phase
    Not given
    Started
    2026-07
    Registry
    NCT07697859

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  186. Recruiting
    SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07700667

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesChangchun, Chengdu, Chongqing, Fuzhou, Harbin, Kunming, Luoyang, Nanchang, Nanjing, Nanning, Shantou, Shenyang, Shijiazhuang, Shiyan, Taiyuan, Tianjin, Xi'an, Zhengzhou

  187. Recruiting
    Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
    Phase
    Phase 3
    Started
    2026-09
    Registry
    NCT07700979

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Shanghai

  188. Recruiting
    Efficacy and Safety of Becotatug Vedotin (MRG003) Combined With Anti-PD1 as Maintenance Therapy for Recurrent and Metastatic Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2026-07
    Registry
    NCT07705243

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  189. Recruiting
    Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2026-07
    Registry
    NCT07706985

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  190. Recruiting
    A Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled IR199 in Patients With Gastric Cancer and Pancreatic Cancer
    Phase
    Early phase 1
    Started
    2026-06
    Registry
    NCT07707531

    Age 18 years to Not stated (registered criteria)

    Led by Huashan HospitalShanghai

  191. Recruiting
    Clinical Study on Using Laparoscopic Sentinel Lymph Node Navigation Combined With Dual Endoscopy Surgery for Early Gastric Cancer
    Phase
    N/A
    Started
    2026-01
    Registry
    NCT07708012

    Age 18 years to 80 years (registered criteria)

    Led by Affiliated Hospital of Qingdao UniversityQingdao

  192. Recruiting
    Phase I/II Study of Anti-CD38 Monoclonal Antibody in Refractory Severe Aplastic Anemia
    Phase
    Phase 1/Phase 2
    Started
    2026-06
    Registry
    NCT07714512

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  193. Recruiting
    TEAS Timing for Gastrectomy Recovery (TEAS-TIME Trial)
    Phase
    N/A
    Started
    2026-07
    Registry
    NCT07714980

    Age 18 years to 80 years (registered criteria)

    Led by Affiliated Hospital of Qingdao University; 5 listed hospitals as study sitesBeijing, Qingdao, Weifang, Weihai, Yantai

  194. Recruiting
    Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07733830

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & Hospital; 6 listed hospitals as study sitesBeijing, Chengdu, Shenyang, Taiyuan, Tianjin, Zhengzhou

  195. Recruiting
    Retrospective Analysis of Early Gastric Cancer Patients Based on Prospective Clinical Dataset
    Phase
    Not given
    Started
    2026-05
    Registry
    NCT07747688

    Age 18 years to 90 years (registered criteria)

    Led by Beijing Friendship HospitalBeijing

  196. Recruiting
    A Clinical Study of SHR-9839 as Monotherapy or in Combination With Chemotherapy Plus Adebrelimab Versus Chemotherapy Plus Adebrelimab in Patients With Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07751341

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Zhengzhou

  197. Recruiting
    68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
    Phase
    N/A
    Started
    2026-08
    Registry
    NCT07760012

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Third HospitalBeijing

  198. Recruiting
    A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2026-09
    Registry
    NCT07760454

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Suzhou

  199. Recruiting
    A Multicenter Prospective Real-World Effectiveness and Safety of Satralizumab in the Early Treatment of Attacks in NMOSD
    Phase
    Not given
    Started
    2026-07
    Registry
    NCT07762872

    Age 18 years to Not stated (registered criteria)

    Led by Xuanwu HospitalBeijing

  200. Recruiting
    Safety, Tolerability, and Preliminary Efficacy of [211At]MABG in Patients With Relapsed or Refractory Neuroblastoma
    Phase
    Early phase 1
    Started
    2026-07
    Registry
    NCT07767630

    Age 1 year to 100 years (registered criteria)

    Led by West China HospitalChengdu

  201. Recruiting
    68Ga-B7-H3 Nanobody ImmunoPET in Osteosarcoma
    Phase
    Early phase 1
    Started
    2026-04
    Registry
    NCT07774533

    Age 10 years to 80 years (registered criteria)

    Led by Peking University First HospitalBeijing

  202. Recruiting
    CT Imaging and Clinical Features to Predict Outcomes in Patients With Gastric Cancer
    Phase
    Not given
    Started
    2026-04
    Registry
    NCT07776067

    Age 18 years to Not stated (registered criteria)

    Led by Union HospitalWuhan

  203. Recruiting
    Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
    Phase
    Phase 2
    Started
    2026-10
    Registry
    NCT07776080

    Age 18 years to 75 years (registered criteria)

    Led by Union HospitalWuhan

  204. Recruiting
    Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma.
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07781358

    Age 18 years to 80 years (registered criteria)

    Led by Eye & ENT Hospital of Fudan UniversityShanghai

  205. Recruiting
    5T MRI and Metabolomics-Based Hemorrhage Risk Prediction in Moyamoya Disease
    Phase
    Not given
    Started
    2026-02
    Registry
    NCT07781579

    Age not stated (registered criteria)

    Led by Beijing HospitalBeijing

  206. Recruiting
    CD38 Targeted -PET/ CT for Multiple Myeloma
    Phase
    N/A
    Started
    2026-07
    Registry
    NCT07782944

    Age 18 years to Not stated (registered criteria)

    Led by Affiliated Hospital of Guilin Medical UniversityGuilin

  207. Recruiting
    Interferon Gamma Plus Camrelizumab as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-03
    Registry
    NCT07787273

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHefei

  208. Recruiting
    A Clinical Study Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression.
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07788196

    Age 18 years to Not stated (registered criteria)

    Led by Xijing HospitalXi'an

  209. Recruiting
    Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
    Phase
    Phase 3
    Started
    2026-12
    Registry
    NCT07789184

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Chongqing, Dalian, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an

  210. Recruiting
    Oral Zinc Supplementation Combined With Targeted Immunotherapy for Unresectable or Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07793695

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of USTCHefei

  211. Recruiting
    GPC3-Targeted PET Imaging of 18F-X12 in Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2026-08
    Registry
    NCT07795437

    Age 18 years to Not stated (registered criteria)

    Led by Peking University First HospitalBeijing

  212. Recruiting
    Prophylactic Nanocrystalline Megestrol Acetate Versus Placebo for Chemoradiotherapy-Related Anorexia in Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2026-09
    Registry
    NCT07796789

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 2 listed hospitals as study sitesChangsha, Fuzhou, Guangzhou

  213. Recruiting
    IRE After Targeted Immunotherapy in HCC With Portal Vein Tumor Thrombus
    Phase
    N/A
    Started
    2026-05
    Registry
    NCT07799922

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  214. Recruiting
    Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07801287

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  215. Recruiting
    Effect of Laparoscopic Hepatectomy Combined With Splenectomy on Hepatic Functional Reserve and Immune Function
    Phase
    Not given
    Started
    2026-08
    Registry
    NCT07811687

    Age 18 years to 80 years (registered criteria)

    Led by Northern Jiangsu People's HospitalYangzhou

  216. Recruiting
    Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07811752

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  217. Recruiting
    Dynamic Risk Prediction of Severe Myelosuppression in Nasopharyngeal Carcinoma
    Phase
    Not given
    Started
    2026-08
    Registry
    NCT07819656

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang HospitalGuangzhou

  218. Recruiting
    Inspiratory Flow Rate Capability in Pulmonary Fibrosis Patients
    Phase
    Not given
    Started
    2026-01
    Registry
    NCT07820254

    Age 18 years to 80 years (registered criteria)

    Led by Shanghai Pulmonary HospitalShanghai

  219. Recruiting
    To Assess the Efficacy and Safety of Utilizing Galactose-deficient IgA1 Biomarker Changes to Guide Pathogenic IgA-targeted Therapeutic Strategies
    Phase
    N/A
    Started
    2026-08
    Registry
    NCT07822100

    Age 18 years to 75 years (registered criteria)

    Led by Peking University First HospitalBeijing

  220. Recruiting
    Effects of Different Stiffness Settings During Robotic Isokinetic Training in Children With SMA
    Phase
    N/A
    Started
    2026-10
    Registry
    NCT07822711

    Age 6 years to 12 years (registered criteria)

    Led by Peking University Third HospitalBeijing

  221. Recruiting
    Efgartigimod in Anti-NMDA Receptor Encephalitis.
    Phase
    Phase 2
    Started
    2026-06
    Registry
    NCT07822776

    Age 18 years to Not stated (registered criteria)

    Led by Beijing Tongren HospitalBeijing

  222. Recruiting
    Image-Guided Platform-Assisted Sentinel Lymph Node Retrieval in Early Gastric Cancer
    Phase
    N/A
    Started
    2026-08
    Registry
    NCT07835087

    Age 18 years to 80 years (registered criteria)

    Led by Beijing Friendship HospitalBeijing

  223. Recruiting
    Dual-Targeted Umbilical Cord Blood CAR-T Cells Against CD19 and CD22 for the Treatment of Relapsed or Refractory Acute B-Cell Lymphoblastic Leukemia
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07838714

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  224. Recruiting
    Biomarker Validation for Treatment Efficacy and Recurrence Prediction in Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2026-10
    Registry
    NCT07840092

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  225. Recruiting
    InstaSure™ Non-Invasive Finger-Press Test for Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2026-06
    Registry
    NCT07848750

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  226. Recruiting
    Silent Evaluation of DeepTRG for Assessing Tumor Response After Preoperative Treatment in Stomach and Gastroesophageal Junction Cancer
    Phase
    Not given
    Started
    2026-09
    Registry
    NCT07849608

    Age 18 years to Not stated (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  227. Recruiting
    BEBT-908 in MEF2D-Rearranged Relapsed/Refractory or MRD-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
    Phase
    Phase 1
    Started
    2026-09
    Registry
    NCT07854652

    Age 14 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  228. Recruiting
    Anti-PD-1 in Combination With Systemic Chemotherapy With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites
    Phase
    Not given
    Started
    2026-07
    Registry
    NCT07855640

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  229. Recruiting
    LECS Combined With LSNNS for Early Gastric Cancer (LENS Trial)
    Phase
    Not given
    Started
    2026-08
    Registry
    NCT07857668

    Age 20 years to 80 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  230. Recruiting
    Radiotherapy Target Volume Delineation in Locally Advanced Esophageal Cancer in the Immunotherapy Era
    Phase
    Not given
    Started
    2026-08
    Registry
    NCT07858630

    Age 18 years to 80 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  231. Recruiting
    A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC (Esophageal Squamous Cell Carcinoma)
    Phase
    Phase 2
    Started
    2026-10
    Registry
    NCT07863141

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  232. Recruiting
    Efficacy and Safety of Ischemic Preconditioning Therapy Versus Optimal Medical Therapy in Reducing the Recurrence of Ischemic Events in Symptomatic Moyamoya Disease
    Phase
    N/A
    Started
    2026-10
    Registry
    NCT07889531

    Age 18 years to 70 years (registered criteria)

    Led by Beijing Tiantan HospitalBeijing

  233. Recruiting
    Becotatug Vedotin in Combination With Immunotherapy and Multimodality Radiotherapy for Esophageal Squamous Cell Carcinoma in the Second-line or Later Setting
    Phase
    Phase 2
    Started
    2026-05
    Registry
    NCT07892833

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Bengbu Medical UniversityBengbu

  234. Recruiting
    Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
    Phase
    Not given
    Started
    2026-08
    Registry
    NCT07894107

    Age 12 years to 70 years (registered criteria)

    Led by Beijing Tiantan Hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Nanchang, Shanghai, Suzhou, Wuhan, Zhengzhou

  235. Recruiting
    Hemophagocytic Lymphohistiocytosis After Allogeneic Stem Cell Transplantation
    Phase
    Not given
    Started
    2026-10
    Registry
    NCT07905066

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  236. Recruiting
    GN001 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia
    Phase
    Phase 1
    Started
    2026-08
    Registry
    NCT07910708

    Age 18 years to 75 years (registered criteria)

    Led by Pu'er People's HospitalPu'er

  237. Recruiting
    Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood Cancers
    Phase
    Phase 1
    Started
    2026-09
    Registry
    NCT07914556

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  238. Recruiting
    68Ga-labeled Cholecystokinin Receptor (CCK2R) Targeted Molecular Probes in Early Tumor Diagnosis
    Phase
    Not given
    Started
    2026-08
    Registry
    NCT07914764

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  239. Recruiting
    CTV Delineation Based Solely on Geometric Expansion From GTV in Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2025-01
    Registry
    NCT06095154

    Age 18 years to 70 years (registered criteria)

    Led by Fujian Cancer HospitalFuzhou

  240. Recruiting
    A Clinical Study on the Efficacy and Safety of Paclitaxel Polymeric Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06356688

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  241. Recruiting
    TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
    Phase
    Phase 1/Phase 2
    Started
    2025-02
    Registry
    NCT06481735

    Age 16 years to 70 years (registered criteria)

    Led by Chinese PLA General Hospital; 3 listed hospitals as study sitesBeijing, Tianjin

  242. Recruiting
    Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT06514508

    Age 18 years to 78 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  243. Recruiting
    Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis
    Phase
    Phase 2
    Started
    2025-02
    Registry
    NCT06519591

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  244. Recruiting
    The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders
    Phase
    Phase 1
    Started
    2025-03
    Registry
    NCT06620809

    Age 18 years to 65 years (registered criteria)

    Led by Tongji HospitalWuhan

  245. Recruiting
    A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
    Phase
    Phase 3
    Started
    2025-03
    Registry
    NCT06644781

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Jining, Linyi, Luoyang, Nanning, Shantou, Shenyang, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou, Zhengzhou

  246. Recruiting
    Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2025-01
    Registry
    NCT06676982

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  247. Recruiting
    A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis
    Phase
    Phase 2
    Started
    2025-02
    Registry
    NCT06685887

    Age 18 years to 75 years (registered criteria)

    Led by Union HospitalWuhan

  248. Recruiting
    A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis
    Phase
    Phase 1
    Started
    2025-03
    Registry
    NCT06688435

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteJinan

  249. Recruiting
    JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia
    Phase
    N/A
    Started
    2025-01
    Registry
    NCT06689917

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  250. Recruiting
    A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma
    Phase
    Early phase 1
    Started
    2025-04
    Registry
    NCT06717113

    Age 18 years to 80 years (registered criteria)

    Led by Peking University First HospitalBeijing

  251. Recruiting
    A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia
    Phase
    Early phase 1
    Started
    2025-07
    Registry
    NCT06730256

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  252. Recruiting
    Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
    Phase
    Phase 3
    Started
    2025-02
    Registry
    NCT06731478

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changzhou, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yinchuan, Zhengzhou

  253. Recruiting
    HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-01
    Registry
    NCT06737913

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 1 listed hospital as study siteGuangzhou, Zhengzhou

  254. Recruiting
    Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma
    Phase
    Phase 1/Phase 2
    Started
    2025-03
    Registry
    NCT06741020

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  255. Recruiting
    A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy
    Phase
    Phase 2
    Started
    2025-03
    Registry
    NCT06742892

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangsha

  256. Recruiting
    A Clinical Study of Ultra-transplantation for the Treatment of Major Thalassemia Scheme
    Phase
    N/A
    Started
    2025-08
    Registry
    NCT06743477

    Age 7 years to 12 years (registered criteria)

    Led by Affiliated Hospital of Kunming University of Science and TechnologyKunming

  257. Recruiting
    QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06749899

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 17 listed hospitals as study sitesChangsha, Chengdu, Dongguan, Foshan, Fuzhou, Guangzhou, Guiyang, Nanjing, Nanning, Shanghai, Tianjin, Wuhan, Xiamen, Zhongshan

  258. Recruiting
    Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in NPC
    Phase
    Phase 3
    Started
    2025-01
    Registry
    NCT06752239

    Age 18 years to 70 years (registered criteria)

    Led by Jiangxi Cancer HospitalNanchang

  259. Recruiting
    A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 1/Phase 2
    Started
    2025-09
    Registry
    NCT06753747

    Age 18 years to 75 years (registered criteria)

    Led by West China HospitalChengdu

  260. Recruiting
    Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies
    Phase
    Phase 1
    Started
    2025-01
    Registry
    NCT06758713

    Age 18 years to 75 years (registered criteria)

    Led by Third Affiliated Hospital of Southern Medical UniversityGuangzhou

  261. Recruiting
    A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
    Phase
    Phase 2
    Started
    2025-02
    Registry
    NCT06760819

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Shanghai

  262. Recruiting
    Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After Surgery
    Phase
    Phase 2
    Started
    2025-02
    Registry
    NCT06762782

    Age 18 years to 80 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  263. Recruiting
    Protein A immuNoaDsorption for the Treatment of Acute Episodes of Neuromyelitis Optica Spectrum Disorder
    Phase
    N/A
    Started
    2025-04
    Registry
    NCT06763848

    Age 18 years to 65 years (registered criteria)

    Led by Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  264. Recruiting
    Nutritional Intervention for Biliary Atresia
    Phase
    N/A
    Started
    2025-02
    Registry
    NCT06764082

    Age 1 day to 3 months (registered criteria)

    Led by Tongji HospitalWuhan

  265. Recruiting
    Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
    Phase
    Phase 2/Phase 3
    Started
    2025-01
    Registry
    NCT06764238

    Age 1 month to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 24 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan, Xi'an

  266. Recruiting
    The Study Evaluating the Improvement of Nutritional Status and Frailty With Silkworm Pupa Powder Among Patients With Motor Neuron Disease
    Phase
    N/A
    Started
    2025-03
    Registry
    NCT06765499

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou

  267. Recruiting
    QL1706 Combined With SOX Used in Theperioperative Treatment
    Phase
    Phase 1/Phase 2
    Started
    2025-03
    Registry
    NCT06766305

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  268. Recruiting
    Stereotactic Radiosurgery Versus Radiofrequency Ablation for Primary Liver Cancer
    Phase
    Phase 2
    Started
    2025-01
    Registry
    NCT06766643

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  269. Recruiting
    A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy
    Phase
    Phase 2
    Started
    2025-01
    Registry
    NCT06769113

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteJinan

  270. Recruiting
    HS-10502 Combination Treatment in Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-05
    Registry
    NCT06769425

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  271. Recruiting
    BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 1
    Started
    2025-02
    Registry
    NCT06773312

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  272. Recruiting
    Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
    Phase
    Phase 1/Phase 2
    Started
    2025-07
    Registry
    NCT06780111

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Hefei, Nanchang, Xiamen, Xuzhou, Zhengzhou

  273. Recruiting
    LDRT and Chemoimmunotherapy in NPC With Liver Metastasis
    Phase
    Phase 2
    Started
    2025-01
    Registry
    NCT06788002

    Age 18 years to 70 years (registered criteria)

    Led by Hunan Cancer Hospital; 2 listed hospitals as study sitesChangsha

  274. Recruiting
    Robotic Versus Laparoscopic Radical Surgery for Locally Advanced Gastric Cancer
    Phase
    N/A
    Started
    2025-02
    Registry
    NCT06791538

    Age 18 years to 75 years (registered criteria)

    Led by Southwest Hospital, Army Medical UniversityChongqing

  275. Recruiting
    A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma
    Phase
    Early phase 1
    Started
    2025-01
    Registry
    NCT06791681

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  276. Recruiting
    Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease
    Phase
    Early phase 1
    Started
    2025-01
    Registry
    NCT06792799

    Age 3 years to Not stated (registered criteria)

    Led by Children's Hospital, Zhejiang University School of MedicineHangzhou

  277. Recruiting
    Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia
    Phase
    Early phase 1
    Started
    2025-01
    Registry
    NCT06793241

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  278. Recruiting
    BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma
    Phase
    Phase 2
    Started
    2025-02
    Registry
    NCT06793449

    Age 18 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  279. Recruiting
    Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease
    Phase
    N/A
    Started
    2025-04
    Registry
    NCT06793475

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  280. Recruiting
    Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 3
    Started
    2025-06
    Registry
    NCT06793917

    Age 18 years to 70 years (registered criteria)

    Led by Fujian Cancer HospitalFuzhou

  281. Recruiting
    COMBO Endoscopy Oropharyngeal Airway Reduces Hypoxia During Sedated Gastrointestinal Endoscopy in Obese Patients: A Multicenter, Randomized, Controlled Clinical Trial
    Phase
    N/A
    Started
    2025-04
    Registry
    NCT06796764

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou

  282. Recruiting
    Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)
    Phase
    Phase 2/Phase 3
    Started
    2025-02
    Registry
    NCT06796803

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan University; 1 listed hospital as study siteHarbin, Shanghai

  283. Recruiting
    Efficacy and Safety of Sirolimus With or Without Cyclosporin A in Chinese Patients With Aplastic Anemia Refractory/Intolerant to Cyclosporin A
    Phase
    Phase 2
    Started
    2025-01
    Registry
    NCT06802055

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  284. Recruiting
    EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
    Phase
    Phase 1/Phase 2
    Started
    2025-07
    Registry
    NCT06802835

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  285. Recruiting
    Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC
    Phase
    Phase 2
    Started
    2025-02
    Registry
    NCT06811844

    Age 18 years to 65 years (registered criteria)

    Led by First Affiliated Hospital of Xiamen University; 1 listed hospital as study siteHaikou, Xiamen

  286. Recruiting
    HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence
    Phase
    Phase 2
    Started
    2025-01
    Registry
    NCT06812039

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 2 listed hospitals as study sitesFuzhou, Shanghai, Tianjin

  287. Recruiting
    A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria
    Phase
    Phase 3
    Started
    2025-02
    Registry
    NCT06819826

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  288. Recruiting
    Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06827717

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  289. Recruiting
    Research on Wireless Brain Implant System for General Control of External Devices
    Phase
    N/A
    Started
    2025-03
    Registry
    NCT06829212

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  290. Recruiting
    HANDLE-a Real World Study on Satralizumab in NMOSD
    Phase
    Not given
    Started
    2025-03
    Registry
    NCT06829524

    Age 12 years to Not stated (registered criteria)

    Led by Huashan HospitalShanghai

  291. Recruiting
    Nanocrystalline Megestrol for First-line Treatment of Advanced Gastric or Colorectal Cancer With Cancer-related Fatigue
    Phase
    N/A
    Started
    2025-01
    Registry
    NCT06830018

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenyang

  292. Recruiting
    Development and Validation of a Deep Learning Model to Predict Distant Metastases in Nasopharyngeal Carcinoma Using Whole Slide Imaging and MRI
    Phase
    Not given
    Started
    2025-02
    Registry
    NCT06831357

    Age not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  293. Recruiting
    To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
    Phase
    Phase 3
    Started
    2025-03
    Registry
    NCT06833983

    Age 18 years to 65 years; men only (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Tangshan, Tianjin, Wuhan, Zhengzhou

  294. Recruiting
    A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06839066

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChangsha, Chengdu, Dongguan, Fuzhou, Ganzhou, Guangzhou, Hangzhou, Nanning, Shenzhen, Wuhan, Zhongshan

  295. Recruiting
    Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC
    Phase
    Phase 3
    Started
    2025-07
    Registry
    NCT06841172

    Age 18 years to 75 years (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  296. Recruiting
    A Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06843889

    Age 18 years to 75 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  297. Recruiting
    A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.
    Phase
    Phase 2/Phase 3
    Started
    2025-03
    Registry
    NCT06844357

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanjing

  298. Recruiting
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    Phase
    Not given
    Started
    2025-02
    Registry
    NCT06846996

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Haikou, Hangzhou, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Taizhou, Tianjin, Xuzhou, Zhengzhou

  299. Recruiting
    A Study to Evaluate the Tolerability, Safety and Efficacy of VGN-R13 in Patients with ALS
    Phase
    Early phase 1
    Started
    2025-01
    Registry
    NCT06849609

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  300. Recruiting
    GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.
    Phase
    Phase 2
    Started
    2025-01
    Registry
    NCT06851247

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  301. Recruiting
    18F-mFBG PET Imaging in the Evaluation of Neuroblastoma
    Phase
    Not given
    Started
    2025-02
    Registry
    NCT06852807

    Age Not stated to 18 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  302. Recruiting
    A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
    Phase
    Phase 1
    Started
    2025-04
    Registry
    NCT06858813

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai

  303. Recruiting
    HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)
    Phase
    Phase 2
    Started
    2025-03
    Registry
    NCT06860490

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  304. Recruiting
    Exploring the Value of Urine Proteomics-based Dynamic Surveillance for Early Recurrence After Radical Surgery for Hepatocellular Carcinoma: a Prospective Cohort Study
    Phase
    Not given
    Started
    2025-02
    Registry
    NCT06861114

    Age 18 years to 75 years (registered criteria)

    Led by Zhujiang HospitalGuangzhou

  305. Recruiting
    A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma
    Phase
    Phase 2
    Started
    2025-03
    Registry
    NCT06869213

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  306. Recruiting
    Comparison and Strategy Optimization of Plasma EBV DNA and P85-Ab with VCA/EBNA1-IgA for Screening Nasopharyngeal Carcinoma in High-risk Areas
    Phase
    N/A
    Started
    2025-01
    Registry
    NCT06870435

    Age 30 years to 69 years (registered criteria)

    Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai

  307. Recruiting
    SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2025-02
    Registry
    NCT06873659

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Jinan, Lanzhou, Nanjing, Shanghai, Xi'an

  308. Recruiting
    KPD Consolidation After ASCT in NDMM Patients
    Phase
    Phase 2/Phase 3
    Started
    2025-03
    Registry
    NCT06879379

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's Hospital; 1 listed hospital as study siteBeijing, Shanghai

  309. Recruiting
    BCMA CAR-T for Dynamic High-risk Multiple Myeloma
    Phase
    Phase 2
    Started
    2025-03
    Registry
    NCT06880393

    Age 18 years to 75 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  310. Recruiting
    Exploratory Study on the Efficacy of Betaine Hydrochloride in Treating Autoimmune Gastritis
    Phase
    N/A
    Started
    2025-01
    Registry
    NCT06881511

    Age 18 years to 80 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  311. Recruiting
    Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
    Phase
    Phase 2/Phase 3
    Started
    2025-03
    Registry
    NCT06882057

    Age 1 year to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 23 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an

  312. Recruiting
    Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSD
    Phase
    Not given
    Started
    2025-07
    Registry
    NCT06885957

    Age 18 years to 65 years (registered criteria)

    Led by Tongji HospitalWuhan

  313. Recruiting
    JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia
    Phase
    N/A
    Started
    2025-03
    Registry
    NCT06890065

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou

  314. Recruiting
    Clinical Study on the Safety and Efficacy of BiTE-EV in Relapsed/Refractory Acute B-Cell Leukemia
    Phase
    Early phase 1
    Started
    2025-01
    Registry
    NCT06890494

    Age 18 years to 70 years (registered criteria)

    Led by Beijing GoBroad HospitalBeijing

  315. Recruiting
    Phase I Study of OriC902 in Treatment of Advanced HCC
    Phase
    Phase 1
    Started
    2025-02
    Registry
    NCT06891742

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer Hospital; 1 listed hospital as study siteBeijing

  316. Recruiting
    ctDNA-MRD Monitoring After Resection in Gastric Cancer
    Phase
    Not given
    Started
    2025-04
    Registry
    NCT06893133

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  317. Recruiting
    Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2025-05
    Registry
    NCT06893887

    Age 18 years to Not stated (registered criteria)

    Led by Nanjing Tianyinshan HospitalNanjing

  318. Recruiting
    TACE Combined Surgery for the Resectable Huge HCC
    Phase
    Not given
    Started
    2025-01
    Registry
    NCT06898398

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  319. Recruiting
    A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06901531

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Shanghai, Shijiazhuang, Tianjin, Wuhan, Xining, Zhengzhou

  320. Recruiting
    A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma
    Phase
    Phase 1/Phase 2
    Started
    2025-07
    Registry
    NCT06902389

    Age 18 years to 75 years (registered criteria)

    Led by Eastern Hepatobiliary Surgery HospitalShanghai

  321. Recruiting
    Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06904183

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  322. Recruiting
    Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06904196

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  323. Recruiting
    Neoadjuvant QL1706 Therapy for ESCC
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06908382

    Age 18 years to 75 years (registered criteria)

    Led by Shandong Provincial HospitalJinan

  324. Recruiting
    SIRT Versus cTACE for Unresectable HCC (CHANCE2506)
    Phase
    N/A
    Started
    2025-04
    Registry
    NCT06909708

    Age 18 years to Not stated (registered criteria)

    Led by Zhongda Hospital, Southeast UniversityNanjing

  325. Recruiting
    Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06912074

    Age 18 years to 80 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  326. Recruiting
    Reduced Dose Radiotherapy vs Standard Dose Radiotherapy for Early Stage Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06912698

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  327. Recruiting
    TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2025-05
    Registry
    NCT06912711

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  328. Recruiting
    Jin-shui Huan-xian Formula for Retarding the Decline of Pulmonary Function in IPF
    Phase
    N/A
    Started
    2025-09
    Registry
    NCT06914713

    Age 40 years to 85 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou

  329. Recruiting
    Metabolomic and Lipidomic Analysis Predicts Immunotherapy-related Adverse Events in Gastric Cancer Patients
    Phase
    Not given
    Started
    2025-02
    Registry
    NCT06915389

    Age 18 years to 80 years (registered criteria)

    Led by Qinghai Red Cross HospitalXining

  330. Recruiting
    Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 3
    Started
    2025-04
    Registry
    NCT06925243

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesGuangzhou, Lanzhou

  331. Recruiting
    A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
    Phase
    Phase 1
    Started
    2025-05
    Registry
    NCT06926283

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Changsha, Hangzhou

  332. Recruiting
    Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma
    Phase
    Phase 2
    Started
    2025-05
    Registry
    NCT06933394

    Age 18 months to 18 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  333. Recruiting
    Reproductive and Mental Health of Patients With Aplastic Anemia
    Phase
    Not given
    Started
    2025-03
    Registry
    NCT06936930

    Age 18 years to 40 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  334. Recruiting
    Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2025-05
    Registry
    NCT06938880

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  335. Recruiting
    Universal Chimeric Antigen Receptor T-Cell (UCAR T-cell) Therapy Targeting CD19/B Cell Maturation Antigen (CD19/BCMA) in Patients With r/r Neurological Autoimmune Diseases
    Phase
    Early phase 1
    Started
    2025-06
    Registry
    NCT06939166

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Huanhu HospitalTianjin

  336. Recruiting
    Real-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in TKI-Treated Advanced Digestive Tumors
    Phase
    Not given
    Started
    2025-03
    Registry
    NCT06940102

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenyang

  337. Recruiting
    JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia
    Phase
    N/A
    Started
    2025-05
    Registry
    NCT06940960

    Age 12 years to 75 years (registered criteria)

    Led by Affiliated Hospital of Guangdong Medical UniversityZhanjiang

  338. Recruiting
    Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Extended Lymphadenectomy Beyond D2 for Locally Advanced Gastric Cancer (FUGES-30)
    Phase
    Not given
    Started
    2025-05
    Registry
    NCT06945718

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  339. Recruiting
    Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT06947291

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou

  340. Recruiting
    Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06949033

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesGuangzhou, Lanzhou

  341. Recruiting
    Textbook Outcomes of Right Hemihepatectomy in Patients With Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2025-04
    Registry
    NCT06950827

    Age 18 years to Not stated (registered criteria)

    Led by West China HospitalChengdu

  342. Recruiting
    GR1803 Injection in Patients With RRMM
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06952075

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  343. Recruiting
    Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence
    Phase
    Phase 2
    Started
    2025-08
    Registry
    NCT06954116

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  344. Recruiting
    JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-05
    Registry
    NCT06954467

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Harbin, Hefei, Nanchang, Shanghai, Shenyang, Zhengzhou

  345. Recruiting
    Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma
    Phase
    N/A
    Started
    2025-04
    Registry
    NCT06961669

    Age 3 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of USTCHefei

  346. Recruiting
    A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
    Phase
    Phase 3
    Started
    2025-07
    Registry
    NCT06963827

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBaotou, Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Nantong, Ningbo, Shanghai, Shenzhen, Wuxi, Xiamen, Zhuhai

  347. Recruiting
    CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC
    Phase
    Phase 3
    Started
    2025-02
    Registry
    NCT06964568

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  348. Recruiting
    Bovine Reinforcement in Stomach, Colorectal and Lung Operation
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06968221

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  349. Recruiting
    Safety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Injectionin the Treatment of Patients With Type 2 Spinal Muscular Atrophy (SMA) - Phase III
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06971094

    Age 2 years to 12 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Shenzhen, Suzhou, Wuhan

  350. Recruiting
    High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed
    Phase
    Early phase 1
    Started
    2025-04
    Registry
    NCT06972602

    Age 1 year to 12 years (registered criteria)

    Led by Eye & ENT Hospital of Fudan UniversityShanghai

  351. Recruiting
    A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06976190

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  352. Recruiting
    A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors
    Phase
    Early phase 1
    Started
    2025-05
    Registry
    NCT06976437

    Age 18 years to Not stated (registered criteria)

    Led by Affiliated Hospital of Jiangsu UniversityChangzhou

  353. Recruiting
    A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
    Phase
    Phase 1
    Started
    2025-05
    Registry
    NCT06978647

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  354. Recruiting
    FGF19 Overexpression Combination Unified Study in HCC-19
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06978933

    Age 18 years to Not stated (registered criteria)

    Led by Renji HospitalShanghai

  355. Recruiting
    Investigating Multigene Methylation Dynamics in Treatment Response Surveillance for Gastric Cancer
    Phase
    Not given
    Started
    2025-05
    Registry
    NCT06979895

    Age 18 years to 75 years (registered criteria)

    Led by Xijing Hospital; 1 listed hospital as study siteXi'an

  356. Recruiting
    Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy
    Phase
    Phase 2
    Started
    2025-05
    Registry
    NCT06985485

    Age 15 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  357. Recruiting
    A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT06986785

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  358. Recruiting
    A Study of CT0596 in Plasma Cell Leukemia
    Phase
    Early phase 1
    Started
    2025-06
    Registry
    NCT06988059

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  359. Recruiting
    A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2025-10
    Registry
    NCT06988488

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Fourth People's HospitalShanghai

  360. Recruiting
    Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma
    Phase
    Phase 1/Phase 2
    Started
    2025-04
    Registry
    NCT06995105

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  361. Recruiting
    Phase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT07000643

    Age 18 years to 75 years (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  362. Recruiting
    Correlation of Psychological Distress and Immune Checkpoint Inhibitors in Gastric Cancer
    Phase
    Not given
    Started
    2025-01
    Registry
    NCT07003334

    Age 18 years to 75 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  363. Recruiting
    Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration
    Phase
    Phase 1
    Started
    2025-05
    Registry
    NCT07003555

    Age 18 years to 75 years (registered criteria)

    Led by Beijing GoBroad HospitalBeijing

  364. Recruiting
    Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration
    Phase
    Phase 1
    Started
    2025-05
    Registry
    NCT07003568

    Age 18 years to 75 years (registered criteria)

    Led by Beijing GoBroad HospitalBeijing

  365. Recruiting
    Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation
    Phase
    N/A
    Started
    2025-02
    Registry
    NCT07003737

    Age 18 years to 65 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  366. Recruiting
    Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer
    Phase
    Phase 2
    Started
    2025-10
    Registry
    NCT07007182

    Age 18 years to 75 years (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  367. Recruiting
    BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL
    Phase
    Phase 1/Phase 2
    Started
    2025-06
    Registry
    NCT07008885

    Age 18 years to 70 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  368. Recruiting
    Head-to-Head Comparison of Hepatocellular Cancer (HCC) Screening Strategies: A Prospective Population-Based Cohort Study in Zhongshan City
    Phase
    Not given
    Started
    2025-03
    Registry
    NCT07010198

    Age 35 years to Not stated (registered criteria)

    Led by Zhongshan City People's HospitalZhongshan

  369. Recruiting
    Dose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic Anemia
    Phase
    Phase 2
    Started
    2025-02
    Registry
    NCT07010237

    Age 65 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  370. Recruiting
    Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT07012447

    Age 14 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  371. Recruiting
    FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07012798

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  372. Recruiting
    Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07014150

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  373. Recruiting
    A Trial of HRS-5965 Capsule in Primary IgA Nephropathy
    Phase
    Phase 3
    Started
    2025-06
    Registry
    NCT07014826

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  374. Recruiting
    Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07018050

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  375. Recruiting
    PIN in Combination With Anti-PD1 in Previously Treated Primary Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2025-06
    Registry
    NCT07018518

    Age 18 years to 75 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  376. Recruiting
    Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
    Phase
    Phase 1/Phase 2
    Started
    2025-04
    Registry
    NCT07022197

    Age 18 years to 60 years (registered criteria)

    Led by Tianjin Medical University General HospitalTianjin

  377. Recruiting
    A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
    Phase
    Phase 3
    Started
    2025-08
    Registry
    NCT07023315

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Fuzhou, Harbin, Shanghai, Shijiazhuang

  378. Recruiting
    IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer
    Phase
    Phase 1/Phase 2
    Started
    2025-06
    Registry
    NCT07025889

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  379. Recruiting
    Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07026149

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  380. Recruiting
    Feasibility of Enhanced Recovery After Surgery Without Prophylactic Abdominal Drainage Tubes After Laparoscopic Distal Gastrectomy For Gastric Cancer
    Phase
    Phase 3
    Started
    2025-06
    Registry
    NCT07029269

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFuzhou, Guangzhou, Hangzhou, Lanzhou, Xi'an

  381. Recruiting
    Nefecon and Ambrisentan in IgA Nephropathy
    Phase
    Phase 4
    Started
    2025-09
    Registry
    NCT07030894

    Age 18 years to 70 years (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  382. Recruiting
    A Cohort Study of Mobile Capsule Gastroscopy for Gastric Pathologies Screening
    Phase
    Not given
    Started
    2025-06
    Registry
    NCT07032961

    Age 45 years to Not stated (registered criteria)

    Led by Nanfang HospitalGuangzhou

  383. Recruiting
    A Randomized Controlled Trial of Spermidine for the Prevention of Radiation-Induced Xerostomia in Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma)
    Phase
    Phase 1/Phase 2
    Started
    2025-06
    Registry
    NCT07035626

    Age 18 years to 80 years (registered criteria)

    Led by West China HospitalChengdu

  384. Recruiting
    Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07038629

    Age 70 years to 90 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  385. Recruiting
    A Study to Evaluate CG-102-12C in Glypican-3 (GPC3) Positive Advanced Hepatocellular Carcinoma (HCC)
    Phase
    N/A
    Started
    2025-06
    Registry
    NCT07039201

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  386. Recruiting
    Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab
    Phase
    Phase 2
    Started
    2025-07
    Registry
    NCT07047586

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  387. Recruiting
    QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07049185

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer Hospital; 1 listed hospital as study siteBeijing

  388. Recruiting
    A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.
    Phase
    Phase 2
    Started
    2025-07
    Registry
    NCT07052253

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan

  389. Recruiting
    PD-1 mRNA LNP Vaccine for Advanced Primary Hepatocellular Carcinoma.
    Phase
    Phase 1
    Started
    2025-10
    Registry
    NCT07053072

    Age 18 years to 70 years (registered criteria)

    Led by West China HospitalChengdu

  390. Recruiting
    Patient Derived Organoids (PDOs) to Observe the Clinical Consistency of Personalized Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
    Phase
    Not given
    Started
    2025-03
    Registry
    NCT07054086

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  391. Recruiting
    GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)
    Phase
    Early phase 1
    Started
    2025-07
    Registry
    NCT07058298

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  392. Recruiting
    A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy.
    Phase
    Phase 1/Phase 2
    Started
    2025-07
    Registry
    NCT07058662

    Age 4 years to 9 years; men only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  393. Recruiting
    Predicting Immunotherapy Response and Survival of Liver Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Liver)
    Phase
    Not given
    Started
    2025-07
    Registry
    NCT07059936

    Age 18 years to Not stated (registered criteria)

    Led by Union HospitalWuhan

  394. Recruiting
    Oncolytic Virus in Esophageal Squamous Cell Carcinoma
    Phase
    Phase 1/Phase 2
    Started
    2025-08
    Registry
    NCT07061704

    Age 18 years to 80 years (registered criteria)

    Led by West China HospitalChengdu

  395. Recruiting
    BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or Oligometastases
    Phase
    Phase 2
    Started
    2025-07
    Registry
    NCT07062055

    Age 18 years to 70 years (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  396. Recruiting
    AI-Based Prediction of HCC Recurrence Patterns After Resection (APAR)
    Phase
    Not given
    Started
    2025-06
    Registry
    NCT07062380

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  397. Recruiting
    Treatment of Moyamoya Disease With iPSC-derived Exosomes
    Phase
    Phase 1
    Started
    2025-05
    Registry
    NCT07065409

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  398. Recruiting
    A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-07
    Registry
    NCT07066657

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Changsha, Chongqing, Hangzhou, Harbin, Shanghai, Wuhan, Zhengzhou

  399. Recruiting
    Safety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma
    Phase
    Early phase 1
    Started
    2025-07
    Registry
    NCT07067346

    Age 12 months to Not stated (registered criteria)

    Led by West China HospitalChengdu

  400. Recruiting
    Clinical Evaluation of GRAPE Model for Gastric Cancer Screening
    Phase
    Not given
    Started
    2025-05
    Registry
    NCT07067983

    Age 18 years to 80 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  401. Recruiting
    A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease
    Phase
    Phase 2/Phase 3
    Started
    2025-07
    Registry
    NCT07068165

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  402. Recruiting
    Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Colorectal Cancer:MetBio-CRC
    Phase
    Not given
    Started
    2025-06
    Registry
    NCT07068529

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  403. Recruiting
    The Construction of a Predictive Model for Gastric Cancer Immunotherapy Response Based on Tumor-Infiltrating Lymphocytes (TILs) and Histone H3K4me3 in the Tumor Microenvironment
    Phase
    Not given
    Started
    2025-01
    Registry
    NCT07069842

    Age 18 years to 75 years (registered criteria)

    Led by Changzhi People's Hospital, Changzhi Medical CollegeChangzhi

  404. Recruiting
    A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
    Phase
    Phase 1/Phase 2
    Started
    2025-08
    Registry
    NCT07070232

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChongqing, Hangzhou, Tianjin, Wuhan

  405. Recruiting
    Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07070479

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChangsha, Guangzhou, Zhongshan, Zhuhai

  406. Recruiting
    Study of GV20-0251 in Participants With Solid Tumor Malignancies
    Phase
    Phase 1/Phase 2
    Started
    2025-07
    Registry
    NCT07070518

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing

  407. Recruiting
    CD19 CAR-T Cell Infusion as Consolidation Therapy in Adolescent and Adult Patients With Acute B-ALL Ineligible for Allogeneic HSCT: A Clinical Study
    Phase
    Phase 1/Phase 2
    Started
    2025-07
    Registry
    NCT07072494

    Age 14 years to 80 years (registered criteria)

    Led by Zhujiang HospitalGuangzhou

  408. Recruiting
    Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Gastric Cancer:MetBio-GC
    Phase
    Not given
    Started
    2025-06
    Registry
    NCT07076979

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  409. Recruiting
    Application of mRNA Vaccine in Liver Transplantation for Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2025-08
    Registry
    NCT07077356

    Age 18 years to Not stated (registered criteria)

    Led by West China HospitalChengdu

  410. Recruiting
    Multicenter Observational Study of Multimodal AI for Upper GI Mesenchymal Tumor Diagnosis
    Phase
    Not given
    Started
    2025-07
    Registry
    NCT07078136

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  411. Recruiting
    Real-world Study Evaluating the Long-term Outcomes of Pegylated Interferon α-2b Treatment in the Families With Clusters of HBV Infection and Unfavorable Prognosis - A Prospective, Controlled, Multicenter, Cohort Study
    Phase
    Not given
    Started
    2025-01
    Registry
    NCT07079150

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of Xi'an Jiaotong UniversityXi'an

  412. Recruiting
    A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)
    Phase
    Phase 2/Phase 3
    Started
    2025-10
    Registry
    NCT07082192

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  413. Recruiting
    Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF
    Phase
    Phase 3
    Started
    2025-10
    Registry
    NCT07082842

    Age 40 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  414. Recruiting
    Iparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC
    Phase
    Phase 2
    Started
    2025-07
    Registry
    NCT07085234

    Age 18 years to 65 years (registered criteria)

    Led by First Affiliated Hospital of Xiamen UniversityXiamen

  415. Recruiting
    Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research
    Phase
    Early phase 1
    Started
    2025-06
    Registry
    NCT07085559

    Age 19 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of USTCHefei

  416. Recruiting
    Effect of Nutritional Management on Patients With Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2025-01
    Registry
    NCT07085988

    Age 18 years to Not stated (registered criteria)

    Led by Jiangxi Cancer HospitalNanchang

  417. Recruiting
    Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2025-07
    Registry
    NCT07086469

    Age 18 years to 80 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  418. Recruiting
    Deep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy
    Phase
    Not given
    Started
    2025-03
    Registry
    NCT07088354

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  419. Recruiting
    A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-08
    Registry
    NCT07090499

    Age 18 years to Not stated (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  420. Recruiting
    Shenqi Fuwei Mixture Combined With Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric Cancer
    Phase
    N/A
    Started
    2025-05
    Registry
    NCT07098026

    Age 18 years to 75 years (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  421. Recruiting
    Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-08
    Registry
    NCT07099274

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  422. Recruiting
    LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
    Phase
    N/A
    Started
    2025-09
    Registry
    NCT07100067

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Tianjin, Wuhan

  423. Recruiting
    Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab
    Phase
    Phase 2
    Started
    2025-08
    Registry
    NCT07100392

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  424. Recruiting
    TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma: Study on Efficacy and Immune Microenvironment
    Phase
    Not given
    Started
    2025-08
    Registry
    NCT07100405

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  425. Recruiting
    An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies
    Phase
    Early phase 1
    Started
    2025-09
    Registry
    NCT07101705

    Age 18 years to 75 years (registered criteria)

    Led by Union HospitalWuhan

  426. Recruiting
    Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial
    Phase
    Phase 2
    Started
    2025-10
    Registry
    NCT07101744

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  427. Recruiting
    A Prediction Model in Pregnant Women With Aplastic Anemia
    Phase
    Not given
    Started
    2025-11
    Registry
    NCT07101770

    Age 20 years to 50 years; women only (registered criteria)

    Led by Peking University People's HospitalBeijing

  428. Recruiting
    Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07102901

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHarbin, Zhengzhou

  429. Recruiting
    A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients
    Phase
    Phase 3
    Started
    2025-08
    Registry
    NCT07103668

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  430. Recruiting
    A Study on the Effect of MRD Detected by FAPI PET / CT on the Recurrence of IgG4-RD
    Phase
    N/A
    Started
    2025-05
    Registry
    NCT07104058

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  431. Recruiting
    Development and Validation of a Risk Prediction Model for Gastric Retention in Patients Undergoing Sedated Gastroscopy
    Phase
    Not given
    Started
    2025-08
    Registry
    NCT07104214

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  432. Recruiting
    Effectiveness and Safety of Blinatumomab and Donor Lymphocyte Infusion in Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for High-risk Ph Negative B Cell Acute Lymphoblastic Leukemia
    Phase
    Phase 2
    Started
    2025-08
    Registry
    NCT07105579

    Age 14 years to 65 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  433. Recruiting
    A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
    Phase
    Phase 2
    Started
    2025-08
    Registry
    NCT07106671

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  434. Recruiting
    ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia
    Phase
    Phase 2
    Started
    2025-08
    Registry
    NCT07106684

    Age 18 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  435. Recruiting
    ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma
    Phase
    Phase 2
    Started
    2025-08
    Registry
    NCT07106710

    Age 18 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  436. Recruiting
    MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma
    Phase
    Phase 2
    Started
    2025-08
    Registry
    NCT07106736

    Age 18 years to 75 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  437. Recruiting
    CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies
    Phase
    Phase 1
    Started
    2025-06
    Registry
    NCT07106749

    Age 18 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  438. Recruiting
    A Study of GV20-0251 in Advanced or Refractory Solid Tumors
    Phase
    Phase 1
    Started
    2025-09
    Registry
    NCT07106827

    Age 18 years to Not stated (registered criteria)

    Led by West China HospitalChengdu

  439. Recruiting
    Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM
    Phase
    Phase 1/Phase 2
    Started
    2025-03
    Registry
    NCT07109323

    Age 18 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  440. Recruiting
    A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer
    Phase
    Phase 2
    Started
    2025-08
    Registry
    NCT07110571

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Shijiazhuang

  441. Recruiting
    A Study of LY4257496 in Participants With Cancer (OMNIRAY)
    Phase
    Phase 1
    Started
    2025-08
    Registry
    NCT07114601

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Tianjin

  442. Recruiting
    The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis
    Phase
    Phase 1
    Started
    2025-09
    Registry
    NCT07118319

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  443. Recruiting
    A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07121413

    Age 40 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesChengdu, Guangzhou, Hangzhou, Hohhot, Nanchang, Nanjing, Shanghai, Tianjin, Xuzhou, Zhengzhou

  444. Recruiting
    Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma
    Phase
    Phase 1/Phase 2
    Started
    2025-08
    Registry
    NCT07123545

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  445. Recruiting
    Multimodal Deep Learning for Lymph Node Metastasis Prediction and Physician Performance Assessment in T1 Gastric Cancer
    Phase
    Not given
    Started
    2025-01
    Registry
    NCT07124754

    Age 18 years to Not stated (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  446. Recruiting
    Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07127822

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer Hospital; 8 listed hospitals as study sitesBeijing, Chengdu, Harbin, Qingdao, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou

  447. Recruiting
    Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2025-07
    Registry
    NCT07136519

    Age 18 years to 65 years (registered criteria)

    Led by Affiliated Hospital of Guangdong Medical UniversityZhanjiang

  448. Recruiting
    Precise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinoma
    Phase
    Not given
    Started
    2025-08
    Registry
    NCT07137052

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of Xiamen UniversityXiamen

  449. Recruiting
    The Clinical Significance of Examining Metastatic Lymph Nodes in Individual Gastric Mesenteries in the Patients With Gastric Cancer Undergoing Gastrectomy
    Phase
    Not given
    Started
    2025-10
    Registry
    NCT07139418

    Age 18 years to 85 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  450. Recruiting
    The Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study
    Phase
    Not given
    Started
    2025-01
    Registry
    NCT07141056

    Age 18 years to Not stated (registered criteria)

    Led by Affiliated Hospital of Guilin Medical University; 1 listed hospital as study siteGuilin, Zhanjiang

  451. Recruiting
    Safety Comparison of Total Laparoscopic Proximal Gastrectomy With or Without Preservation of the Celiac Branch of the Vagus Nerve for Early Upper Gastric Cancer: A Randomized Controlled Clinical Trial
    Phase
    N/A
    Started
    2025-01
    Registry
    NCT07142122

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Cancer HospitalFuzhou

  452. Recruiting
    Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment
    Phase
    Not given
    Started
    2025-09
    Registry
    NCT07147101

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  453. Recruiting
    The Role of Serum AKR1B10 in Early Warning of Hepatocellular Carcinoma in Cirrhosis Patients
    Phase
    Not given
    Started
    2025-05
    Registry
    NCT07147335

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, University of South ChinaHengyang

  454. Recruiting
    Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07148791

    Age 18 years to 75 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  455. Recruiting
    PBC Long-term Outcomes Study
    Phase
    Not given
    Started
    2025-05
    Registry
    NCT07149675

    Age not stated (registered criteria)

    Led by Beijing Friendship HospitalBeijing

  456. Recruiting
    The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine
    Phase
    Phase 4
    Started
    2025-11
    Registry
    NCT07150624

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of USTCHefei

  457. Recruiting
    Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
    Phase
    Phase 3
    Started
    2025-03
    Registry
    NCT07152041

    Age 1 month to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 20 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan

  458. Recruiting
    Adaptive Immunotherapy for Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2025-11
    Registry
    NCT07154069

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  459. Recruiting
    Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07154082

    Age 18 years to 70 years (registered criteria)

    Led by Tongji HospitalWuhan

  460. Recruiting
    ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
    Phase
    Phase 2
    Started
    2025-02
    Registry
    NCT07157969

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  461. Recruiting
    dCRT vs. Surgery in Resectable ESCC Patients Achieving cCR/PR After Induction Chemoimmunotherapy
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07162506

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  462. Recruiting
    Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)
    Phase
    Phase 2
    Started
    2025-07
    Registry
    NCT07165847

    Age 18 years to Not stated (registered criteria)

    Led by Daping Hospital, Army Medical UniversityChongqing

  463. Recruiting
    Safety and Efficacy of NK510 to Treat Gastric Cancer and Colorectal Cancer
    Phase
    Early phase 1
    Started
    2025-10
    Registry
    NCT07166263

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanjing

  464. Recruiting
    Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients
    Phase
    Phase 1/Phase 2
    Started
    2025-03
    Registry
    NCT07169500

    Age 18 years to 50 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  465. Recruiting
    Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
    Phase
    Not given
    Started
    2025-09
    Registry
    NCT07170345

    Age 18 years to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Nanning, Shanghai, Shenyang, Wenzhou, Zhengzhou, Zhuhai

  466. Recruiting
    Combination of COMBO Endoscopy Oropharyngeal Airway and HFNC Oxygenation in Sedated Gastrointestinal Endoscopy for Morbidly Obese Patients
    Phase
    N/A
    Started
    2025-10
    Registry
    NCT07175155

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang University; 2 listed hospitals as study sitesBeijing, Hangzhou, Taizhou

  467. Recruiting
    The PRE-VAIL Study
    Phase
    N/A
    Started
    2025-09
    Registry
    NCT07176624

    Age 18 years to Not stated (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  468. Recruiting
    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2025-11
    Registry
    NCT07176650

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou

  469. Recruiting
    Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2025-09
    Registry
    NCT07177443

    Age 18 years to 65 years (registered criteria)

    Led by Union HospitalWuhan

  470. Recruiting
    Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC
    Phase
    Phase 3
    Started
    2025-09
    Registry
    NCT07177794

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  471. Recruiting
    A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
    Phase
    Phase 1
    Started
    2025-12
    Registry
    NCT07179679

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesChengde, Chongqing, Guangzhou, Nanchang, Nanchong, Nanjing, Shanghai, Suzhou, Xi'an

  472. Recruiting
    Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-03
    Registry
    NCT07179900

    Age 18 years to Not stated (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  473. Recruiting
    The Possible Range of No.4sb Lymph Node Dissection of Locally Advanced Distal Gastric Cancer
    Phase
    Not given
    Started
    2025-08
    Registry
    NCT07183150

    Age 18 years to 80 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  474. Recruiting
    A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
    Phase
    Not given
    Started
    2025-11
    Registry
    NCT07187440

    Age 7 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Nanjing, Shantou, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Xi'an

  475. Recruiting
    Safety and Dystrophin Expression of SPOT-03 in Duchenne Muscular Dystrophy (DMD) Patients
    Phase
    Early phase 1
    Started
    2025-08
    Registry
    NCT07188012

    Age 2 years to 7 years; men only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  476. Recruiting
    Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2025-07
    Registry
    NCT07188103

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of USTCHefei

  477. Recruiting
    Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer
    Phase
    Phase 3
    Started
    2025-08
    Registry
    NCT07188584

    Age 18 years to 70 years (registered criteria)

    Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai

  478. Recruiting
    Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07192185

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  479. Recruiting
    Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07194005

    Age 18 years to 70 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  480. Recruiting
    A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
    Phase
    Early phase 1
    Started
    2025-07
    Registry
    NCT07203404

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  481. Recruiting
    A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
    Phase
    Early phase 1
    Started
    2025-09
    Registry
    NCT07205315

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  482. Recruiting
    A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
    Phase
    Phase 3
    Started
    2025-11
    Registry
    NCT07208058

    Age 16 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang, Shijiazhuang, Wuhan, Zhengzhou

  483. Recruiting
    GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07209813

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Nanchang, Nanjing, Zhengzhou

  484. Recruiting
    The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial
    Phase
    Phase 2
    Started
    2025-07
    Registry
    NCT07212933

    Age 18 years to 70 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  485. Recruiting
    A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
    Phase
    Phase 1
    Started
    2025-10
    Registry
    NCT07213791

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  486. Recruiting
    Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
    Phase
    Phase 1
    Started
    2025-09
    Registry
    NCT07215650

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesChangchun, Chengdu, Fuzhou, Guangzhou, Guiyang, Shanghai, Taiyuan, Tianjin, Zhengzhou

  487. Recruiting
    Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
    Phase
    Phase 1/Phase 2
    Started
    2025-12
    Registry
    NCT07227012

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  488. Recruiting
    Deep Learning-Based Multidimensional Body Composition Mapping for Outcome Prediction in HCC Patients Undergoing TACE
    Phase
    Not given
    Started
    2025-11
    Registry
    NCT07235410

    Age 18 years to Not stated (registered criteria)

    Led by Union HospitalWuhan

  489. Recruiting
    Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07238881

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  490. Recruiting
    Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07239245

    Age 18 years to 75 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMS; 2 listed hospitals as study sitesBeijing, Shenyang, Zhengzhou

  491. Recruiting
    A Clinical Study on the Treatment of Wilson Disease With ATP7B mRNA/LNP (DSL101)
    Phase
    Early phase 1
    Started
    2025-12
    Registry
    NCT07240896

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHefei

  492. Recruiting
    TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors
    Phase
    Early phase 1
    Started
    2025-12
    Registry
    NCT07242417

    Age 18 years to 75 years (registered criteria)

    Led by Beijing GoBroad HospitalBeijing

  493. Recruiting
    Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2025-12
    Registry
    NCT07243691

    Age 18 years to Not stated (registered criteria)

    Led by Sir Run Run Shaw HospitalHangzhou

  494. Recruiting
    Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL
    Phase
    Phase 2
    Started
    2025-01
    Registry
    NCT07244406

    Age 3 years to 25 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  495. Recruiting
    A Study of DEG6498 in Participants With Solid Tumors
    Phase
    Phase 1
    Started
    2025-11
    Registry
    NCT07244835

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou

  496. Recruiting
    Universal CAR-T Cell Therapy for MM
    Phase
    N/A
    Started
    2025-04
    Registry
    NCT07248176

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalShanghai

  497. Recruiting
    CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma
    Phase
    Early phase 1
    Started
    2025-03
    Registry
    NCT07249073

    Age 18 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  498. Recruiting
    AI-Assisted Detection and Staging of Gastric Cancer Using Contrast-Enhanced CT
    Phase
    Not given
    Started
    2025-08
    Registry
    NCT07250347

    Age 18 years to 85 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  499. Recruiting
    Distribution Characteristics of Helicobacter Pylori
    Phase
    Not given
    Started
    2025-10
    Registry
    NCT07253948

    Age 18 years to 80 years (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  500. Recruiting
    A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
    Phase
    Phase 1/Phase 2
    Started
    2025-11
    Registry
    NCT07258979

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Dongguan, Fuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Jiangmen, Kunming, Nanchang, Nanning, Shanghai, Shaoguan, Xiamen

  501. Recruiting
    A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer
    Phase
    Phase 2
    Started
    2025-10
    Registry
    NCT07263386

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  502. Recruiting
    Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07263919

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteXi'an

  503. Recruiting
    Clinical Study of Adbelimumab in the Adjuvant Treatment of Esophageal Squamous Cell Carcinoma.
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07266480

    Age 18 years to Not stated (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  504. Recruiting
    Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC
    Phase
    Phase 3
    Started
    2025-10
    Registry
    NCT07267806

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  505. Recruiting
    TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan Criteria
    Phase
    N/A
    Started
    2025-12
    Registry
    NCT07268131

    Age 18 years to 75 years (registered criteria)

    Led by Huashan HospitalShanghai

  506. Recruiting
    Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma
    Phase
    Phase 4
    Started
    2025-11
    Registry
    NCT07270835

    Age 14 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  507. Recruiting
    JMT106 Injection in the Treatment of Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-09
    Registry
    NCT07275073

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou

  508. Recruiting
    Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07277439

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  509. Recruiting
    Induction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carcinoma (Single-Arm Phase II)
    Phase
    Phase 2
    Started
    2025-10
    Registry
    NCT07277764

    Age 18 years to 75 years (registered criteria)

    Led by Jiangxi Cancer HospitalNanchang

  510. Recruiting
    Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention
    Phase
    Phase 1/Phase 2
    Started
    2025-10
    Registry
    NCT07282184

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  511. Recruiting
    A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07282353

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBaoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Harbin, Hefei, Linyi, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shiyan, Taizhou, Tianjin, Xi'an, Xiamen, Zhanjiang, Zhengzhou

  512. Recruiting
    The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD
    Phase
    Phase 2/Phase 3
    Started
    2025-10
    Registry
    NCT07285850

    Age 18 years to Not stated (registered criteria)

    Led by Eastern Hepatobiliary Surgery HospitalShanghai

  513. Recruiting
    The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia
    Phase
    Phase 1/Phase 2
    Started
    2025-12
    Registry
    NCT07287228

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  514. Recruiting
    Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC)
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07289997

    Age 18 years to Not stated (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  515. Recruiting
    The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07290010

    Age 18 years to Not stated (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  516. Recruiting
    A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
    Phase
    Early phase 1
    Started
    2025-12
    Registry
    NCT07294625

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province Hospital; 4 listed hospitals as study sitesNanjing, Shanghai, Xi'an, Xuzhou, Zhengzhou

  517. Recruiting
    Novel Humanized Ferritin-Based NIR Fluorescent Probe for Identifying Sentinel Lymph Node Metastasis in Early Gastric Cancer
    Phase
    Not given
    Started
    2025-07
    Registry
    NCT07294638

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang HospitalGuangzhou

  518. Recruiting
    PDL1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07294664

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  519. Recruiting
    FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07296458

    Age 18 years to 75 years (registered criteria)

    Led by Xijing Hospital; 1 listed hospital as study siteGuangzhou, Xi'an

  520. Recruiting
    Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients
    Phase
    Not given
    Started
    2025-07
    Registry
    NCT07296627

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  521. Recruiting
    A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07297329

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  522. Recruiting
    Clinical Trial on the Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastric Cancer
    Phase
    Phase 1
    Started
    2025-12
    Registry
    NCT07298200

    Age 18 years to 70 years (registered criteria)

    Led by Nanjing Drum Tower HospitalNanjing

  523. Recruiting
    Clinical Application of PET Imaging Targeting CLDN18.2 in Malignant Tumors
    Phase
    Not given
    Started
    2025-09
    Registry
    NCT07301814

    Age 18 years to Not stated (registered criteria)

    Led by Union HospitalWuhan

  524. Recruiting
    Individualized Neck Cervical Irradiation Prophylaxis Trial of NPC
    Phase
    Phase 3
    Started
    2025-09
    Registry
    NCT07303023

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChengdu, Chongqing, Hangzhou, Shanghai

  525. Recruiting
    CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
    Phase
    Phase 1
    Started
    2025-12
    Registry
    NCT07305116

    Age 3 years to Not stated (registered criteria)

    Led by Children's Hospital, Zhejiang University School of MedicineHangzhou

  526. Recruiting
    Randomised Controlled Trial of Artificial Intelligence-assisted Health Education
    Phase
    N/A
    Started
    2025-06
    Registry
    NCT07305337

    Age 18 years to 90 years (registered criteria)

    Led by Zhongnan Hospital of Wuhan UniversityWuhan

  527. Recruiting
    High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients
    Phase
    N/A
    Started
    2025-12
    Registry
    NCT07307560

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  528. Recruiting
    Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07311772

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Kunming, Nanning, Shanghai, Shantou, Wuzhou, Zhuhai

  529. Recruiting
    A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 2
    Started
    2025-07
    Registry
    NCT07312188

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  530. Recruiting
    Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07315854

    Age 18 years to 80 years (registered criteria)

    Led by Beijing Friendship HospitalBeijing

  531. Recruiting
    β-alanine in the Treatment of Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07317414

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College Hospital; 2 listed hospitals as study sitesBeijing, Nanjing, Xuzhou

  532. Recruiting
    Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)
    Phase
    Phase 1
    Started
    2025-07
    Registry
    NCT07317609

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  533. Recruiting
    68Ga-BCMA PET/CT in Multiple Myeloma
    Phase
    Phase 2/Phase 3
    Started
    2025-12
    Registry
    NCT07319897

    Age 18 years to 80 years (registered criteria)

    Led by Peking University First Hospital; 2 listed hospitals as study sitesBeijing, Changchun, Shijiazhuang

  534. Recruiting
    DEB-TACE vs cTACE in HCC After TIPS
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07322848

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  535. Recruiting
    NWRD06 DNA Plasmid for HCC After Curative Resection.
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07324304

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Harbin

  536. Recruiting
    Perioprative Study of IBI363 in Patients With MHC-II-Negative Locally Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07325630

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  537. Recruiting
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07327034

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Xuzhou, Yinchuan, Zhengzhou

  538. Recruiting
    QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07327788

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang HospitalGuangzhou

  539. Recruiting
    Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
    Phase
    Phase 3
    Started
    2025-11
    Registry
    NCT07328841

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesChangsha, Guangzhou, Nanning, Shantou, Wuhan, Wuzhou, Zhongshan, Zhuhai

  540. Recruiting
    40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2025-11
    Registry
    NCT07328854

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChangsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Kunming, Nanning, Shantou, Wuzhou, Zhongshan, Zhuhai

  541. Recruiting
    Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07331883

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin Hospital; 2 listed hospitals as study sitesChangchun, Shanghai

  542. Recruiting
    Efcacy and Safety of Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With mFOLFOX in Hepatocellular Carcinoma With High-risk Recurrence Factors
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07337421

    Age 18 years to 75 years (registered criteria)

    Led by Northern Jiangsu People's HospitalYangzhou

  543. Recruiting
    Efficacy and Safety of Icaritin Combined With mFOLFOX in Postoperative HCC With High-risk Recurrence Factors
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07337460

    Age 18 years to 75 years (registered criteria)

    Led by Northern Jiangsu People's HospitalYangzhou

  544. Recruiting
    CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
    Phase
    Early phase 1
    Started
    2025-12
    Registry
    NCT07337785

    Age 18 years to 70 years (registered criteria)

    Led by Tongji HospitalWuhan

  545. Recruiting
    Prospective Single-Arm Clinical Trial of GO Regimen for HLH.
    Phase
    Phase 2/Phase 3
    Started
    2025-06
    Registry
    NCT07339345

    Age 14 years to 70 years (registered criteria)

    Led by Beijing Friendship HospitalBeijing

  546. Recruiting
    Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07339488

    Age 18 years to 75 years (registered criteria)

    Led by Shantou University Medical College hospitalsShantou

  547. Recruiting
    Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07340515

    Age 18 years to 70 years (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  548. Recruiting
    Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric Cancer
    Phase
    Phase 2
    Started
    2025-05
    Registry
    NCT07353684

    Age 18 years to 75 years (registered criteria)

    Led by Beijing Friendship HospitalBeijing

  549. Recruiting
    Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma
    Phase
    N/A
    Started
    2025-11
    Registry
    NCT07359014

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  550. Recruiting
    Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia
    Phase
    Not given
    Started
    2025-11
    Registry
    NCT07359586

    Age not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  551. Recruiting
    Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07366528

    Age 18 years to 80 years (registered criteria)

    Led by Ruijin Hospital; 3 listed hospitals as study sitesShanghai

  552. Recruiting
    Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1
    Started
    2025-10
    Registry
    NCT07369895

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  553. Recruiting
    An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2025-12
    Registry
    NCT07371663

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Hangzhou, Zhengzhou

  554. Recruiting
    A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2025-06
    Registry
    NCT07376707

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  555. Recruiting
    Efficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) for Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder (NMOSD)
    Phase
    N/A
    Started
    2025-12
    Registry
    NCT07377305

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu HospitalXi'an

  556. Recruiting
    MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
    Phase
    Phase 1
    Started
    2025-08
    Registry
    NCT07391839

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesFuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing, Shanghai, Zhengzhou

  557. Recruiting
    Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07392346

    Age 18 years to Not stated (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  558. Recruiting
    RCT of EFTR Versus STER for GIST Treatment
    Phase
    N/A
    Started
    2025-02
    Registry
    NCT07411118

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  559. Recruiting
    Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen
    Phase
    Phase 3
    Started
    2025-10
    Registry
    NCT07413809

    Age 18 years to 65 years (registered criteria)

    Led by Affiliated People's Hospital of Ningbo UniversityNingbo

  560. Recruiting
    Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning
    Phase
    Not given
    Started
    2025-11
    Registry
    NCT07417800

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  561. Recruiting
    Exploratory Clinical Trial of Oral Paclitaxel Plus Radiotherapy in Patients With Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07435454

    Age 70 years to Not stated (registered criteria)

    Led by Jiangsu Cancer HospitalNanjing

  562. Recruiting
    Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arterial Infusion Chemotherapy Combined With Targeted and Immunotherapy
    Phase
    Not given
    Started
    2025-12
    Registry
    NCT07436845

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang HospitalGuangzhou

  563. Recruiting
    CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
    Phase
    Phase 3
    Started
    2025-11
    Registry
    NCT07441291

    Age 3 years to 79 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  564. Recruiting
    A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07464912

    Age 40 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  565. Recruiting
    cfDNA Methylation for Liver Cancer Recurrence Detection
    Phase
    Not given
    Started
    2025-09
    Registry
    NCT07466602

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan

  566. Recruiting
    KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07481058

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  567. Recruiting
    Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis
    Phase
    N/A
    Started
    2025-10
    Registry
    NCT07488728

    Age Not stated to 18 years (registered criteria)

    Led by Beijing Children's HospitalBeijing

  568. Recruiting
    Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07489534

    Age 14 years to Not stated (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  569. Recruiting
    A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection
    Phase
    Phase 1/Phase 2
    Started
    2025-09
    Registry
    NCT07495215

    Age 18 years to 75 years (registered criteria)

    Led by Sir Run Run Shaw HospitalHangzhou

  570. Recruiting
    Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
    Phase
    Not given
    Started
    2025-11
    Registry
    NCT07497165

    Age 18 years to 75 years (registered criteria)

    Led by Shanxi Bethune HospitalTaiyuan

  571. Recruiting
    A Multicenter, Randomized, Open-Label Study of Haplo-Cord HSCT for the Treatment of Aplastic Anemia
    Phase
    N/A
    Started
    2025-10
    Registry
    NCT07499284

    Age 14 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow University; 2 listed hospitals as study sitesHangzhou, Suzhou, Xuzhou

  572. Recruiting
    IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07509086

    Age 18 years to 80 years (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  573. Recruiting
    Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07530094

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanjing

  574. Recruiting
    Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment
    Phase
    Phase 2
    Started
    2025-07
    Registry
    NCT07559864

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  575. Recruiting
    Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT07564453

    Age 15 years to 65 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  576. Recruiting
    Brain Cognitive Network Abnormalities in Anemia Patients Using fNIRS
    Phase
    Not given
    Started
    2025-10
    Registry
    NCT07578675

    Age 18 years to 65 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  577. Recruiting
    Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07581821

    Age 18 years to 65 years (registered criteria)

    Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai

  578. Recruiting
    Early Application of Budesonide Enteric-coated Capsules in the Treatment of Primary IgA Nephropathy.
    Phase
    Not given
    Started
    2025-10
    Registry
    NCT07585981

    Age 18 years to Not stated (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  579. Recruiting
    Single-port Versus Conventional Laparoscopic Surgery for Radical Proximal Gastric Cancer: A Randomized Controlled Trial
    Phase
    N/A
    Started
    2025-11
    Registry
    NCT07586384

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Wenzhou Medical UniversityWenzhou

  580. Recruiting
    To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
    Phase
    Phase 1
    Started
    2025-08
    Registry
    NCT07594964

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing

  581. Recruiting
    A IIT Study of 177Lu-DOTA-SNA040
    Phase
    Early phase 1
    Started
    2025-11
    Registry
    NCT07595237

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  582. Recruiting
    KXV01 Injection in Patients With Advanced Solid Tumor (Including Osteosarcoma and Sarcoma)
    Phase
    Phase 1
    Started
    2025-12
    Registry
    NCT07596693

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  583. Recruiting
    A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA Nephropathy
    Phase
    Phase 2
    Started
    2025-08
    Registry
    NCT07616700

    Age not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  584. Recruiting
    Exploratory Clinical Study of Camrelizumab Combined With Concurrent Chemoradiotherapy as an Organ-preserving Strategy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07622797

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Henan University of Science and TechnologyLuoyang

  585. Recruiting
    Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2025-07
    Registry
    NCT07652138

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  586. Recruiting
    TAIC FOLFOX for Locally Advanced G/GEJA
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07655024

    Age 18 years to Not stated (registered criteria)

    Led by Guang'anmen HospitalBeijing

  587. Recruiting
    Prospective Evaluation of Dynamic Serum ProGRP for Treatment Response Monitoring in Ewing Sarcoma
    Phase
    Not given
    Started
    2025-09
    Registry
    NCT07725783

    Age 10 years to 60 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  588. Recruiting
    The Necessity of Surgery in Patients With mGC Achieving Radiological Response After Conversion Therapy
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07757165

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  589. Recruiting
    Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients
    Phase
    Not given
    Started
    2025-08
    Registry
    NCT07763054

    Age 18 years to 75 years (registered criteria)

    Led by Affiliated Hospital of Central South UniversityHaikou

  590. Recruiting
    Peg IFNα-2b Therapy for Unresectable Mid to Late Stage HBV-HCC
    Phase
    N/A
    Started
    2025-12
    Registry
    NCT07769827

    Age 18 years to Not stated (registered criteria)

    Led by Jinling HospitalNanjing

  591. Recruiting
    A Random, Non-controlled, Open Clinical Study of Apatinib Mesylate Combined With Albumin-bound Paclitaxel ± Adebrelimab in Treating Advanced Second-line Gastric Cancer
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07770113

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou University; 1 listed hospital as study siteLuoyang, Zhengzhou

  592. Recruiting
    Adebrelimab With Famitinib and Chemotherapy as Neoadjuvant Therapy for ESCC
    Phase
    Phase 2
    Started
    2025-10
    Registry
    NCT07796113

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Xi'an Jiaotong UniversityXi'an

  593. Recruiting
    Anlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II Study
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT07806292

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  594. Recruiting
    Predicting Efficacy of Preoperative Immunotherapy in Advanced Gastric Cancer
    Phase
    Not given
    Started
    2025-06
    Registry
    NCT07824479

    Age 18 years to 80 years (registered criteria)

    Led by Ruijin HospitalShanghai

  595. Recruiting
    Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT07832006

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  596. Recruiting
    Neoadjuvant Iparomlimab and Tuvonralimab With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal Junction Cancer
    Phase
    Phase 2
    Started
    2025-02
    Registry
    NCT07867392

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  597. Recruiting
    Candonilimab Combined With Fruquintinib and Paclitaxel Albumin-Bound as Second-Line Treatment for Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
    Phase
    Phase 2
    Started
    2025-07
    Registry
    NCT07920224

    Age 18 years to 75 years (registered criteria)

    Led by Union HospitalWuhan

  598. Recruiting
    Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in China
    Phase
    Not given
    Started
    2024-02
    Registry
    NCT04535843

    Age 0 years to 90 years (registered criteria)

    Led by Huashan Hospital; 1 listed hospital as study siteShanghai

  599. Recruiting
    Exploring the Difference Between Gastric Cardia Cancer and Non-cardia Gastric Cancer Based on Multiomics
    Phase
    Not given
    Started
    2024-03
    Registry
    NCT05812287

    Age 18 years to 75 years (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  600. Recruiting
    Feasibility and Safety of Robotic Assisted Proximal Gastrectomy With Double-flap Technique for Proximal Early Gastric Cancer
    Phase
    N/A
    Started
    2024-06
    Registry
    NCT05892289

    Age 20 years to 80 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  601. Recruiting
    IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
    Phase
    Phase 3
    Started
    2024-01
    Registry
    NCT05941741

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 2 listed hospitals as study sitesGuangzhou, Nanchang, Nanning

  602. Recruiting
    A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
    Phase
    Phase 2
    Started
    2024-01
    Registry
    NCT05956587

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChongqing, Fuzhou, Guangzhou, Hangzhou, Linyi, Liuzhou, Nanchang, Tianjin, Wuhan, Xi'an, Zhengzhou

  603. Recruiting
    Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine
    Phase
    Phase 1
    Started
    2024-03
    Registry
    NCT06060782

    Age 18 years to 65 years (registered criteria)

    Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai

  604. Recruiting
    A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Registry
    NCT06083207

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Nanjing, Nanning, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an, Xuzhou

  605. Recruiting
    Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs
    Phase
    Phase 2/Phase 3
    Started
    2024-01
    Registry
    NCT06111638

    Age 18 years to Not stated; men only (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Guiyang, Kunming, Suzhou, Tianjin, Wuhan, Xi'an

  606. Recruiting
    SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen
    Phase
    Phase 3
    Started
    2024-01
    Registry
    NCT06123494

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  607. Recruiting
    Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
    Phase
    N/A
    Started
    2024-09
    Registry
    NCT06128252

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu Hospital; 11 listed hospitals as study sitesChongqing, Nanjing, Shanghai, Shenyang, Urumqi, Wuhan, Xi'an

  608. Recruiting
    NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor
    Phase
    Phase 1
    Started
    2024-11
    Registry
    NCT06134960

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  609. Recruiting
    Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore
    Phase
    Phase 2
    Started
    2024-06
    Registry
    NCT06157996

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang HospitalGuangzhou

  610. Recruiting
    A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
    Phase
    Phase 2
    Started
    2024-02
    Registry
    NCT06172478

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChengdu, Guangzhou

  611. Recruiting
    CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL
    Phase
    Phase 2
    Started
    2024-01
    Registry
    NCT06179524

    Age Not stated to 25 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  612. Recruiting
    The Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC
    Phase
    Not given
    Started
    2024-01
    Registry
    NCT06182657

    Age 18 years to Not stated (registered criteria)

    Led by Jiangxi Cancer HospitalNanchang

  613. Recruiting
    Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2024-09
    Registry
    NCT06194656

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  614. Recruiting
    A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer
    Phase
    Phase 3
    Started
    2024-02
    Registry
    NCT06194734

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  615. Recruiting
    AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer
    Phase
    Phase 2
    Started
    2024-04
    Registry
    NCT06196697

    Age 18 years to 75 years (registered criteria)

    Led by Harbin Medical University HospitalHarbin

  616. Recruiting
    Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC
    Phase
    Not given
    Started
    2024-07
    Registry
    NCT06197776

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  617. Recruiting
    Evaluation of the Safety, Tolerability and Efficacy of a Gene Therapy Drug for the Treatment of Pediatric Fabry Disease
    Phase
    Early phase 1
    Started
    2024-02
    Registry
    NCT06207552

    Age 7 years to 18 years (registered criteria)

    Led by Children's Hospital of Fudan UniversityShanghai

  618. Recruiting
    Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2024-03
    Registry
    NCT06215651

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  619. Recruiting
    DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
    Phase
    Phase 2/Phase 3
    Started
    2024-02
    Registry
    NCT06221748

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Chengdu, Harbin, Jinan, Kunming, Qingdao, Shanghai, Wuhan, Xiamen, Xuzhou, Zhengzhou

  620. Recruiting
    Adjuvant vs Surgery Only in Early-stage Recurrent NPC
    Phase
    Phase 3
    Started
    2024-06
    Registry
    NCT06228079

    Age 18 years to 75 years (registered criteria)

    Led by Eye & ENT Hospital of Fudan University; 6 listed hospitals as study sitesFuzhou, Nanning, Shanghai, Shenzhen

  621. Recruiting
    The Prognostic Value of CPCs Quantified by Flow Cytometry in Patients With Multiple Myeloma: a Prospective, Multicenter Clinical Trial
    Phase
    Not given
    Started
    2024-04
    Registry
    NCT06228794

    Age 18 years to 80 years (registered criteria)

    Led by Union HospitalWuhan

  622. Recruiting
    A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.
    Phase
    Phase 1/Phase 2
    Started
    2024-02
    Registry
    NCT06232096

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  623. Recruiting
    Early Detection and Post-operative Monitoring of Gastric Cancer
    Phase
    Not given
    Started
    2024-02
    Registry
    NCT06232395

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  624. Recruiting
    Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC
    Phase
    Phase 3
    Started
    2024-07
    Registry
    NCT06235203

    Age 18 years to 75 years (registered criteria)

    Led by Eye & ENT Hospital of Fudan University; 6 listed hospitals as study sitesFuzhou, Nanning, Shanghai, Shenzhen

  625. Recruiting
    Safety and Efficacy Study of NGGT003 in Hemophilia A Patients
    Phase
    Early phase 1
    Started
    2024-01
    Registry
    NCT06238908

    Age 18 years to Not stated; men only (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  626. Recruiting
    Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
    Phase
    Phase 3
    Started
    2024-03
    Registry
    NCT06239727

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 21 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Dongguan, Foshan, Fuzhou, Guangzhou, Guiyang, Haikou, Hangzhou, Nanchang, Nanjing, Nanning, Shantou, Tianjin, Wuhan, Xi'an, Xiamen, Zhanjiang

  627. Recruiting
    Immunotherapy for Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2024-03
    Registry
    NCT06241326

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  628. Recruiting
    Myasthenia Gravis Registry in China
    Phase
    Not given
    Started
    2024-02
    Registry
    NCT06241521

    Age not stated (registered criteria)

    Led by Huashan Hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Nanchang, Shanghai, Suzhou, Tianjin, Xi'an, Xuzhou, Zhengzhou

  629. Recruiting
    A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
    Phase
    Phase 2/Phase 3
    Started
    2024-02
    Registry
    NCT06241599

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  630. Recruiting
    Individualized Elective Neck Irradiation in NPC Patients
    Phase
    Phase 3
    Started
    2024-04
    Registry
    NCT06241612

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  631. Recruiting
    HAIC (Hepatic Artery Infusion Chemotherapy,HAIC)Plus Sintilimab and Donafenib in the First-line Treatment of Unresectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2024-01
    Registry
    NCT06244225

    Age 18 years to Not stated (registered criteria)

    Led by Union HospitalWuhan

  632. Recruiting
    A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
    Phase
    Phase 1
    Started
    2024-03
    Registry
    NCT06249438

    Age 18 years to 70 years (registered criteria)

    Led by Renji HospitalShanghai

  633. Recruiting
    RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.
    Phase
    Phase 2
    Started
    2024-02
    Registry
    NCT06250959

    Age 15 years to 65 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  634. Recruiting
    Efficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma (ESICON)
    Phase
    Phase 2
    Started
    2024-03
    Registry
    NCT06255210

    Age 18 years to Not stated (registered criteria)

    Led by Eye & ENT Hospital of Fudan UniversityShanghai

  635. Recruiting
    Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases
    Phase
    N/A
    Started
    2024-02
    Registry
    NCT06265350

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  636. Recruiting
    A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers.
    Phase
    Early phase 1
    Started
    2024-01
    Registry
    NCT06267183

    Age 18 years to 45 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  637. Recruiting
    Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of Immunotherapy
    Phase
    Phase 2
    Started
    2024-03
    Registry
    NCT06272214

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  638. Recruiting
    Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2024-03
    Registry
    NCT06277050

    Age 18 years to 70 years (registered criteria)

    Led by Jiangxi Cancer Hospital; 2 listed hospitals as study sitesGanzhou, Nanchang

  639. Recruiting
    UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
    Phase
    N/A
    Started
    2024-04
    Registry
    NCT06279026

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteSuzhou

  640. Recruiting
    A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib
    Phase
    Phase 2
    Started
    2024-03
    Registry
    NCT06280105

    Age 18 years to 75 years (registered criteria)

    Led by Mengchao Hepatobiliary Hospital of Fujian Medical UniversityFuzhou

  641. Recruiting
    Impact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With Cirrhotic Portal Hypertension
    Phase
    Not given
    Started
    2024-03
    Registry
    NCT06280313

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  642. Recruiting
    β-Thalassemia Treatment With KL003 Cell Injection
    Phase
    Phase 1/Phase 2
    Started
    2024-04
    Registry
    NCT06280378

    Age 3 years to 35 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Tianjin

  643. Recruiting
    The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases
    Phase
    Phase 1
    Started
    2024-03
    Registry
    NCT06285279

    Age 18 years to 65 years (registered criteria)

    Led by Jinling HospitalNanjing

  644. Recruiting
    A Mucosal Contouring Method Based on Swallowing-induced Breakthrough Pain for Radiation-induced Oropharyngeal Mucositis
    Phase
    Not given
    Started
    2024-03
    Registry
    NCT06287788

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang HospitalGuangzhou

  645. Recruiting
    A Prospective Study on Esophagogastrostomy by an Innovative Surgical Technique
    Phase
    N/A
    Started
    2024-01
    Registry
    NCT06300879

    Age 18 years to 75 years (registered criteria)

    Led by Huashan HospitalShanghai

  646. Recruiting
    TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2024-03
    Registry
    NCT06301165

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesDongguan, Foshan, Guangzhou, Shenzhen, Wuhan

  647. Recruiting
    Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study
    Phase
    Phase 2
    Started
    2024-03
    Registry
    NCT06301399

    Age 17 years to 79 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  648. Recruiting
    Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2024-02
    Registry
    NCT06304350

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  649. Recruiting
    Effectiveness of Risk-based Sequential Screening for Esophageal and Gastric Cancer
    Phase
    N/A
    Started
    2024-06
    Registry
    NCT06306755

    Age 50 years to 69 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  650. Recruiting
    Plasma SAA1 Levels in Predicting Response to Radiotherapy-induced Oral Mucositis
    Phase
    Not given
    Started
    2024-02
    Registry
    NCT06307314

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang HospitalGuangzhou

  651. Recruiting
    The Safety and Efficacy of RD06-03 CART Cell Injection in Patients With R/R Acute B-lymphoblastic Leukemia
    Phase
    Early phase 1
    Started
    2024-03
    Registry
    NCT06307600

    Age 3 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of USTC; 1 listed hospital as study siteHefei, Wuhan

  652. Recruiting
    A Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2024-03
    Registry
    NCT06307925

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  653. Recruiting
    A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal Mucositis
    Phase
    Not given
    Started
    2024-04
    Registry
    NCT06308328

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang Hospital; 9 listed hospitals as study sitesChengdu, Guangzhou, Shanghai, Shaoguan, Shenzhen, Zhuhai

  654. Recruiting
    Phase 2 Study of WGI-0301 for Advanced HCC
    Phase
    Phase 2
    Started
    2024-07
    Registry
    NCT06309485

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangsha, Chengdu, Hangzhou, Harbin, Nanchang, Wuhan

  655. Recruiting
    Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma
    Phase
    Phase 4
    Started
    2024-04
    Registry
    NCT06311929

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  656. Recruiting
    Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402)
    Phase
    Phase 2
    Started
    2024-04
    Registry
    NCT06313190

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  657. Recruiting
    De-escalated Radiotherapy for Primary Tumor After Neoadjuvant Therapy With Toripalimab Plus Chemotherapy for Nasopharyngeal Carcinoma
    Phase
    N/A
    Started
    2024-03
    Registry
    NCT06313450

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  658. Recruiting
    Metronomic Capecitabine in Stage III Gastric Cancer
    Phase
    Phase 3
    Started
    2024-03
    Registry
    NCT06313567

    Age 18 years to 80 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  659. Recruiting
    Sequencing-based Counting of Plasma Epstein-Barr Virus DNA in Non-metastatic Nasopharyngeal Carcinoma
    Phase
    Not given
    Started
    2024-01
    Registry
    NCT06321939

    Age 18 years to Not stated (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  660. Recruiting
    SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2024-07
    Registry
    NCT06323239

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  661. Recruiting
    Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
    Phase
    Phase 1/Phase 2
    Started
    2024-06
    Registry
    NCT06324357

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangchun, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Zhengzhou

  662. Recruiting
    Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer
    Phase
    Phase 3
    Started
    2024-03
    Registry
    NCT06338683

    Age 18 years to 80 years (registered criteria)

    Led by Qinghai Red Cross HospitalXining

  663. Recruiting
    Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2024-03
    Registry
    NCT06339619

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  664. Recruiting
    Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma
    Phase
    Phase 1
    Started
    2024-03
    Registry
    NCT06340204

    Age 8 years to 40 years (registered criteria)

    Led by Peking University People's Hospital; 2 listed hospitals as study sitesBeijing, Jinan

  665. Recruiting
    Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM
    Phase
    Phase 2
    Started
    2024-04
    Registry
    NCT06341595

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  666. Recruiting
    Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2024-03
    Registry
    NCT06342167

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesAnyang, Fuzhou, Taizhou, Tianjin, Xinxiang, Yinchuan

  667. Recruiting
    Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients
    Phase
    N/A
    Started
    2024-04
    Registry
    NCT06343090

    Age 1 year to 70 years (registered criteria)

    Led by Beijing GoBroad HospitalBeijing

  668. Recruiting
    Fecal Microbiota Transplantation (FMT) in Patients With Advanced Gastric Cancer
    Phase
    N/A
    Started
    2024-04
    Registry
    NCT06346093

    Age 18 years to Not stated (registered criteria)

    Led by Changhai HospitalShanghai

  669. Recruiting
    CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL
    Phase
    Early phase 1
    Started
    2024-05
    Registry
    NCT06346912

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  670. Recruiting
    Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT
    Phase
    Phase 2
    Started
    2024-04
    Registry
    NCT06349317

    Age 18 years to 75 years (registered criteria)

    Led by Mengchao Hepatobiliary Hospital of Fujian Medical UniversityFuzhou

  671. Recruiting
    Adebrelimab and Chemoradiotherapy in High-risk LANPC
    Phase
    Phase 2
    Started
    2024-07
    Registry
    NCT06349889

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 3 listed hospitals as study sitesChengdu, Guangzhou, Xiamen

  672. Recruiting
    A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.
    Phase
    Phase 2
    Started
    2024-08
    Registry
    NCT06349980

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  673. Recruiting
    DEB-TACE Prior to Liver Transplantation in the Treatment of HCC
    Phase
    Phase 4
    Started
    2024-10
    Registry
    NCT06353126

    Age 18 years to 75 years (registered criteria)

    Led by Renji HospitalShanghai

  674. Recruiting
    PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY
    Phase
    Phase 2
    Started
    2024-05
    Registry
    NCT06354140

    Age 18 years to 75 years (registered criteria)

    Led by Daping Hospital, Army Medical UniversityChongqing

  675. Recruiting
    CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+
    Phase
    N/A
    Started
    2024-02
    Registry
    NCT06355739

    Age 3 years to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  676. Recruiting
    Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC
    Phase
    Phase 2
    Started
    2024-01
    Registry
    NCT06360042

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  677. Recruiting
    Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer
    Phase
    Phase 1
    Started
    2024-03
    Registry
    NCT06363006

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  678. Recruiting
    Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis
    Phase
    Phase 1
    Started
    2024-07
    Registry
    NCT06371040

    Age 18 years to 80 years (registered criteria)

    Led by Tangdu HospitalXi'an

  679. Recruiting
    A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma
    Phase
    Phase 3
    Started
    2024-08
    Registry
    NCT06371157

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesChangsha, Hangzhou, Nanjing, Zhengzhou

  680. Recruiting
    Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1
    Started
    2024-05
    Registry
    NCT06375044

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Nanjing, Tianjin, Zhengzhou

  681. Recruiting
    Biomarkers and Molecular Mechanism Study of Hepatocellular Carcinoma After Radical Resection and Conversion Therapy
    Phase
    Not given
    Started
    2024-05
    Registry
    NCT06382103

    Age not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  682. Recruiting
    PET Imaging Study of 68Ga-NB381 in Multiple Myeloma
    Phase
    Early phase 1
    Started
    2024-04
    Registry
    NCT06385652

    Age 18 years to 90 years (registered criteria)

    Led by Peking University First HospitalBeijing

  683. Recruiting
    Neoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS)
    Phase
    Phase 2
    Started
    2024-06
    Registry
    NCT06385730

    Age 76 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  684. Recruiting
    Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL
    Phase
    Phase 2
    Started
    2024-04
    Registry
    NCT06387121

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  685. Recruiting
    Pretreatment With HCQ Before Radiotherapy and Chemotherapy in Advanced NPC Patients
    Phase
    N/A
    Started
    2024-08
    Registry
    NCT06389201

    Age 20 years to 70 years (registered criteria)

    Led by Affiliated Hospital of Nantong UniversityNantong

  686. Recruiting
    CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction
    Phase
    N/A
    Started
    2024-05
    Registry
    NCT06389305

    Age 1 year to 39 years (registered criteria)

    Led by Beijing GoBroad HospitalBeijing

  687. Recruiting
    Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis
    Phase
    Phase 2
    Started
    2024-05
    Registry
    NCT06389422

    Age 18 years to 90 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  688. Recruiting
    Evaluation of the Safety and Efficacy of Late-onset Pompe Disease Gene Therapy Drug
    Phase
    Phase 1/Phase 2
    Started
    2024-04
    Registry
    NCT06391736

    Age 6 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  689. Recruiting
    Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL
    Phase
    Phase 2
    Started
    2024-04
    Registry
    NCT06393985

    Age 18 years to 65 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  690. Recruiting
    Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC
    Phase
    Phase 2
    Started
    2024-05
    Registry
    NCT06397222

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  691. Recruiting
    DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC
    Phase
    Phase 2
    Started
    2024-05
    Registry
    NCT06397235

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  692. Recruiting
    FMT+SOX+Sintilimab As First-line Treatment for Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2024-06
    Registry
    NCT06405113

    Age 18 years to 80 years (registered criteria)

    Led by Changzhou No.2 People's HospitalChangzhou

  693. Recruiting
    Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2024-05
    Registry
    NCT06406634

    Age 18 years to 75 years (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  694. Recruiting
    Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma
    Phase
    Early phase 1
    Started
    2024-06
    Registry
    NCT06407947

    Age 18 years to Not stated (registered criteria)

    Led by Changzheng HospitalShanghai

  695. Recruiting
    Short-course Hypofractionated Radiotherapy in Combination With Raltitrexed and Tislelizumab
    Phase
    Not given
    Started
    2024-03
    Registry
    NCT06408584

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of USTCHefei

  696. Recruiting
    Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
    Phase
    Phase 4
    Started
    2024-06
    Registry
    NCT06409702

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  697. Recruiting
    Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2024-06
    Registry
    NCT06413342

    Age 70 years to 85 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  698. Recruiting
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    Phase
    Phase 2/Phase 3
    Started
    2024-07
    Registry
    NCT06413654

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Zhengzhou

  699. Recruiting
    A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 2
    Started
    2024-05
    Registry
    NCT06415669

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Xiamen UniversityXiamen

  700. Recruiting
    Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma
    Phase
    Not given
    Started
    2024-04
    Registry
    NCT06417892

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  701. Recruiting
    A Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC Patients
    Phase
    Early phase 1
    Started
    2024-10
    Registry
    NCT06418659

    Age 18 years to Not stated (registered criteria)

    Led by Changzheng HospitalShanghai

  702. Recruiting
    Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer
    Phase
    Phase 2
    Started
    2024-05
    Registry
    NCT06421376

    Age 18 years to 80 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMS; 2 listed hospitals as study sitesAnyang, Beijing, Xinxiang

  703. Recruiting
    Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients
    Phase
    Phase 1/Phase 2
    Started
    2024-05
    Registry
    NCT06421831

    Age 2 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  704. Recruiting
    Targeting NUDT21 siRNA Drugs for Patients With Refractory Retinoblastoma
    Phase
    Early phase 1
    Started
    2024-12
    Registry
    NCT06424301

    Age 6 months to Not stated (registered criteria)

    Led by Eye & ENT Hospital of Fudan UniversityShanghai

  705. Recruiting
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Registry
    NCT06427941

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou

  706. Recruiting
    Research on Early Diagnosis and Clinical Transformation of Nuclide Probe Based on Bioorthogonal-gastric Cancer Mucin Target Visualization
    Phase
    N/A
    Started
    2024-08
    Registry
    NCT06429891

    Age 18 years to 70 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  707. Recruiting
    Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer
    Phase
    Phase 2
    Started
    2024-04
    Registry
    NCT06430658

    Age 18 years to 75 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  708. Recruiting
    Recurrent Liver Cancer: Reconceptualization and Reevaluation
    Phase
    Not given
    Started
    2024-07
    Registry
    NCT06430983

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Nanjing Medical UniversityNanjing

  709. Recruiting
    A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
    Phase
    Phase 2
    Started
    2024-06
    Registry
    NCT06437522

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  710. Recruiting
    Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial
    Phase
    Phase 3
    Started
    2024-05
    Registry
    NCT06438627

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  711. Recruiting
    Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma
    Phase
    Not given
    Started
    2024-05
    Registry
    NCT06445088

    Age not stated (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 4 listed hospitals as study sitesFuzhou, Guangzhou, Nanning, Wuzhou, Zhongshan

  712. Recruiting
    CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL
    Phase
    Phase 1
    Started
    2024-05
    Registry
    NCT06445803

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanchang, Shanghai

  713. Recruiting
    Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2024-12
    Registry
    NCT06446154

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  714. Recruiting
    Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2024-06
    Registry
    NCT06446726

    Age 18 years to 75 years (registered criteria)

    Led by West China HospitalChengdu

  715. Recruiting
    A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
    Phase
    Phase 2/Phase 3
    Started
    2024-07
    Registry
    NCT06447597

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Wuhan, Xi'an, Zunyi

  716. Recruiting
    Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
    Phase
    Not given
    Started
    2024-06
    Registry
    NCT06450067

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Jinan, Shanghai, Tianjin, Wuhan, Xuzhou, Zhengzhou

  717. Recruiting
    Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.
    Phase
    Phase 2
    Started
    2024-06
    Registry
    NCT06452602

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  718. Recruiting
    Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection
    Phase
    Phase 2
    Started
    2024-07
    Registry
    NCT06454578

    Age 18 years to Not stated (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  719. Recruiting
    GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2024-06
    Registry
    NCT06455410

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen Memorial Hospital; 7 listed hospitals as study sitesFoshan, Guangzhou, Liuzhou, Nanning, Shantou, Shenzhen

  720. Recruiting
    Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2024-07
    Registry
    NCT06461624

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  721. Recruiting
    Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 2
    Started
    2024-06
    Registry
    NCT06461910

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  722. Recruiting
    Deep Learning-based sbORN Diagnostic Model
    Phase
    Not given
    Started
    2024-07
    Registry
    NCT06463392

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  723. Recruiting
    Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
    Phase
    Phase 3
    Started
    2024-06
    Registry
    NCT06463587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Shanghai, Shenyang, Shijiazhuang, Wuhan, Zhengzhou, Zunyi

  724. Recruiting
    A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2024-03
    Registry
    NCT06463834

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Cancer HospitalFuzhou

  725. Recruiting
    Stapler Reinforcement Patches Compared to Standard Staplers in Gastrojejunostomy
    Phase
    N/A
    Started
    2024-05
    Registry
    NCT06464978

    Age 18 years to 85 years (registered criteria)

    Led by Nanchong Central HospitalNanchong

  726. Recruiting
    A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
    Phase
    Phase 1
    Started
    2024-07
    Registry
    NCT06465069

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Shanghai

  727. Recruiting
    A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major
    Phase
    Phase 1
    Started
    2024-01
    Registry
    NCT06465550

    Age 3 years to 35 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou, Nanning, Shanghai

  728. Recruiting
    Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC
    Phase
    Phase 2
    Started
    2024-09
    Registry
    NCT06467799

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  729. Recruiting
    Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06468280

    Age 18 years to 79 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  730. Recruiting
    Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
    Phase
    Phase 1/Phase 2
    Started
    2024-09
    Registry
    NCT06469944

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBeijing, Fuzhou, Hangzhou, Nanchang, Shanghai, Urumqi, Xiamen, Zhengzhou

  731. Recruiting
    Palliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2024-06
    Registry
    NCT06470256

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  732. Recruiting
    Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC
    Phase
    Phase 2
    Started
    2024-07
    Registry
    NCT06472713

    Age 18 years to 70 years (registered criteria)

    Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai

  733. Recruiting
    Efficacy and Safety of Calculus Bovis Sativus (CBS) for Idiopathic Inflammatory Demyelinating Disease (CBSinIIDD)
    Phase
    N/A
    Started
    2024-08
    Registry
    NCT06474520

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  734. Recruiting
    A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
    Phase
    Phase 2
    Started
    2024-06
    Registry
    NCT06475300

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  735. Recruiting
    Backline Treatment of Advanced Hepatocellular Carcinoma With Palbociclib
    Phase
    N/A
    Started
    2024-01
    Registry
    NCT06478927

    Age 18 years to 75 years (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  736. Recruiting
    A Long-term Follow-up Study in Participants Who Received CS-101
    Phase
    N/A
    Started
    2024-06
    Registry
    NCT06479616

    Age 3 years to 17 years (registered criteria)

    Led by Children's Hospital of Fudan UniversityShanghai

  737. Recruiting
    Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL
    Phase
    N/A
    Started
    2024-06
    Registry
    NCT06481228

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  738. Recruiting
    Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL
    Phase
    N/A
    Started
    2024-06
    Registry
    NCT06481241

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  739. Recruiting
    Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT
    Phase
    Phase 2
    Started
    2024-06
    Registry
    NCT06482801

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  740. Recruiting
    A Clinical Study of SHR-9539 in Patients With Multiple Myeloma
    Phase
    Phase 1
    Started
    2024-08
    Registry
    NCT06484777

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteChengdu

  741. Recruiting
    Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2024-03
    Registry
    NCT06484829

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteChengdu

  742. Recruiting
    TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma
    Phase
    Phase 3
    Started
    2024-08
    Registry
    NCT06485466

    Age 18 years to 80 years (registered criteria)

    Led by Sichuan Cancer HospitalChengdu

  743. Recruiting
    Short Course Radiotherapy With Sequential Disitamab Vedotin Combined With S-1 and Sintilimab as Whole Course Neoadjuvant Therapy for HER2 Expressed Locally Progressive Gastric Cancer
    Phase
    Phase 2
    Started
    2024-05
    Registry
    NCT06487429

    Age 18 years to 75 years (registered criteria)

    Led by Union HospitalWuhan

  744. Recruiting
    AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06489197

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  745. Recruiting
    Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT
    Phase
    Phase 3
    Started
    2024-08
    Registry
    NCT06492395

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  746. Recruiting
    Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.
    Phase
    Phase 2
    Started
    2024-07
    Registry
    NCT06492408

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  747. Recruiting
    Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease
    Phase
    Early phase 1
    Started
    2024-07
    Registry
    NCT06497361

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  748. Recruiting
    Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease
    Phase
    Early phase 1
    Started
    2024-07
    Registry
    NCT06497387

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  749. Recruiting
    A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma
    Phase
    Not given
    Started
    2024-05
    Registry
    NCT06497738

    Age 65 years to Not stated (registered criteria)

    Led by Jiangsu Province Hospital; 2 listed hospitals as study sitesChangzhou, Nanjing, Nantong

  750. Recruiting
    A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis
    Phase
    Phase 4
    Started
    2024-06
    Registry
    NCT06498089

    Age 18 years to 65 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  751. Recruiting
    Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab
    Phase
    Phase 2
    Started
    2024-07
    Registry
    NCT06498622

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of USTCHefei

  752. Recruiting
    A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
    Phase
    Phase 1
    Started
    2024-07
    Registry
    NCT06500052

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  753. Recruiting
    Biomarkers in Autoimmune Disease of Nervous System
    Phase
    Not given
    Started
    2024-07
    Registry
    NCT06502015

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  754. Recruiting
    To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer
    Phase
    Phase 2/Phase 3
    Started
    2024-08
    Registry
    NCT06504732

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHarbin, Shenyang

  755. Recruiting
    A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC)
    Phase
    Phase 2
    Started
    2024-07
    Registry
    NCT06506292

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  756. Recruiting
    Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL
    Phase
    Phase 1
    Started
    2024-04
    Registry
    NCT06507514

    Age 15 years to 65 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  757. Recruiting
    Evaluate the Efficacy and Safety of Radiotherapy Combined With Ripretinib in the Treatment of Unresectable Advanced GIST
    Phase
    N/A
    Started
    2024-05
    Registry
    NCT06507683

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Chongqing Medical UniversityChongqing

  758. Recruiting
    A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
    Phase
    Phase 3
    Started
    2024-06
    Registry
    NCT06508983

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Suzhou, Tianjin, Wuhan, Xi'an, Zhengzhou

  759. Recruiting
    Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2024-08
    Registry
    NCT06509009

    Age 18 years to 75 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  760. Recruiting
    Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma(CRIS-2 Trial)
    Phase
    Phase 2
    Started
    2024-08
    Registry
    NCT06509568

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  761. Recruiting
    Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2024-12
    Registry
    NCT06510010

    Age 18 years to 75 years (registered criteria)

    Led by Sixth Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  762. Recruiting
    Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 Encephalitis
    Phase
    Phase 2
    Started
    2024-12
    Registry
    NCT06510283

    Age 14 years to Not stated (registered criteria)

    Led by Beijing Tongren HospitalBeijing

  763. Recruiting
    Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC
    Phase
    Phase 2
    Started
    2024-04
    Registry
    NCT06510660

    Age 18 years to 70 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  764. Recruiting
    CVI Alterations in FD: a Prospective, Multicenter, Observational Cohort Study
    Phase
    Not given
    Started
    2024-12
    Registry
    NCT06512571

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  765. Recruiting
    HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors
    Phase
    Phase 1
    Started
    2024-10
    Registry
    NCT06515314

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  766. Recruiting
    Online Adaptive Radiotherapy for Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2024-05
    Registry
    NCT06516133

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  767. Recruiting
    Prospective Real-World Study of HAIC With Raltitrexed or 5-Fluorouracil for the Treatment of Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2024-08
    Registry
    NCT06519578

    Age 18 years to 75 years (registered criteria)

    Led by Renji HospitalShanghai

  768. Recruiting
    Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients
    Phase
    Phase 3
    Started
    2024-08
    Registry
    NCT06520176

    Age 18 years to 75 years (registered criteria)

    Led by Affiliated People's Hospital of Ningbo University; 6 listed hospitals as study sitesHangzhou, Ningbo, Taizhou, Wenzhou

  769. Recruiting
    A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
    Phase
    Phase 1/Phase 2
    Started
    2024-09
    Registry
    NCT06530251

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Jinan

  770. Recruiting
    A Phase I Study of XS-02 Capsules in Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2024-08
    Registry
    NCT06531486

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  771. Recruiting
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    Phase
    Phase 3
    Started
    2024-11
    Registry
    NCT06532006

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lanzhou, Luoyang, Nanchang, Nanjing, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Xiamen, Xining, Xuzhou, Yinchuan, Zhengzhou

  772. Recruiting
    Endoscopic Surgery vs. Intensity Modulated Radiotherapy for Stage I Nasopharyngeal Carcinoma.
    Phase
    N/A
    Started
    2024-03
    Registry
    NCT06533267

    Age 18 years to 75 years (registered criteria)

    Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai

  773. Recruiting
    Anti-PD-1/PD-L1 Antibodies Plus Anti-VEGF Antibody Treatment in Patients With Advanced-Stage HCC
    Phase
    Not given
    Started
    2024-08
    Registry
    NCT06537908

    Age 18 years to 90 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  774. Recruiting
    Evaluate the Safety and Preliminary Efficacy of EXG110 in Subjects With Fabry Disease
    Phase
    N/A
    Started
    2024-10
    Registry
    NCT06539624

    Age 7 years to Not stated (registered criteria)

    Led by Children's Hospital, Zhejiang University School of Medicine; 1 listed hospital as study siteHangzhou, Shanghai

  775. Recruiting
    Intestinal Flora and Immunity in Monoclonal Gammopathy Patients
    Phase
    Not given
    Started
    2024-05
    Registry
    NCT06539832

    Age 45 years to Not stated (registered criteria)

    Led by Zhujiang HospitalGuangzhou

  776. Recruiting
    Sun Yat-Sen Cohort of CNS Idiopathic Inflammatory Demyelinating Diseases
    Phase
    Not given
    Started
    2024-01
    Registry
    NCT06541626

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  777. Recruiting
    Study on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2024-09
    Registry
    NCT06542796

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  778. Recruiting
    Preliminary Study on the Diagnostic Value Comparison of 18F-FAPI-04 PET/CT and PET/MR in Gastric Cancer
    Phase
    Not given
    Started
    2024-01
    Registry
    NCT06543108

    Age 18 years to 90 years (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  779. Recruiting
    Early-stage Detection of Liver Cancer by Proteins in Peripheral Blood
    Phase
    Not given
    Started
    2024-02
    Registry
    NCT06544083

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  780. Recruiting
    Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2024-08
    Registry
    NCT06550921

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  781. Recruiting
    Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL
    Phase
    Phase 2
    Started
    2024-08
    Registry
    NCT06554626

    Age 40 years to Not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  782. Recruiting
    A Single-arm, Phase II Exploratory Study of Sintilimab in Combination With Chemoradiotherapy in Elderly Patients With Locally Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2024-08
    Registry
    NCT06555471

    Age 75 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  783. Recruiting
    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation
    Phase
    Phase 1
    Started
    2024-12
    Registry
    NCT06556394

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Chengdu, Hangzhou

  784. Recruiting
    Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression
    Phase
    Phase 2
    Started
    2024-09
    Registry
    NCT06560528

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  785. Recruiting
    Individualized Tumor-Informed CtDNA Analysis for Monitoring Postoperative Recurrence in ESCC (NEOCRTEC2401)
    Phase
    Not given
    Started
    2024-08
    Registry
    NCT06561178

    Age not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  786. Recruiting
    Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)
    Phase
    Not given
    Started
    2024-08
    Registry
    NCT06561399

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Provincial Hospital; 2 listed hospitals as study sitesFuzhou

  787. Recruiting
    Sintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma
    Phase
    Phase 3
    Started
    2024-02
    Registry
    NCT06563869

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  788. Recruiting
    Oral Fecal Microbiota Transplantation in Advanced Hepatocellular Carcinoma After Progression on ICI-TKI Therapy
    Phase
    Phase 2
    Started
    2024-09
    Registry
    NCT06563947

    Age 18 years to 75 years (registered criteria)

    Led by Shenzhen Third People's HospitalShenzhen

  789. Recruiting
    A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma
    Phase
    Phase 2
    Started
    2024-09
    Registry
    NCT06564272

    Age 12 years to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  790. Recruiting
    Neoadjuvant Triple Therapy for Resectable HCC
    Phase
    Not given
    Started
    2024-09
    Registry
    NCT06569498

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Provincial Hospital; 4 listed hospitals as study sitesFuzhou, Xiamen

  791. Recruiting
    Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens
    Phase
    Phase 1/Phase 2
    Started
    2024-09
    Registry
    NCT06572319

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  792. Recruiting
    A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1
    Started
    2024-06
    Registry
    NCT06574568

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Harbin, Jinan, Taiyuan, Zhengzhou

  793. Recruiting
    Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma
    Phase
    Not given
    Started
    2024-05
    Registry
    NCT06574698

    Age 1 year to 21 years (registered criteria)

    Led by Guangzhou Women and Children's Medical CenterGuangzhou

  794. Recruiting
    Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2024-08
    Registry
    NCT06576973

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  795. Recruiting
    Study of YK012 in B-cell Acute Lymphoblastic Leukemia
    Phase
    Phase 1/Phase 2
    Started
    2024-09
    Registry
    NCT06580301

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesChangchun, Guangzhou, Guiyang, Hangzhou, Nanchang, Xuzhou

  796. Recruiting
    Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers
    Phase
    Phase 2
    Started
    2024-09
    Registry
    NCT06580574

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  797. Recruiting
    Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia
    Phase
    N/A
    Started
    2024-10
    Registry
    NCT06581081

    Age 12 years to 65 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  798. Recruiting
    Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2024-08
    Registry
    NCT06581315

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  799. Recruiting
    Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 2
    Started
    2024-09
    Registry
    NCT06581640

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Xiamen UniversityXiamen

  800. Recruiting
    Lymphocyte-sparing Thoracic Radiotherapy for Esophageal Squamous Cell Carcinoma
    Phase
    N/A
    Started
    2024-06
    Registry
    NCT06596954

    Age 18 years to 80 years (registered criteria)

    Led by Ruijin HospitalShanghai

  801. Recruiting
    Proximal Gastrectomy vs Total Gastrectomy in Locally Advanced Upper Gastric Cancer After Neoadjuvant Therapy
    Phase
    N/A
    Started
    2024-03
    Registry
    NCT06597227

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  802. Recruiting
    The Role of 18F-FDG&68Ga-FAPI PET/CT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastasis.
    Phase
    Not given
    Started
    2024-06
    Registry
    NCT06597526

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  803. Recruiting
    Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC
    Phase
    Phase 2
    Started
    2024-07
    Registry
    NCT06601309

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  804. Recruiting
    Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002)
    Phase
    Not given
    Started
    2024-09
    Registry
    NCT06602011

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Provincial Hospital; 4 listed hospitals as study sitesFuzhou, Xiamen

  805. Recruiting
    ImmunoPET Imaging of Pancreatic Cancer
    Phase
    N/A
    Started
    2024-11
    Registry
    NCT06602037

    Age 18 years to 70 years (registered criteria)

    Led by Renji HospitalShanghai

  806. Recruiting
    Neoadjuvant Chemoimmunotherapy Followed by Surgery and Postoperative Radioimmunotherapy
    Phase
    N/A
    Started
    2024-01
    Registry
    NCT06602843

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of USTCHefei

  807. Recruiting
    mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria
    Phase
    Phase 2
    Started
    2024-02
    Registry
    NCT06607107

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  808. Recruiting
    Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia
    Phase
    Phase 2/Phase 3
    Started
    2024-05
    Registry
    NCT06607419

    Age 1 month to 18 years (registered criteria)

    Led by Shanghai Children's Medical Center; 1 listed hospital as study siteHefei, Shanghai

  809. Recruiting
    Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.
    Phase
    Phase 2
    Started
    2024-08
    Registry
    NCT06608732

    Age 16 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  810. Recruiting
    The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2024-10
    Registry
    NCT06609850

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  811. Recruiting
    dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2024-10
    Registry
    NCT06609863

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  812. Recruiting
    Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC
    Phase
    N/A
    Started
    2024-10
    Registry
    NCT06609876

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  813. Recruiting
    Study of IBI363 in Patients with Advanced First-line Gastric Cancer
    Phase
    Phase 1
    Started
    2024-10
    Registry
    NCT06610799

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  814. Recruiting
    Concurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal Carcinoma
    Phase
    Phase 1
    Started
    2024-08
    Registry
    NCT06611150

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  815. Recruiting
    A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (KYLIN-02)
    Phase
    Phase 3
    Started
    2024-10
    Registry
    NCT06618664

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHefei

  816. Recruiting
    TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT
    Phase
    N/A
    Started
    2024-10
    Registry
    NCT06622031

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  817. Recruiting
    Correlation Study of Lipid Metabolites as Markers of Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2024-07
    Registry
    NCT06623474

    Age 18 years to 80 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  818. Recruiting
    Phase I Study of Umbilical Cord Blood Natural Killer (NK) Cell Therapy for Children With High-risk, R/R Neuroblastoma.
    Phase
    Phase 1
    Started
    2024-11
    Registry
    NCT06631391

    Age 1 day to 18 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  819. Recruiting
    A Phase 2 Clinical Study of ABSK061 and ABSK043
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06632262

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChengdu, Guiyang, Hangzhou, Harbin, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xiamen, Xiangyang, Xuzhou, Zhengzhou

  820. Recruiting
    AI-Assisted Non-Contrast CT for Multi-Cancer Screening
    Phase
    N/A
    Started
    2024-10
    Registry
    NCT06632886

    Age 18 years to Not stated (registered criteria)

    Led by Changhai HospitalShanghai

  821. Recruiting
    CD7 CAR-T Bridging to alloHSCT for Severe Aplastic Anemia
    Phase
    Early phase 1
    Started
    2024-10
    Registry
    NCT06633328

    Age not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  822. Recruiting
    Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC
    Phase
    Phase 2
    Started
    2024-10
    Registry
    NCT06637163

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan University; 4 listed hospitals as study sitesHangzhou, Shanghai, Shantou, Shenyang, Tianjin

  823. Recruiting
    A Study of Olverembatinib in SDH-deficient GIST.
    Phase
    Phase 3
    Started
    2024-11
    Registry
    NCT06640361

    Age 12 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  824. Recruiting
    HAIC Compared With TACE in Huge Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2024-10
    Registry
    NCT06641713

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  825. Recruiting
    Evaluation of the Safety and Efficacy of BBM-D101 to Treat Patients with Duchenne Muscular Dystrophy
    Phase
    Early phase 1
    Started
    2024-07
    Registry
    NCT06641895

    Age 4 years to 8 years; men only (registered criteria)

    Led by Shanghai Children's Medical CenterShanghai

  826. Recruiting
    A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
    Phase
    Phase 1
    Started
    2024-10
    Registry
    NCT06644118

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  827. Recruiting
    Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2024-10
    Registry
    NCT06644430

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  828. Recruiting
    Single-arm Clinical Trial of TACE in Combination With Icaritin as Adjuvant Therapy After Surgery in Patients With Hepatocellular Carcinoma at High Risk of Recurrence
    Phase
    Phase 2/Phase 3
    Started
    2024-11
    Registry
    NCT06644937

    Age 18 years to 75 years (registered criteria)

    Led by Zhujiang HospitalGuangzhou

  829. Recruiting
    Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2024-04
    Registry
    NCT06646588

    Age 18 years to Not stated (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  830. Recruiting
    A Clinical Study to Evaluate the Safety and Efficacy of LY-M003 Injection in Patients With Wilson Disease
    Phase
    Early phase 1
    Started
    2024-09
    Registry
    NCT06650319

    Age 10 years to 60 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  831. Recruiting
    Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Registry
    NCT06650332

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  832. Recruiting
    Umbilical Cord Blood-Supported Haplo-HSCT for Aplastic Anemia Treatment Study
    Phase
    N/A
    Started
    2024-06
    Registry
    NCT06650553

    Age 6 years to 75 years (registered criteria)

    Led by Shanxi Bethune HospitalTaiyuan

  833. Recruiting
    Clinical Study of SN301A Injection in the Treatment of Hepatocellular Carcinoma
    Phase
    Early phase 1
    Started
    2024-11
    Registry
    NCT06652243

    Age 18 years to 70 years (registered criteria)

    Led by Shanghai General HospitalShanghai

  834. Recruiting
    Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Hepatocellular Carcinoma Recurrence Surveillance
    Phase
    Not given
    Started
    2024-11
    Registry
    NCT06653062

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  835. Recruiting
    Efficacy and Safety of Telitacicept in IgAN
    Phase
    N/A
    Started
    2024-12
    Registry
    NCT06654596

    Age 18 years to 70 years (registered criteria)

    Led by Ruijin HospitalShanghai

  836. Recruiting
    IMmune Proteomics to Predict neoAdjuvant Chemotherapy and immunoTherapy Response in Gastric Cancer
    Phase
    Not given
    Started
    2024-08
    Registry
    NCT06662110

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  837. Recruiting
    Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study
    Phase
    Phase 2
    Started
    2024-10
    Registry
    NCT06663059

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu HospitalXi'an

  838. Recruiting
    Clinical Study of Regulatory T Cells (Tregs) in the Treatment of Neurodegenerative Diseases
    Phase
    Phase 1
    Started
    2024-11
    Registry
    NCT06671236

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou

  839. Recruiting
    Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2024-10
    Registry
    NCT06675201

    Age 18 years to 80 years (registered criteria)

    Led by West China HospitalChengdu

  840. Recruiting
    Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.
    Phase
    Phase 3
    Started
    2024-07
    Registry
    NCT06675214

    Age 18 years to 65 years (registered criteria)

    Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai

  841. Recruiting
    A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy
    Phase
    Not given
    Started
    2024-10
    Registry
    NCT06676007

    Age 18 years to 75 years (registered criteria)

    Led by Sichuan Provincial People's HospitalChengdu

  842. Recruiting
    TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC
    Phase
    Phase 3
    Started
    2024-11
    Registry
    NCT06676449

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  843. Recruiting
    SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06676722

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Xiamen UniversityXiamen

  844. Recruiting
    Application of a New Surgical Technique in Proximal Gastrectomy: a Prospective, Multicenter Randomized Controlled Study
    Phase
    N/A
    Started
    2024-12
    Registry
    NCT06679244

    Age 18 years to 80 years (registered criteria)

    Led by Huashan Hospital; 2 listed hospitals as study sitesShanghai

  845. Recruiting
    Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients
    Phase
    Not given
    Started
    2024-09
    Registry
    NCT06682156

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  846. Recruiting
    Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06684600

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  847. Recruiting
    Mts105 for Advanced Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2024-11
    Registry
    NCT06689540

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  848. Recruiting
    Characteristics and Clinical Significance of Gut Microbiota in Patients With Monoclonal Gammopathy
    Phase
    Not given
    Started
    2024-12
    Registry
    NCT06690593

    Age 45 years to Not stated (registered criteria)

    Led by Zhujiang HospitalGuangzhou

  849. Recruiting
    Intravascular Radiofrequency Ablation of Sympathetic Nerves for the Treatment of Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2024-02
    Registry
    NCT06694636

    Age 25 years to 75 years (registered criteria)

    Led by Zhongda Hospital, Southeast UniversityNanjing

  850. Recruiting
    Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
    Phase
    Early phase 1
    Started
    2024-12
    Registry
    NCT06696833

    Age 14 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  851. Recruiting
    Risk Stratification and MRD-driven Maintenance for MM After ASCT
    Phase
    N/A
    Started
    2024-12
    Registry
    NCT06697483

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's Hospital; 2 listed hospitals as study sitesBeijing, Harbin

  852. Recruiting
    Trilaciclib for the Prevention of Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell Carcinoma
    Phase
    Not given
    Started
    2024-04
    Registry
    NCT06698692

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  853. Recruiting
    A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma
    Phase
    Phase 1
    Started
    2024-11
    Registry
    NCT06700395

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChengdu, Shanghai

  854. Recruiting
    Integrative Analysis of Exosome-Mediated Single-Cell Transcriptomics and Proteomics in Gastric Cardia Cancer
    Phase
    Not given
    Started
    2024-12
    Registry
    NCT06702891

    Age 18 years to Not stated (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  855. Recruiting
    Y-90 SIRT for Unresectable HCC Larger Than 7cm
    Phase
    Phase 2
    Started
    2024-12
    Registry
    NCT06707233

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  856. Recruiting
    A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06709417

    Age 20 years to 75 years (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  857. Recruiting
    Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06711471

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  858. Recruiting
    Effect of Premedication With Pronase on Mucosal Cleanliness During EGD
    Phase
    N/A
    Started
    2024-12
    Registry
    NCT06713421

    Age 18 years to 70 years (registered criteria)

    Led by Changhai HospitalShanghai

  859. Recruiting
    Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06714383

    Age 14 years to 70 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  860. Recruiting
    Target-specific immunoPET Imaging of Digestive System Carcinoma
    Phase
    N/A
    Started
    2024-12
    Registry
    NCT06715839

    Age 18 years to 75 years (registered criteria)

    Led by Renji HospitalShanghai

  861. Recruiting
    Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1
    Phase
    Phase 2
    Started
    2024-12
    Registry
    NCT06718244

    Age 16 years to 70 years (registered criteria)

    Led by Ruijin HospitalShanghai

  862. Recruiting
    a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia
    Phase
    Early phase 1
    Started
    2024-12
    Registry
    NCT06718270

    Age 18 years to Not stated (registered criteria)

    Led by Changzheng HospitalShanghai

  863. Recruiting
    Longitudinal Cohort of Thrombosis and Hemostasis Diseases
    Phase
    Not given
    Started
    2024-11
    Registry
    NCT06727669

    Age not stated (registered criteria)

    Led by Peking University People's Hospital; 4 listed hospitals as study sitesBeijing, Chongqing, Zhengzhou

  864. Recruiting
    Analysis of Lymph Node Metastasis and Tumor Deposit in the Short Gastric Mesentery Following Total Gastrectomy for Gastric Cancer
    Phase
    Not given
    Started
    2024-05
    Registry
    NCT06728878

    Age 18 years to 85 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  865. Recruiting
    Analysis of Tumor Deposit at the Fusion Site of the Right Gastric Mesentery and Left Gastric Mesentery in the Patients With Gastric Cancer Who Received Proximal Gastrectomy
    Phase
    Not given
    Started
    2024-05
    Registry
    NCT06728891

    Age 18 years to 85 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  866. Recruiting
    First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
    Phase
    Phase 2
    Started
    2024-10
    Registry
    NCT06730373

    Age 18 years to 75 years (registered criteria)

    Led by Qilu Hospital of Shandong University; 7 listed hospitals as study sitesJinan, Linyi, Qingdao, Yantai, Zhengzhou, Zibo

  867. Recruiting
    Clinical Study of Super Transplantation in the Treatment of Severe β-thalassemia
    Phase
    N/A
    Started
    2024-10
    Registry
    NCT06734520

    Age 7 years to 10 years (registered criteria)

    Led by Guangzhou Women and Children's Medical CenterGuangzhou

  868. Recruiting
    CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-11
    Registry
    NCT06735495

    Age 3 years to 75 years (registered criteria)

    Led by Union HospitalWuhan

  869. Recruiting
    Exploration of Lymph Node Metastasis and Tumor Deposit in the Posterior Gastric Mesentery for Distal Gastric Cancer
    Phase
    Not given
    Started
    2024-05
    Registry
    NCT06736847

    Age 18 years to 85 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  870. Recruiting
    XELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJC
    Phase
    Phase 1/Phase 2
    Started
    2024-12
    Registry
    NCT06742411

    Age 18 years to 75 years (registered criteria)

    Led by West China HospitalChengdu

  871. Recruiting
    PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC
    Phase
    Phase 2
    Started
    2024-10
    Registry
    NCT06742424

    Age 18 years to 75 years (registered criteria)

    Led by West China HospitalChengdu

  872. Recruiting
    Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL
    Phase
    Phase 2
    Started
    2024-10
    Registry
    NCT06742515

    Age 15 years to 59 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  873. Recruiting
    BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma
    Phase
    N/A
    Started
    2024-12
    Registry
    NCT06745687

    Age 18 years to 78 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  874. Recruiting
    The Value of 68Ga-FAPI PET/CT in the Efficacy Evaluation of Advanced Unresectable Hepatocellular Carcinoma Patients Undergoing Systemic Antitumor Therapy
    Phase
    Not given
    Started
    2024-12
    Registry
    NCT06746194

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  875. Recruiting
    Safety and Efficacy of Traction Robot-assisted Endoscopic Submucosal Dissection for Early Gastric Cancer
    Phase
    N/A
    Started
    2024-12
    Registry
    NCT06748352

    Age 18 years to 80 years (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  876. Recruiting
    MCB vs EUS-FNA for Preoperative Pathological Evaluation of Gastric SMT
    Phase
    N/A
    Started
    2024-01
    Registry
    NCT06748690

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  877. Recruiting
    Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma
    Phase
    Phase 1
    Started
    2024-12
    Registry
    NCT06751134

    Age 1 year to 12 years (registered criteria)

    Led by Children's Hospital of Nanjing Medical UniversityNanjing

  878. Recruiting
    CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.
    Phase
    Phase 1
    Started
    2024-10
    Registry
    NCT06752785

    Age 1 year to 18 years (registered criteria)

    Led by Guangzhou Women and Children's Medical CenterGuangzhou

  879. Recruiting
    Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL
    Phase
    Phase 2
    Started
    2024-12
    Registry
    NCT06754267

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  880. Recruiting
    Fenofibrate in Primary Biliary Cholangitis: a Real World Study
    Phase
    Phase 3
    Started
    2024-01
    Registry
    NCT06755151

    Age 18 years to 75 years (registered criteria)

    Led by Xijing HospitalXi'an

  881. Recruiting
    Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis: a Real World Study
    Phase
    Phase 3
    Started
    2024-01
    Registry
    NCT06755541

    Age 18 years to 75 years (registered criteria)

    Led by Xijing HospitalXi'an

  882. Recruiting
    Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids for Gastric Cancer Malignant Ascites
    Phase
    Phase 1/Phase 2
    Started
    2024-09
    Registry
    NCT06759064

    Age 18 years to 75 years (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  883. Recruiting
    A Prospective Cohort Study on the Treatment of Locally Advanced Gastric Cancer
    Phase
    Not given
    Started
    2024-12
    Registry
    NCT06760858

    Age 18 years to 80 years (registered criteria)

    Led by Southwest Hospital, Army Medical UniversityChongqing

  884. Recruiting
    Clinical Study of Induced Pluripotent Stem Cells Derived Motor Neuron Precursor Cell Therapy for Amyotrophic Lateral Sclerosis (ALS)
    Phase
    N/A
    Started
    2024-03
    Registry
    NCT06765564

    Age 18 years to 60 years (registered criteria)

    Led by Shanghai East Hospital, Tongji University; 1 listed hospital as study siteShanghai

  885. Recruiting
    A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemia
    Phase
    Phase 1
    Started
    2024-12
    Registry
    NCT06772766

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHaikou, Nanning

  886. Recruiting
    A Phase Ib/II Study of Adebrelimab in Combination with Capecitabine and Oxaliplatin in Cancer
    Phase
    Phase 1/Phase 2
    Started
    2024-08
    Registry
    NCT06776770

    Age 18 years to Not stated (registered criteria)

    Led by Cancer Hospital CAMS – ShenzhenShenzhen

  887. Recruiting
    A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2024-12
    Registry
    NCT06783569

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHarbin, Shenyang

  888. Recruiting
    The Relationship of Psychological Stress With Therapy Efficacy and Prognosis of Gastric Cancer
    Phase
    Not given
    Started
    2024-09
    Registry
    NCT06786169

    Age 18 years to 80 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  889. Recruiting
    "Xijiang Project" Screening Cohort for NPC
    Phase
    Not given
    Started
    2024-11
    Registry
    NCT06787456

    Age 30 years to 69 years (registered criteria)

    Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai

  890. Recruiting
    Fluorescence Guided Laparoscopic-Endoscopic Cooperative Sentinel Lymph Node Navigation Surgery Strategy for Early Gastric Cancer(IDEAL Stage 2b)
    Phase
    N/A
    Started
    2024-02
    Registry
    NCT06788548

    Age 18 years to 80 years (registered criteria)

    Led by Beijing Friendship HospitalBeijing

  891. Recruiting
    Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer
    Phase
    Phase 2
    Started
    2024-06
    Registry
    NCT06791083

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou

  892. Recruiting
    Low-dose Radiotherapy Combined With Chemotherapy and AK112 as Second-line Treatment in Patients With Advanced G/GEJ Cancer
    Phase
    Phase 2
    Started
    2024-07
    Registry
    NCT06791148

    Age 18 years to 75 years (registered criteria)

    Led by Nanjing Drum Tower HospitalNanjing

  893. Recruiting
    BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
    Phase
    Phase 2
    Started
    2024-12
    Registry
    NCT06794008

    Age 18 years to 65 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  894. Recruiting
    Study on Evaluating the Effectiveness of Statins in the Treatment of Moyamoya Disease
    Phase
    Not given
    Started
    2024-12
    Registry
    NCT06817434

    Age 18 years to 60 years (registered criteria)

    Led by Beijing Tiantan HospitalBeijing

  895. Recruiting
    A Clinical Study Evaluating LY-M001 Injection in the Treatment of Adult Patients With Type I Gaucher Disease
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Registry
    NCT06818838

    Age 18 years to 60 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou, Taiyuan, Tianjin

  896. Recruiting
    Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With Neuroblastoma
    Phase
    N/A
    Started
    2024-06
    Registry
    NCT06818916

    Age Not stated to 18 years (registered criteria)

    Led by Beijing Children's HospitalBeijing

  897. Recruiting
    Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors
    Phase
    Phase 1
    Started
    2024-07
    Registry
    NCT06821048

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  898. Recruiting
    Safety and Efficacy Study of Sorbitol With Neoadjuvant Chemotherapy Combined With Tirellizumab (PD-1 Inhibitor) in Patients With Locally Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06826079

    Age 18 years to 70 years (registered criteria)

    Led by Union HospitalWuhan

  899. Recruiting
    A Deep Learning Model for Diagnosing Lymph Node Metastasis in Nasopharyngeal Carcinoma(NPC)
    Phase
    Not given
    Started
    2024-11
    Registry
    NCT06829147

    Age not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  900. Recruiting
    Study on the Mechanism of Cognitive Impairment in Patients with Moyamoya Disease
    Phase
    Not given
    Started
    2024-12
    Registry
    NCT06832839

    Age 18 years to 60 years (registered criteria)

    Led by Beijing Tiantan HospitalBeijing

  901. Recruiting
    Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial.
    Phase
    Phase 1/Phase 2
    Started
    2024-12
    Registry
    NCT06836505

    Age 1 year to 50 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 1 listed hospital as study siteDongguan, Guangzhou

  902. Recruiting
    Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal Data
    Phase
    Not given
    Started
    2024-12
    Registry
    NCT06849180

    Age 18 years to Not stated (registered criteria)

    Led by Zhongda Hospital, Southeast UniversityNanjing

  903. Recruiting
    Baricitinib in the Treatment of Intestinal Behçet's Syndrome
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06849908

    Age 18 years to 65 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  904. Recruiting
    Trop2-targeted immunoPET Imaging of Solid Tumors
    Phase
    Phase 2/Phase 3
    Started
    2024-12
    Registry
    NCT06851663

    Age 18 years to 75 years (registered criteria)

    Led by Renji HospitalShanghai

  905. Recruiting
    CD70-targeted immunoPET Imaging of Malignant Cancers
    Phase
    Phase 2
    Started
    2024-12
    Registry
    NCT06852638

    Age 18 years to 80 years (registered criteria)

    Led by Renji HospitalShanghai

  906. Recruiting
    Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2024-09
    Registry
    NCT06864221

    Age 18 years to 80 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  907. Recruiting
    Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis
    Phase
    Phase 3
    Started
    2024-11
    Registry
    NCT06867991

    Age 12 years to Not stated (registered criteria)

    Led by Third Affiliated Hospital of Soochow University; 1 listed hospital as study siteChangzhou, Zhengzhou

  908. Recruiting
    Energy CT in Imaging and Diagnosis of Gastric Cancer
    Phase
    Not given
    Started
    2024-09
    Registry
    NCT06869694

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  909. Recruiting
    Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL
    Phase
    Phase 1/Phase 2
    Started
    2024-11
    Registry
    NCT06880913

    Age 12 years to 65 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  910. Recruiting
    The Safety and Efficacy of Robotic Assisted Surgery Using Vessel Sealer Extend in Locally Advanced Gastric Cancer
    Phase
    Not given
    Started
    2024-11
    Registry
    NCT06881043

    Age 18 years to 75 years (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  911. Recruiting
    Robotic Gastrectomy for Locally Advanced Gastric Cancer After Neoadjuvant Therapy
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06895447

    Age 18 years to 80 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  912. Recruiting
    Evaluation of the Safety, Tolerability, and Efficacy of LE051 in Patients With Duchenne Muscular Dystrophy
    Phase
    Early phase 1
    Started
    2024-10
    Registry
    NCT06900049

    Age 4 years to 8 years; men only (registered criteria)

    Led by Shanghai Children's Medical CenterShanghai

  913. Recruiting
    Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2/Phase 3
    Started
    2024-01
    Registry
    NCT06907602

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  914. Recruiting
    The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-11
    Registry
    NCT06911710

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University General HospitalTianjin

  915. Recruiting
    A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
    Phase
    Phase 1
    Started
    2024-09
    Registry
    NCT06927466

    Age 3 years to 25 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Nanchang, Shanghai, Suzhou, Wuhan, Xuzhou

  916. Recruiting
    The Effect of Different Digestive Tract Reconstruction Methods on Postoperative Quality of Life After Proximal Gastrectomy
    Phase
    Not given
    Started
    2024-11
    Registry
    NCT06929949

    Age 18 years to 75 years (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  917. Recruiting
    A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk
    Phase
    Phase 4
    Started
    2024-12
    Registry
    NCT06930573

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  918. Recruiting
    CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors
    Phase
    Early phase 1
    Started
    2024-12
    Registry
    NCT06937567

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  919. Recruiting
    Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2024-03
    Registry
    NCT06988956

    Age 75 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  920. Recruiting
    A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma
    Phase
    Early phase 1
    Started
    2024-09
    Registry
    NCT06999031

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Nanchang UniversityNanchang

  921. Recruiting
    Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell Cancer
    Phase
    Phase 2
    Started
    2024-08
    Registry
    NCT07016724

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  922. Recruiting
    Post-operative Monitoring of Gastric Cancer
    Phase
    Not given
    Started
    2024-02
    Registry
    NCT07026240

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  923. Recruiting
    Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
    Phase
    Not given
    Started
    2024-12
    Registry
    NCT07028970

    Age not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Tianjin, Wuhan, Zhengzhou

  924. Recruiting
    Efficacy and Safety of Minimally Invasive D2+PAND Gastrectomy for Gastric Cancer With PAN Metastasis After Conversion Immunochemotherapy
    Phase
    N/A
    Started
    2024-11
    Registry
    NCT07056010

    Age 18 years to 80 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  925. Recruiting
    Digital Early Warning System for Acute Lung Injury in Liver Surgery
    Phase
    Not given
    Started
    2024-11
    Registry
    NCT07070362

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Chongqing

  926. Recruiting
    An Exploratory Study on Developing an Integrated Approach Combining Multimodal Imaging and Multi-omics Characterization of Tumor Heterogeneity for Precision Diagnosis and Treatment Optimization in Liver Cancer.
    Phase
    Not given
    Started
    2024-08
    Registry
    NCT07101237

    Age 18 years to 70 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  927. Recruiting
    Effect of Goal-Oriented Albumin Infusion on Postoperative Complication Management in Gastric Cancer Surgery
    Phase
    Phase 2
    Started
    2024-10
    Registry
    NCT07119463

    Age 18 years to 80 years (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  928. Recruiting
    Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/Paraganglioma
    Phase
    Not given
    Started
    2024-12
    Registry
    NCT07195500

    Age 6 months to Not stated (registered criteria)

    Led by Jiangsu Province Hospital; 1 listed hospital as study siteNanjing

  929. Recruiting
    Adebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line Therapy
    Phase
    Phase 2
    Started
    2024-07
    Registry
    NCT07309185

    Age 18 years to 75 years (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  930. Recruiting
    Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer
    Phase
    Phase 1/Phase 2
    Started
    2024-02
    Registry
    NCT07334431

    Age 18 years to 75 years (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  931. Recruiting
    The Efficacy of PD-1 Monoclonal Antibody Combined With Chemotherapy in Metastatic Gastric Cancer Based on Gut Microbiota
    Phase
    Not given
    Started
    2024-03
    Registry
    NCT07400354

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  932. Recruiting
    Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma
    Phase
    N/A
    Started
    2024-12
    Registry
    NCT07430579

    Age 18 years to 80 years (registered criteria)

    Led by Second Hospital of Shandong University; 1 listed hospital as study siteJinan

  933. Recruiting
    Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients.
    Phase
    Phase 3
    Started
    2024-04
    Registry
    NCT07437404

    Age Not stated to 6 years; men only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  934. Recruiting
    Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study
    Phase
    Phase 2
    Started
    2024-09
    Registry
    NCT07437898

    Age 18 years to 75 years (registered criteria)

    Led by Affiliated Hospital of Putian UniversityPutian

  935. Recruiting
    Family-Based Moyamoya Susceptibility and Early Detection
    Phase
    Not given
    Started
    2024-11
    Registry
    NCT07517354

    Age not stated (registered criteria)

    Led by Beijing Tiantan Hospital; 1 listed hospital as study siteBeijing

  936. Recruiting
    A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)
    Phase
    Not given
    Started
    2024-12
    Registry
    NCT07547787

    Age not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  937. Recruiting
    Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies
    Phase
    Phase 1/Phase 2
    Started
    2024-04
    Registry
    NCT07584889

    Age 18 years to 75 years (registered criteria)

    Led by Shenzhen University General HospitalShenzhen

  938. Recruiting
    An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency
    Phase
    Phase 1/Phase 2
    Started
    2024-05
    Registry
    NCT07644832

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangsha, Hefei, Jinan, Lanzhou, Taiyuan, Xi'an, Zhengzhou

  939. Recruiting
    Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma
    Phase
    Phase 1
    Started
    2024-09
    Registry
    NCT07648069

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  940. Recruiting
    Cohort Study on Neuroimmune Diseases in the Reproductive Age
    Phase
    Not given
    Started
    2024-04
    Registry
    NCT07653984

    Age 20 years to 55 years; women only (registered criteria)

    Led by Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  941. Recruiting
    Blinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALL
    Phase
    Phase 1
    Started
    2024-12
    Registry
    NCT07677878

    Age 18 years to 70 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  942. Recruiting
    Neoadjuvant Cardonilizumab Combined With Neoadjuvant Chemoradiotherapy Can Resect Locally Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2024-01
    Registry
    NCT07699185

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  943. Recruiting
    Helicobacter Pylori Infection Status and Pathological Features for Predicting Gastric Cancer Biological Behavior and Prognosis: A Real-World Observational Study
    Phase
    Not given
    Started
    2024-01
    Registry
    NCT07724496

    Age 18 years to 80 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  944. Recruiting
    Validating a Medical AI Fine-Tuning Platform for Major Diseases
    Phase
    Not given
    Started
    2024-11
    Registry
    NCT07795645

    Age 18 years to Not stated (registered criteria)

    Led by Beijing Friendship HospitalBeijing

  945. Recruiting
    Multimodalomics-based Construction of Spatiotemporal Characteristics of Dynamic Liver Cancer Microenvironment to Characterize the Clinical Application of Immune Mechanisms in Liver Cancer
    Phase
    Not given
    Started
    2024-10
    Registry
    NCT07838415

    Age 18 years to 80 years (registered criteria)

    Led by Tongji HospitalWuhan

  946. Recruiting
    TEAS for Gastrectomy Recovery
    Phase
    N/A
    Started
    2024-10
    Registry
    NCT07898293

    Age 18 years to 80 years (registered criteria)

    Led by Affiliated Hospital of Qingdao University; 2 listed hospitals as study sitesQingdao, Weifang, Yantai

  947. Recruiting
    Aspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple Myeloma
    Phase
    Phase 4
    Started
    2024-02
    Registry
    NCT07907211

    Age 18 years to 70 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  948. Recruiting
    A Phase I Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2024-07
    Registry
    NCT07923214

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesChengdu, Fuzhou, Shanghai

  949. Recruiting
    Postoperative Radiotherapy in Thoracic Esophageal Squamous Cell Carcinoma With Neoadjuvant Chemoradiotherapy
    Phase
    N/A
    Started
    2023-05
    Registry
    NCT03734952

    Age 18 years to 65 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  950. Recruiting
    Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab
    Phase
    Phase 1/Phase 2
    Started
    2023-02
    Registry
    NCT05319639

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Cancer HospitalFuzhou

  951. Recruiting
    A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
    Phase
    Phase 1/Phase 2
    Started
    2023-05
    Registry
    NCT05319730

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Hangzhou, Hefei, Shanghai, Xiamen, Xinxiang, Zhengzhou

  952. Recruiting
    Downstaging Protocol Containing Immunotherapy for HCC Beyond the Milan Criteria Before Liver Transplantation
    Phase
    Phase 2
    Started
    2023-06
    Registry
    NCT05475613

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  953. Recruiting
    A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection
    Phase
    Phase 3
    Started
    2023-01
    Registry
    NCT05489289

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  954. Recruiting
    Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2023-02
    Registry
    NCT05565807

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Hangzhou

  955. Recruiting
    Transarterial Neoadjuvant Chemotherapy vs.Traditional Intravenous Chemotherapy For Locally Advanced Gastric Cancer With SOX+PD-1
    Phase
    Phase 3
    Started
    2023-03
    Registry
    NCT05593458

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  956. Recruiting
    Stereotactic Body Radiation Therapy for the Safety and Prognosis of Small Intrahepatic Recurrent HCC
    Phase
    N/A
    Started
    2023-05
    Registry
    NCT05596630

    Age 18 years to 80 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  957. Recruiting
    Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
    Phase
    Phase 3
    Started
    2023-01
    Registry
    NCT05613478

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  958. Recruiting
    A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
    Phase
    Phase 1/Phase 2
    Started
    2023-02
    Registry
    NCT05667506

    Age 3 years to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesChongqing, Guangzhou, Hefei, Nanchang, Nanjing, Tianjin, Wuhan, Xuzhou

  959. Recruiting
    Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer
    Phase
    Phase 2
    Started
    2023-03
    Registry
    NCT05671822

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  960. Recruiting
    Screening and Therapeutic Monitoring of Multiple Myeloma by MALDI-TOF MS Analysis
    Phase
    Not given
    Started
    2023-01
    Registry
    NCT05686447

    Age not stated (registered criteria)

    Led by Zhujiang HospitalGuangzhou

  961. Recruiting
    Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
    Phase
    Phase 2
    Started
    2023-03
    Registry
    NCT05687357

    Age 18 years to 75 years (registered criteria)

    Led by Nanjing Drum Tower Hospital; 2 listed hospitals as study sitesNanjing, Taiyuan, Wuhan

  962. Recruiting
    Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer
    Phase
    Phase 2/Phase 3
    Started
    2023-05
    Registry
    NCT05699655

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Cancer HospitalFuzhou

  963. Recruiting
    APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2023-02
    Registry
    NCT05701306

    Age 5 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou, Tianjin, Wuhan

  964. Recruiting
    Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics
    Phase
    Not given
    Started
    2023-01
    Registry
    NCT05722275

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Kunming, Taiyuan, Zhengzhou

  965. Recruiting
    Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC
    Phase
    Phase 2
    Started
    2023-03
    Registry
    NCT05738434

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  966. Recruiting
    Prevention of Postoperative Recurrence of Hepatocellular Carcinoma by Blocking RAK Cells With Anti-TIM-3
    Phase
    N/A
    Started
    2023-02
    Registry
    NCT05738980

    Age 18 years to 75 years (registered criteria)

    Led by Beijing HospitalBeijing

  967. Recruiting
    Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis
    Phase
    Phase 2/Phase 3
    Started
    2023-02
    Registry
    NCT05749822

    Age 18 years to 75 years (registered criteria)

    Led by Xijing Hospital; 11 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Kunming, Nanjing, Shenyang, Tianjin, Xi'an, Yan'an, Zhengzhou

  968. Recruiting
    Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial
    Phase
    Phase 2
    Started
    2023-03
    Registry
    NCT05751343

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  969. Recruiting
    Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST
    Phase
    N/A
    Started
    2023-02
    Registry
    NCT05751733

    Age 18 years to Not stated (registered criteria)

    Led by Xiangya HospitalChangsha

  970. Recruiting
    Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis
    Phase
    Phase 3
    Started
    2023-02
    Registry
    NCT05751967

    Age 18 years to 75 years (registered criteria)

    Led by Xijing Hospital; 6 listed hospitals as study sitesChengdu, Guangzhou, Lanzhou, Nanjing, Shenyang, Tianjin, Xi'an

  971. Recruiting
    A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
    Phase
    Phase 1
    Started
    2023-03
    Registry
    NCT05759793

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  972. Recruiting
    A Study Evaluating the Safety and Efficacy of LentiRed Drug Product in Transfusion-dependent β-Thalassemia [TDT]
    Phase
    Early phase 1
    Started
    2023-02
    Registry
    NCT05762510

    Age 5 years to 35 years (registered criteria)

    Led by First Affiliated Hospital of Guangxi Medical UniversityNanning

  973. Recruiting
    Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy
    Phase
    Phase 2
    Started
    2023-05
    Registry
    NCT05775042

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  974. Recruiting
    Study of Comparing of With and Without Sequential Therapy of S-1
    Phase
    Phase 3
    Started
    2023-01
    Registry
    NCT05813015

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  975. Recruiting
    Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients
    Phase
    Phase 1/Phase 2
    Started
    2023-02
    Registry
    NCT05824169

    Age 0 months to 6 months (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shenyang, Suzhou

  976. Recruiting
    ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
    Phase
    Phase 2
    Started
    2023-06
    Registry
    NCT05830123

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hangzhou, Shanghai, Tianjin, Zhengzhou

  977. Recruiting
    Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell Carcinoma
    Phase
    Not given
    Started
    2023-07
    Registry
    NCT05833594

    Age 18 years to 85 years (registered criteria)

    Led by First Affiliated Hospital of USTCHefei

  978. Recruiting
    Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's Syndrome
    Phase
    Phase 2
    Started
    2023-06
    Registry
    NCT05845723

    Age 18 years to 65 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  979. Recruiting
    Preoperative Serum FGF19 in the Prognosis of Biliary Atresia
    Phase
    Not given
    Started
    2023-10
    Registry
    NCT05848310

    Age not stated (registered criteria)

    Led by Children's Hospital of Fudan UniversityShanghai

  980. Recruiting
    Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC
    Phase
    Phase 3
    Started
    2023-05
    Registry
    NCT05854849

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  981. Recruiting
    Two Cycles VS Three Cycles Induction Chemotherapy in T1-4N2-3 Locally Advanced Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2023-05
    Registry
    NCT05860868

    Age 18 years to 65 years (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  982. Recruiting
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    Phase
    Phase 3
    Started
    2023-05
    Registry
    NCT05862337

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou

  983. Recruiting
    Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)
    Phase
    Not given
    Started
    2023-03
    Registry
    NCT05870969

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  984. Recruiting
    Reduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2023-05
    Registry
    NCT05877872

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  985. Recruiting
    Screening Effect of Dual-energy CT Combined With Nasopharyngeal Endoscopy for Screening Nasopharyngeal Carcinoma
    Phase
    Not given
    Started
    2023-02
    Registry
    NCT05884983

    Age 30 years to 69 years (registered criteria)

    Led by Zhongshan City People's HospitalZhongshan

  986. Recruiting
    ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor
    Phase
    Phase 4
    Started
    2023-11
    Registry
    NCT05888870

    Age 14 years to 65 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  987. Recruiting
    Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
    Phase
    N/A
    Started
    2023-06
    Registry
    NCT05892354

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of Guangxi Medical University; 13 listed hospitals as study sitesFuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Liuzhou, Nanchang, Nanning, Wuzhou

  988. Recruiting
    Influence Mechanism of Tumor Microenvironment Changes on Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma
    Phase
    Not given
    Started
    2023-05
    Registry
    NCT05894369

    Age 18 years to 80 years (registered criteria)

    Led by Renmin Hospital of Wuhan UniversityWuhan

  989. Recruiting
    Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC
    Phase
    Phase 2
    Started
    2023-06
    Registry
    NCT05917431

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  990. Recruiting
    Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 3
    Started
    2023-04
    Registry
    NCT05918094

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 7 listed hospitals as study sitesChengdu, Dalian, Guangzhou, Harbin, Nanchang, Shanghai, Wuhan, Zhengzhou

  991. Recruiting
    A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 3
    Started
    2023-07
    Registry
    NCT05919030

    Age 18 years to Not stated (registered criteria)

    Led by Renmin Hospital of Wuhan UniversityWuhan

  992. Recruiting
    Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors
    Phase
    Phase 2
    Started
    2023-07
    Registry
    NCT05920863

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  993. Recruiting
    Clinical Study to Evaluate the Efficacy and Safety of FB1006 in the Treatment of ALS Patients
    Phase
    Phase 4
    Started
    2023-01
    Registry
    NCT05923905

    Age 18 years to 80 years (registered criteria)

    Led by Peking University Third HospitalBeijing

  994. Recruiting
    Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy
    Phase
    N/A
    Started
    2023-07
    Registry
    NCT05925309

    Age 14 days to 90 days (registered criteria)

    Led by Children's Hospital of Fudan UniversityShanghai

  995. Recruiting
    GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2023-01
    Registry
    NCT05926726

    Age 18 years to 75 years (registered criteria)

    Led by Renji HospitalShanghai

  996. Recruiting
    A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study
    Phase
    Phase 2
    Started
    2023-07
    Registry
    NCT05934331

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  997. Recruiting
    Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma
    Phase
    Phase 1/Phase 2
    Started
    2023-09
    Registry
    NCT05937438

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of USTCHefei

  998. Recruiting
    A Cohort Study on the Safety of Laparoscopic Resection of 5cm or Larger Gastric Gastrointestinal Stromal Tumors
    Phase
    Not given
    Started
    2023-05
    Registry
    NCT05938309

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  999. Recruiting
    Minimally Residual of Esophageal Cancer 001
    Phase
    Not given
    Started
    2023-02
    Registry
    NCT05952661

    Age 18 years to 75 years (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  1000. Recruiting
    Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2023-09
    Registry
    NCT05954897

    Age 18 years to Not stated (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  1001. Recruiting
    The Role of Extracellular DNA (ecDNA) in the Occurrence and Development of Gastric
    Phase
    Not given
    Started
    2023-08
    Registry
    NCT05956847

    Age 18 years to 80 years (registered criteria)

    Led by Xijing HospitalXi'an

  1002. Recruiting
    The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE Study
    Phase
    Not given
    Started
    2023-07
    Registry
    NCT05965115

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  1003. Recruiting
    Helical Tomotherapy in Multiple Myeloma
    Phase
    N/A
    Started
    2023-06
    Registry
    NCT05970198

    Age 18 years to 75 years (registered criteria)

    Led by Zhongnan Hospital of Wuhan UniversityWuhan

  1004. Recruiting
    Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2023-11
    Registry
    NCT05970666

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Xiamen UniversityXiamen

  1005. Recruiting
    Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer
    Phase
    Phase 2
    Started
    2023-01
    Registry
    NCT05975749

    Age 20 years to 80 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  1006. Recruiting
    Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2023-01
    Registry
    NCT05978193

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest Hospital; 1 listed hospital as study siteShanghai

  1007. Recruiting
    A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia
    Phase
    Phase 2
    Started
    2023-08
    Registry
    NCT05979363

    Age 18 years to 75 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  1008. Recruiting
    Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma
    Phase
    Phase 1
    Started
    2023-08
    Registry
    NCT05984342

    Age 18 years to 70 years (registered criteria)

    Led by Shantou University Medical College hospitalsShantou

  1009. Recruiting
    TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT
    Phase
    N/A
    Started
    2023-08
    Registry
    NCT05984511

    Age 18 years to 75 years (registered criteria)

    Led by Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  1010. Recruiting
    Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC
    Phase
    Phase 3
    Started
    2023-08
    Registry
    NCT05985798

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  1011. Recruiting
    Reducing High Risk Primary Tumor Clinical Target Volumes (CTVp1) in Non-metastatic Nasopharyngeal Carcinoma
    Phase
    N/A
    Started
    2023-08
    Registry
    NCT05994170

    Age 18 years to 70 years (registered criteria)

    Led by Zhongshan City People's HospitalZhongshan

  1012. Recruiting
    SIRT for Potentially Resectable HCC
    Phase
    N/A
    Started
    2023-08
    Registry
    NCT05994859

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  1013. Recruiting
    A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors
    Phase
    Phase 2
    Started
    2023-11
    Registry
    NCT06008054

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  1014. Recruiting
    Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma
    Phase
    Phase 2
    Started
    2023-06
    Registry
    NCT06013618

    Age 12 months to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  1015. Recruiting
    Doxepin Solution for Alleviation of Stubborn Breakthrough Pain Induced by Swallowing in Patients Receiving Radiotherapy for Nasopharyngeal Carcinoma
    Phase
    N/A
    Started
    2023-10
    Registry
    NCT06017895

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang HospitalGuangzhou

  1016. Recruiting
    Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC
    Phase
    Phase 2
    Started
    2023-09
    Registry
    NCT06023758

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  1017. Recruiting
    GNT Induction Treatment in Locally Advanced NPC
    Phase
    Phase 3
    Started
    2023-09
    Registry
    NCT06026878

    Age 18 years to 75 years (registered criteria)

    Led by Xijing HospitalXi'an

  1018. Recruiting
    Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial
    Phase
    Phase 2
    Started
    2023-09
    Registry
    NCT06031285

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  1019. Recruiting
    AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
    Phase
    Not given
    Started
    2023-09
    Registry
    NCT06035250

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Fuzhou, Guangzhou, Kunming, Nanning, Qingdao, Shanghai, Shenyang, Suzhou, Tianjin, Zhengzhou

  1020. Recruiting
    Cardiac Toxicity and Prognostic Value of New Echocardiographic Indicators in the Treatment of Primary Multiple Myeloma
    Phase
    Not given
    Started
    2023-11
    Registry
    NCT06039735

    Age 18 years to 70 years (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  1021. Recruiting
    Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
    Phase
    Phase 3
    Started
    2023-10
    Registry
    NCT06041477

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  1022. Recruiting
    Functional Magnetic Resonance-Based Observations of Brain Networks in Moyamoya Disease Patients Under Anesthesia
    Phase
    Not given
    Started
    2023-10
    Registry
    NCT06041659

    Age 18 years to 65 years (registered criteria)

    Led by Beijing Tiantan HospitalBeijing

  1023. Recruiting
    A Multicenter, RCT Study of the Clinical Efficacy of Robotic and Laparoscopic Gastrectomy in Neoadjuvant Gastric Cancer
    Phase
    N/A
    Started
    2023-07
    Registry
    NCT06042998

    Age 18 years to 75 years (registered criteria)

    Led by Affiliated Hospital of Qingdao UniversityQingdao

  1024. Recruiting
    A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
    Phase
    Phase 1
    Started
    2023-08
    Registry
    NCT06043466

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou

  1025. Recruiting
    To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL
    Phase
    Early phase 1
    Started
    2023-07
    Registry
    NCT06045091

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  1026. Recruiting
    A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2023-10
    Registry
    NCT06049290

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Guangzhou, Guiyang, Haikou, Hangzhou, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Suzhou, Taiyuan, Wenzhou, Wuhan, Wuhu, Xi'an, Xiamen, Zhengzhou

  1027. Recruiting
    Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
    Phase
    Phase 3
    Started
    2023-09
    Registry
    NCT06051617

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Shanghai, Urumqi, Wuhan, Xi'an, Zhengzhou

  1028. Recruiting
    Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (PLOF) for Resectable Locally Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2023-10
    Registry
    NCT06054906

    Age 18 years to Not stated (registered criteria)

    Led by Huashan HospitalShanghai

  1029. Recruiting
    Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2023-09
    Registry
    NCT06056336

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  1030. Recruiting
    Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
    Phase
    Phase 4
    Started
    2023-10
    Registry
    NCT06057402

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Jinan

  1031. Recruiting
    Study on the Quantitative Assessment of the Risk of Hepatocellular Carcinoma in Patients With Chronic Liver Disease Using Multi-parameter Magnetic Resonance Imaging
    Phase
    Not given
    Started
    2023-09
    Registry
    NCT06060769

    Age 18 years to Not stated (registered criteria)

    Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai

  1032. Recruiting
    The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy Procedure
    Phase
    N/A
    Started
    2023-12
    Registry
    NCT06081647

    Age 18 years to 60 years (registered criteria)

    Led by Renji Hospital; 7 listed hospitals as study sitesHangzhou, Jinan, Nanchang, Nanjing, Shanghai

  1033. Recruiting
    Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy
    Phase
    Phase 3
    Started
    2023-10
    Registry
    NCT06092957

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  1034. Recruiting
    Pulmonary Resectable Osteosarcoma Treated by Metastasectomy and Pre-operative Immunotherapy and Stereotactic Body Radiotherapy (PROMIS): a Prospective Clinical Trial
    Phase
    Phase 2
    Started
    2023-06
    Registry
    NCT06114225

    Age 10 years to 65 years (registered criteria)

    Led by Ruijin HospitalShanghai

  1035. Recruiting
    Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer
    Phase
    Phase 2
    Started
    2023-01
    Registry
    NCT06121700

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  1036. Recruiting
    SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
    Phase
    Phase 2/Phase 3
    Started
    2023-06
    Registry
    NCT06125327

    Age 40 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  1037. Recruiting
    Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes(CAR-T) for CEA Positive Advanced Malignant Solid Tumors
    Phase
    Phase 1
    Started
    2023-11
    Registry
    NCT06126406

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhu

  1038. Recruiting
    A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2023-11
    Registry
    NCT06131840

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai

  1039. Recruiting
    Clinical Study of EBV-TCR-T Cells for EBV-associated Hemophagocytic Lymphohistiocytosis or EBV Infection
    Phase
    Phase 1
    Started
    2023-08
    Registry
    NCT06135922

    Age 1 year to 60 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  1040. Recruiting
    Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
    Phase
    Phase 2
    Started
    2023-10
    Registry
    NCT06140966

    Age 18 years to 70 years (registered criteria)

    Led by Union HospitalWuhan

  1041. Recruiting
    A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
    Phase
    Phase 3
    Started
    2023-11
    Registry
    NCT06145893

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Guangzhou, Guilin, Hangzhou, Linyi, Nanchang, Shanghai, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Xiamen, Xuzhou

  1042. Recruiting
    Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 2
    Started
    2023-11
    Registry
    NCT06155383

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Harbin, Jinan, Kunming, Xiamen, Zhengzhou

  1043. Recruiting
    Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA
    Phase
    Not given
    Started
    2023-11
    Registry
    NCT06157060

    Age 18 years to 75 years (registered criteria)

    Led by Zhujiang Hospital; 3 listed hospitals as study sitesGuangzhou

  1044. Recruiting
    DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma
    Phase
    Phase 2
    Started
    2023-12
    Registry
    NCT06158269

    Age 18 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  1045. Recruiting
    All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma
    Phase
    Phase 2
    Started
    2023-11
    Registry
    NCT06158412

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Xiamen UniversityXiamen

  1046. Recruiting
    A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer
    Phase
    N/A
    Started
    2023-11
    Registry
    NCT06158919

    Age 18 years to 80 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  1047. Recruiting
    3D-4K-ICG Laparoscopic Gastrectomy for Gastric Cancer
    Phase
    Phase 3
    Started
    2023-01
    Registry
    NCT06161207

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  1048. Recruiting
    A Study of the Safety and Preliminary Efficacy of LY-M001 Injection in the Treatment of Adult Patients With Gaucher Disease Type I
    Phase
    N/A
    Started
    2023-11
    Registry
    NCT06162338

    Age 18 years to 60 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  1049. Recruiting
    Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC
    Phase
    Phase 3
    Started
    2023-07
    Registry
    NCT06172205

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  1050. Recruiting
    Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer
    Phase
    Phase 1/Phase 2
    Started
    2023-01
    Registry
    NCT06173986

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  1051. Recruiting
    M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
    Phase
    Phase 3
    Started
    2023-12
    Registry
    NCT06177041

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  1052. Recruiting
    Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC
    Phase
    Phase 3
    Started
    2023-12
    Registry
    NCT06177301

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  1053. Recruiting
    OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
    Phase
    Phase 1/Phase 2
    Started
    2023-10
    Registry
    NCT06182696

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Nanjing, Shanghai, Wuhan

  1054. Recruiting
    HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2023-12
    Registry
    NCT06187961

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  1055. Recruiting
    A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC
    Phase
    Phase 2
    Started
    2023-10
    Registry
    NCT06190639

    Age 18 years to Not stated (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  1056. Recruiting
    DEB-TACE With Visualable Microspheres Versus PVA Microspheres for HCC
    Phase
    N/A
    Started
    2023-12
    Registry
    NCT06190665

    Age 18 years to 80 years (registered criteria)

    Led by Zhongda Hospital, Southeast University; 1 listed hospital as study siteBeijing, Nanjing

  1057. Recruiting
    Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)
    Phase
    Phase 1/Phase 2
    Started
    2023-12
    Registry
    NCT06196255

    Age 18 years to 70 years (registered criteria)

    Led by Affiliated Hospital of Xuzhou Medical UniversityXuzhou

  1058. Recruiting
    Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer
    Phase
    Phase 2
    Started
    2023-11
    Registry
    NCT06199895

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  1059. Recruiting
    FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial
    Phase
    Phase 3
    Started
    2023-12
    Registry
    NCT06201065

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  1060. Recruiting
    Atrophic Gastritis Predicts the Risk of Gastric Cancer
    Phase
    Not given
    Started
    2023-12
    Registry
    NCT06203327

    Age 18 years to 70 years (registered criteria)

    Led by Renji HospitalShanghai

  1061. Recruiting
    Application of ICG@HSA Complexes in Fluorescence Image-Guided Laparoscopic Anatomical Liver Resection
    Phase
    N/A
    Started
    2023-12
    Registry
    NCT06219096

    Age 18 years to 75 years (registered criteria)

    Led by West China HospitalChengdu

  1062. Recruiting
    Mitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2023-11
    Registry
    NCT06246162

    Age 18 years to 70 years (registered criteria)

    Led by Affiliated Hospital of Nantong UniversityNantong

  1063. Recruiting
    Dara-PD in the Treatment of Patients With First Relapse of Multiple Myeloma
    Phase
    Not given
    Started
    2023-06
    Registry
    NCT06252792

    Age 18 years to Not stated (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  1064. Recruiting
    Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness
    Phase
    Phase 2
    Started
    2023-02
    Registry
    NCT06254560

    Age 18 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  1065. Recruiting
    An Exploratory Clinical Trial of VGN-R08b in Patients With Type II Gaucher Disease
    Phase
    Early phase 1
    Started
    2023-03
    Registry
    NCT06272149

    Age 0 months to 24 months (registered criteria)

    Led by Xinhua HospitalShanghai

  1066. Recruiting
    A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients
    Phase
    N/A
    Started
    2023-01
    Registry
    NCT06277024

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  1067. Recruiting
    Xerostomia-optimised IMRT Versus Standard IMRT in NPC
    Phase
    N/A
    Started
    2023-10
    Registry
    NCT06282497

    Age 18 years to 70 years (registered criteria)

    Led by Zhongshan City People's HospitalZhongshan

  1068. Recruiting
    Blinatumomab for Relapsed Acute B Lymphoblastic Leukemia After Transplantation
    Phase
    Phase 4
    Started
    2023-09
    Registry
    NCT06339775

    Age Not stated to 65 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  1069. Recruiting
    Serplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age
    Phase
    Phase 2
    Started
    2023-12
    Registry
    NCT06354218

    Age 75 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  1070. Recruiting
    Study on the Clinical Application Value of PET Imaging Targeting GPC3 in Hepatocellular Carcinoma
    Phase
    Early phase 1
    Started
    2023-09
    Registry
    NCT06383520

    Age 18 years to 65 years (registered criteria)

    Led by Union HospitalWuhan

  1071. Recruiting
    Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2023-03
    Registry
    NCT06410651

    Age 18 years to 80 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  1072. Recruiting
    Exploratory Study of Precise Therapy for Advanced Tumor Patients With Malignant Hydrothorax or Ascites by Using PTC Drug Sensitivity Testing
    Phase
    Not given
    Started
    2023-08
    Registry
    NCT06413212

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  1073. Recruiting
    Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients
    Phase
    Phase 2
    Started
    2023-03
    Registry
    NCT06429839

    Age 18 years to 80 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  1074. Recruiting
    a Single-arm, Single-center, Open Clinical Study
    Phase
    Not given
    Started
    2023-07
    Registry
    NCT06431100

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou

  1075. Recruiting
    Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer
    Phase
    Phase 2
    Started
    2023-05
    Registry
    NCT06451211

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  1076. Recruiting
    Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not
    Phase
    Not given
    Started
    2023-12
    Registry
    NCT06463717

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  1077. Recruiting
    A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2023-04
    Registry
    NCT06508307

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou

  1078. Recruiting
    Image Driven Hepatocellular Carcinoma Invasiveness Evaluation Research
    Phase
    Not given
    Started
    2023-01
    Registry
    NCT06559761

    Age 18 years to 80 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  1079. Recruiting
    CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
    Phase
    Phase 1
    Started
    2023-10
    Registry
    NCT06560827

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou

  1080. Recruiting
    JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia
    Phase
    N/A
    Started
    2023-09
    Registry
    NCT06678282

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou

  1081. Recruiting
    Surgery Alone Verus Sugery Combined with Dose-reduced Radiotherapy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma
    Phase
    N/A
    Started
    2023-11
    Registry
    NCT06688760

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Zhuhai

  1082. Recruiting
    A Study to Evaluate the Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease (NMOSD)
    Phase
    Phase 2
    Started
    2023-05
    Registry
    NCT06697535

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangsha

  1083. Recruiting
    The Correlation Between Blood Concentration of Sintilimab and Efficacy and Adverse Reactions in Patients with Advanced Gastric Cancer
    Phase
    Not given
    Started
    2023-02
    Registry
    NCT06702683

    Age 18 years to Not stated (registered criteria)

    Led by Zhongda Hospital, Southeast UniversityNanjing

  1084. Recruiting
    Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2023-03
    Registry
    NCT06718205

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  1085. Recruiting
    Study on the Value of Three DWI Scanning Sequences in Staging of Gastric Cancer
    Phase
    N/A
    Started
    2023-12
    Registry
    NCT06735105

    Age 18 years to 80 years (registered criteria)

    Led by Yunnan Cancer HospitalKunming

  1086. Recruiting
    Study on the Treatment of Hepatitis B Virus(HBV) Infected Individuals With Peginterferon α-2b Combined With NA.
    Phase
    Not given
    Started
    2023-05
    Registry
    NCT06746701

    Age 18 years to 65 years (registered criteria)

    Led by Xiangya Hospital; 2 listed hospitals as study sitesChangsha, Guangzhou, Hengyang

  1087. Recruiting
    Longitudinal Data Registry of Plasma Cell Dyscrasia
    Phase
    Not given
    Started
    2023-03
    Registry
    NCT06760052

    Age 19 years to 99 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  1088. Recruiting
    A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG
    Phase
    Phase 2
    Started
    2023-09
    Registry
    NCT06774222

    Age 18 years to 75 years (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  1089. Recruiting
    A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors
    Phase
    N/A
    Started
    2023-12
    Registry
    NCT06783816

    Age not stated (registered criteria)

    Led by Shanxi Bethune HospitalTaiyuan

  1090. Recruiting
    Prospective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2023-03
    Registry
    NCT06788353

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  1091. Recruiting
    PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer
    Phase
    Phase 2
    Started
    2023-04
    Registry
    NCT06792162

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Third HospitalBeijing

  1092. Recruiting
    Metastatic Nasopharyngeal Carcinoma
    Phase
    Phase 1
    Started
    2023-07
    Registry
    NCT06886347

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  1093. Recruiting
    Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC
    Phase
    Phase 2
    Started
    2023-10
    Registry
    NCT06904014

    Age 18 years to 70 years (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  1094. Recruiting
    Construction of A Multimodal Digital Assessment Model for Myasthenia Gravis
    Phase
    Not given
    Started
    2023-08
    Registry
    NCT07146425

    Age 18 years to Not stated (registered criteria)

    Led by Huashan HospitalShanghai

  1095. Recruiting
    High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)
    Phase
    Not given
    Started
    2023-09
    Registry
    NCT07205523

    Age not stated (registered criteria)

    Led by Affiliated Hospital of Qinghai UniversityXining

  1096. Recruiting
    Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2023-12
    Registry
    NCT07266493

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  1097. Recruiting
    Efficacy and Safety of Tislelizumab Plus Chemotherapy as Conversion Therapy in Unresectable Locally Advanced ESCC
    Phase
    Not given
    Started
    2023-05
    Registry
    NCT07549100

    Age 18 years to 75 years (registered criteria)

    Led by Shandong Provincial HospitalJinan

  1098. Recruiting
    APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma
    Phase
    Early phase 1
    Started
    2022-05
    Registry
    NCT04657861

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  1099. Recruiting
    18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2022-01
    Registry
    NCT04813705

    Age 18 years to 80 years (registered criteria)

    Led by Taizhou HospitalTaizhou

  1100. Recruiting
    Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction
    Phase
    Phase 2
    Started
    2022-01
    Registry
    NCT04840264

    Age 18 years to 75 years (registered criteria)

    Led by Sixth Affiliated Hospital of Sun Yat-sen University; 1 listed hospital as study siteGuangzhou

  1101. Recruiting
    Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC
    Phase
    Phase 2/Phase 3
    Started
    2022-03
    Registry
    NCT04973306

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  1102. Recruiting
    Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
    Phase
    Phase 2
    Started
    2022-07
    Registry
    NCT05067348

    Age 18 years to 80 years (registered criteria)

    Led by Tangdu Hospital; 5 listed hospitals as study sitesBeijing, Changsha, Chengdu, Shanghai, Tianjin, Xi'an

  1103. Recruiting
    Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)
    Phase
    Early phase 1
    Started
    2022-04
    Registry
    NCT05145361

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Taiyuan, Tianjin, Xi'an

  1104. Recruiting
    Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2022-03
    Registry
    NCT05147844

    Age 18 years to 75 years (registered criteria)

    Led by Xinqiao Hospital, Army Medical UniversityChongqing

  1105. Recruiting
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2022-01
    Registry
    NCT05150691

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou

  1106. Recruiting
    A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2022-02
    Registry
    NCT05155189

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang University; 1 listed hospital as study siteHangzhou, Zhengzhou

  1107. Recruiting
    A Study of Perioperative Camrelizumab Combined With Chemotherapy in Patients With Resectable ESCC
    Phase
    Phase 2
    Started
    2022-01
    Registry
    NCT05182944

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  1108. Recruiting
    A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
    Phase
    Phase 4
    Started
    2022-03
    Registry
    NCT05201781

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Xi'an

  1109. Recruiting
    A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2022-10
    Registry
    NCT05208762

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai

  1110. Recruiting
    Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2022-09
    Registry
    NCT05214222

    Age 18 years to 75 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  1111. Recruiting
    A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
    Phase
    Phase 1
    Started
    2022-03
    Registry
    NCT05219721

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  1112. Recruiting
    Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
    Phase
    Phase 3
    Started
    2022-09
    Registry
    NCT05243797

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Hangzhou, Jinan, Shanghai, Shenyang, Tianjin, Wenzhou, Wuhan, Zhengzhou

  1113. Recruiting
    Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients
    Phase
    Phase 2
    Started
    2022-06
    Registry
    NCT05252078

    Age 18 years to Not stated (registered criteria)

    Led by Jiangxi Cancer HospitalNanchang

  1114. Recruiting
    A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
    Phase
    Phase 1
    Started
    2022-02
    Registry
    NCT05262491

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Jinan, Nanchang, Tianjin

  1115. Recruiting
    Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
    Phase
    Phase 2
    Started
    2022-04
    Registry
    NCT05294055

    Age 18 years to 65 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 6 listed hospitals as study sitesBeijing, Hefei, Jinan, Tianjin, Zhengzhou

  1116. Recruiting
    A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2022-08
    Registry
    NCT05299424

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  1117. Recruiting
    Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer
    Phase
    Phase 1/Phase 2
    Started
    2022-02
    Registry
    NCT05323201

    Age 18 years to 70 years (registered criteria)

    Led by Affiliated Hospital of Xuzhou Medical UniversityXuzhou

  1118. Recruiting
    The Relationship Between Scar Formation and ESD Depth in Therapy for Gastric Carcinoma
    Phase
    N/A
    Started
    2022-01
    Registry
    NCT05323929

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  1119. Recruiting
    Surgery or Chemoradiotherapy for Cervical Esophageal Cancer
    Phase
    N/A
    Started
    2022-04
    Registry
    NCT05327517

    Age 18 years to 75 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  1120. Recruiting
    Long-term Outcomes of Conservative Management in Patients with Moyamoya Disease and Their First-degree Relatives (LAMORA)
    Phase
    Not given
    Started
    2022-05
    Registry
    NCT05332756

    Age 2 years to 60 years (registered criteria)

    Led by Beijing Tiantan HospitalBeijing

  1121. Recruiting
    A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
    Phase
    Phase 2
    Started
    2022-01
    Registry
    NCT05334823

    Age 3 years to 21 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Hangzhou, Nanchang, Nanjing, Shenzhen, Suzhou, Tianjin, Wuhan, Zhengzhou

  1122. Recruiting
    Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
    Phase
    Phase 3
    Started
    2022-04
    Registry
    NCT05340491

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 10 listed hospitals as study sitesChengdu, Fuzhou, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanning, Shanghai, Wuhan, Xi'an, Xiamen

  1123. Recruiting
    Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2022-04
    Registry
    NCT05342792

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  1124. Recruiting
    Detection of Peritoneal Metastasis of Gastric Cancer by Liquid Biopsy in Peripheral Blood: A Prospective Study
    Phase
    Not given
    Started
    2022-03
    Registry
    NCT05347524

    Age 18 years to 74 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  1125. Recruiting
    Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma
    Phase
    N/A
    Started
    2022-06
    Registry
    NCT05352321

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 1 listed hospital as study siteGuangzhou

  1126. Recruiting
    PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
    Phase
    Phase 3
    Started
    2022-11
    Registry
    NCT05357846

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  1127. Recruiting
    A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
    Phase
    Phase 1
    Started
    2022-06
    Registry
    NCT05365581

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesGuangzhou, Hangzhou, Shanghai, Wuhan, Zhengzhou

  1128. Recruiting
    Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody
    Phase
    Not given
    Started
    2022-08
    Registry
    NCT05392413

    Age 18 years to 75 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  1129. Recruiting
    Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.
    Phase
    Phase 2
    Started
    2022-06
    Registry
    NCT05397769

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  1130. Recruiting
    Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Liquid Biopsy MRD
    Phase
    Not given
    Started
    2022-01
    Registry
    NCT05408897

    Age not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  1131. Recruiting
    A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2022-08
    Registry
    NCT05409482

    Age 18 years to 75 years (registered criteria)

    Led by Mengchao Hepatobiliary Hospital of Fujian Medical UniversityFuzhou

  1132. Recruiting
    KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy
    Phase
    Phase 2/Phase 3
    Started
    2022-04
    Registry
    NCT05427383

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  1133. Recruiting
    CT-guided Localization for Micro Hepatocellular Carcinoma Before Surgical Resection
    Phase
    N/A
    Started
    2022-05
    Registry
    NCT05433467

    Age 18 years to Not stated (registered criteria)

    Led by Northern Jiangsu People's HospitalYangzhou

  1134. Recruiting
    Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)
    Phase
    Not given
    Started
    2022-07
    Registry
    NCT05443841

    Age not stated (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 8 listed hospitals as study sitesHefei, Nantong, Shanghai, Shijiazhuang, Taizhou (Jiangsu), Tianjin, Xi'an, Zhengzhou

  1135. Recruiting
    Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2022-07
    Registry
    NCT05444478

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangsha

  1136. Recruiting
    Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening
    Phase
    Not given
    Started
    2022-07
    Registry
    NCT05447169

    Age 30 years to 62 years; men only (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  1137. Recruiting
    OGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap Method
    Phase
    N/A
    Started
    2022-09
    Registry
    NCT05450835

    Age 18 years to 75 years (registered criteria)

    Led by Nanfang Hospital; 7 listed hospitals as study sitesChangchun, Changsha, Guangzhou, Shantou, Shenyang

  1138. Recruiting
    A Study of FVIII Gene Therapy for Hemophilia A
    Phase
    Early phase 1
    Started
    2022-07
    Registry
    NCT05454774

    Age 18 years to Not stated; men only (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  1139. Recruiting
    Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA
    Phase
    Not given
    Started
    2022-07
    Registry
    NCT05461664

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  1140. Recruiting
    A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal Tumors
    Phase
    Not given
    Started
    2022-07
    Registry
    NCT05464875

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  1141. Recruiting
    Efficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCC
    Phase
    N/A
    Started
    2022-08
    Registry
    NCT05484908

    Age 18 years to 65 years (registered criteria)

    Led by Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  1142. Recruiting
    XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma
    Phase
    Phase 2
    Started
    2022-03
    Registry
    NCT05494060

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  1143. Recruiting
    Dual-Port Laparoscopic Distal Gastrectomy for Gastric Cancer
    Phase
    N/A
    Started
    2022-08
    Registry
    NCT05494086

    Age 18 years to 75 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  1144. Recruiting
    Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 3
    Started
    2022-08
    Registry
    NCT05495152

    Age 18 years to 70 years (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  1145. Recruiting
    Ofatumumab in AQP4-IgG Seropositive NMOSD
    Phase
    Phase 1/Phase 2
    Started
    2022-06
    Registry
    NCT05504694

    Age 18 years to Not stated (registered criteria)

    Led by Tangdu HospitalXi'an

  1146. Recruiting
    Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC
    Phase
    Phase 2
    Started
    2022-08
    Registry
    NCT05507411

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer Hospital; 2 listed hospitals as study sitesHangzhou, Ningbo

  1147. Recruiting
    Nituzumab (Taixinsheng ®) A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2022-04
    Registry
    NCT05508347

    Age 18 years to 70 years (registered criteria)

    Led by Sichuan Cancer HospitalChengdu

  1148. Recruiting
    Radiotherapy Combined With Endostatin and Capecitabine for NPC
    Phase
    Phase 2
    Started
    2022-08
    Registry
    NCT05514275

    Age 18 years to 65 years (registered criteria)

    Led by Zhejiang Cancer Hospital; 2 listed hospitals as study sitesHangzhou, Ningbo

  1149. Recruiting
    Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2022-05
    Registry
    NCT05515315

    Age 18 years to 70 years (registered criteria)

    Led by 900th Hospital of the PLA Joint Logistics Support ForceFuzhou

  1150. Recruiting
    A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2022-11
    Registry
    NCT05521802

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  1151. Recruiting
    Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2022-11
    Registry
    NCT05527470

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuilin, Wuzhou

  1152. Recruiting
    The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
    Phase
    Phase 2
    Started
    2022-09
    Registry
    NCT05536102

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai General HospitalShanghai

  1153. Recruiting
    Laparoscopic vs Open Total Gastrectomy for Gastric Cancer
    Phase
    N/A
    Started
    2022-10
    Registry
    NCT05537129

    Age 20 years to 80 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  1154. Recruiting
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 3
    Started
    2022-10
    Registry
    NCT05552222

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  1155. Recruiting
    TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma
    Phase
    Phase 1
    Started
    2022-12
    Registry
    NCT05562024

    Age 1 year to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesJinan, Tianjin

  1156. Recruiting
    Construction of a Database for TTP
    Phase
    Not given
    Started
    2022-10
    Registry
    NCT05571774

    Age not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  1157. Recruiting
    A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
    Phase
    Phase 1/Phase 2
    Started
    2022-11
    Registry
    NCT05579132

    Age 2 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesChengdu, Chongqing, Guangzhou, Hangzhou, Tianjin, Wuhan, Xuzhou, Zhengzhou

  1158. Recruiting
    Human BCMA Targeted T Cells Injection(BCMA CAR-T)for Subjects With R/R MM
    Phase
    Phase 2
    Started
    2022-07
    Registry
    NCT05594797

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Wenzhou

  1159. Recruiting
    Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC
    Phase
    Phase 3
    Started
    2022-11
    Registry
    NCT05608213

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  1160. Recruiting
    A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
    Phase
    Phase 3
    Started
    2022-12
    Registry
    NCT05611801

    Age 1 year to 17 years; men only (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Tianjin, Wuhan

  1161. Recruiting
    The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
    Phase
    N/A
    Started
    2022-09
    Registry
    NCT05618041

    Age 14 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTaiyuan

  1162. Recruiting
    Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Lymph Node Dissection for Remnant Gastric Cancer
    Phase
    Phase 2
    Started
    2022-06
    Registry
    NCT05618821

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  1163. Recruiting
    The Evolution and Prognosis of Moyamoya Disease
    Phase
    Not given
    Started
    2022-09
    Registry
    NCT05619068

    Age 10 years to 60 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  1164. Recruiting
    Study of GPC-3 CAR-T Cells in Treating With Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2022-11
    Registry
    NCT05620706

    Age 40 years to 70 years (registered criteria)

    Led by Shenzhen University General HospitalShenzhen

  1165. Recruiting
    Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T
    Phase
    N/A
    Started
    2022-10
    Registry
    NCT05620732

    Age 18 years to 75 years (registered criteria)

    Led by Shenzhen University General HospitalShenzhen

  1166. Recruiting
    A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
    Phase
    Phase 3
    Started
    2022-11
    Registry
    NCT05623020

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan

  1167. Recruiting
    ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)
    Phase
    Phase 1/Phase 2
    Started
    2022-07
    Registry
    NCT05632380

    Age 18 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  1168. Recruiting
    SBRT Combined With Chemotherapy and Tislelizumab in Metastatic NPC
    Phase
    Phase 2
    Started
    2022-09
    Registry
    NCT05652192

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  1169. Recruiting
    Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
    Phase
    Phase 1/Phase 2
    Started
    2022-12
    Registry
    NCT05652920

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Hangzhou, Shanghai

  1170. Recruiting
    CAV Regimen for R/R Ph- B-ALL
    Phase
    N/A
    Started
    2022-10
    Registry
    NCT05657652

    Age 15 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  1171. Recruiting
    Clinical Outcomes of HBeAg-negative CHB Patients With Indeterminate Phase
    Phase
    Not given
    Started
    2022-12
    Registry
    NCT05661786

    Age 18 years to Not stated (registered criteria)

    Led by Nanjing Drum Tower HospitalNanjing

  1172. Recruiting
    Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma
    Phase
    Not given
    Started
    2022-07
    Registry
    NCT05707819

    Age 18 years to 70 years (registered criteria)

    Led by Guangxi Medical University Cancer HospitalNanning

  1173. Recruiting
    Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma
    Phase
    N/A
    Started
    2022-12
    Registry
    NCT05717790

    Age 18 years to 70 years (registered criteria)

    Led by Fourth Affiliated Hospital of Guangxi Medical University; 6 listed hospitals as study sitesGuangzhou, Guilin, Liuzhou, Wuzhou, Zhongshan

  1174. Recruiting
    Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma
    Phase
    Phase 4
    Started
    2022-07
    Registry
    NCT05722405

    Age 18 years to 80 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  1175. Recruiting
    Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement
    Phase
    N/A
    Started
    2022-07
    Registry
    NCT05789030

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  1176. Recruiting
    Laparoscopic Gastrectomy With D2 Lymphadenectomy Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) or Not
    Phase
    Phase 3
    Started
    2022-11
    Registry
    NCT05871099

    Age 18 years to 80 years (registered criteria)

    Led by Affiliated Hospital of Qingdao UniversityQingdao

  1177. Recruiting
    Goal-directed LCVP Based on HP in Laparoscopic Hepatectomy
    Phase
    N/A
    Started
    2022-05
    Registry
    NCT05887661

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  1178. Recruiting
    Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell
    Phase
    Phase 2
    Started
    2022-08
    Registry
    NCT06006650

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu HospitalXi'an

  1179. Recruiting
    CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia
    Phase
    Phase 2
    Started
    2022-01
    Registry
    NCT06081478

    Age 14 years to 85 years (registered criteria)

    Led by Beijing Tongren HospitalBeijing

  1180. Recruiting
    Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor
    Phase
    Phase 3
    Started
    2022-09
    Registry
    NCT06190782

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  1181. Recruiting
    Surgery Plus Reduced Target Chemoradiotherapy vs Surgery Plus Reduced Dose Chemoradiotherapy for Newly Diagnosed Operable Nasopharyngeal Carcinoma.
    Phase
    N/A
    Started
    2022-11
    Registry
    NCT06529562

    Age 18 years to 70 years (registered criteria)

    Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai

  1182. Recruiting
    First-Line and Neoadjuvant Immunotherapy for Gastric Cancer
    Phase
    Not given
    Started
    2022-01
    Registry
    NCT06727981

    Age 18 years to 100 years (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  1183. Recruiting
    Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
    Phase
    Not given
    Started
    2022-09
    Registry
    NCT06822413

    Age not stated (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang University; 3 listed hospitals as study sitesHangzhou, Nanchang, Shanghai

  1184. Recruiting
    Efficacy and Safety of Radiotherapy in Oligoprogressive HCC Following First-line PD-1 Therapy
    Phase
    Phase 2
    Started
    2022-07
    Registry
    NCT06870942

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  1185. Recruiting
    Clinical Application Study of [123I]Metaiodobenzylguanidine and Somatostatin Receptor-Targeted Imaging in the Diagnosis and Staging of Neuroblastoma
    Phase
    Not given
    Started
    2022-07
    Registry
    NCT07064746

    Age Not stated to 18 years (registered criteria)

    Led by Jiangsu Province Hospital; 1 listed hospital as study siteNanjing

  1186. Recruiting
    Sapylin Versus Dexamethasone Inhalation for CCRT-Induced Oral Mucositis in Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2022-08
    Registry
    NCT07327216

    Age 18 years to 75 years (registered criteria)

    Led by Affiliated Hospital of Guangdong Medical UniversityZhanjiang

  1187. Recruiting
    Serial ctDNA and Molecular Residual Disease Monitoring in Neuroblastoma
    Phase
    Not given
    Started
    2022-01
    Registry
    NCT07516678

    Age not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  1188. Recruiting
    Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer
    Phase
    Phase 3
    Started
    2021-01
    Registry
    NCT04415853

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  1189. Recruiting
    Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition
    Phase
    Phase 3
    Started
    2021-08
    Registry
    NCT04436965

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  1190. Recruiting
    A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy
    Phase
    Phase 3
    Started
    2021-03
    Registry
    NCT04478292

    Age Not stated to 18 years (registered criteria)

    Led by Shanghai Children's Medical CenterShanghai

  1191. Recruiting
    Oxaliplatin Combined With S-1(SOX) Neoadjuvant Chemotherapy for Different Cycles in Patients With Gastric Cancer
    Phase
    Phase 3
    Started
    2021-01
    Registry
    NCT04483076

    Age 18 years to 70 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  1192. Recruiting
    A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 2
    Started
    2021-02
    Registry
    NCT04634552

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Suzhou, Tianjin, Xi'an

  1193. Recruiting
    CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases
    Phase
    Early phase 1
    Started
    2021-11
    Registry
    NCT04662294

    Age not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  1194. Recruiting
    Multicenter Study on Laparoscopic Total Gastrectomy for Advanced Gastric Cancer
    Phase
    N/A
    Started
    2021-01
    Registry
    NCT04710758

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  1195. Recruiting
    Gene Therapy for Chinese Hemophilia A
    Phase
    N/A
    Started
    2021-03
    Registry
    NCT04728841

    Age 18 years to Not stated; men only (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  1196. Recruiting
    Neo-TACE-HAIC for High-risk BCLC A Stage HCC (NeoconceptA)
    Phase
    N/A
    Started
    2021-02
    Registry
    NCT04777942

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  1197. Recruiting
    Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2021-03
    Registry
    NCT04778956

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesFoshan, Guangzhou, Zhongshan

  1198. Recruiting
    Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
    Phase
    Phase 2
    Started
    2021-01
    Registry
    NCT04803318

    Age 18 years to 85 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  1199. Recruiting
    Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)
    Phase
    Phase 3
    Started
    2021-12
    Registry
    NCT04807673

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  1200. Recruiting
    Comparation of Endoscopic Biopsy and Postoperative Specimen for the Molecular Diagnosis of Gastric Cancer
    Phase
    Not given
    Started
    2021-05
    Registry
    NCT04809025

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  1201. Recruiting
    A Phase III Study Comparing Total and Partial Omentectomy for Patients With Advanced Gastric Cancer
    Phase
    N/A
    Started
    2021-01
    Registry
    NCT04843215

    Age 18 years to 70 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  1202. Recruiting
    Relationship Between Perioperative Treatment Efficacy and The Tumor Microenvironment for Locally Advanced Resectable Gastric Cancer.
    Phase
    Not given
    Started
    2021-05
    Registry
    NCT04850729

    Age 18 years to 75 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  1203. Recruiting
    China Amyotrophic Lateral Sclerosis Registry of Patients With Traditional Chinese Medicine
    Phase
    Not given
    Started
    2021-03
    Registry
    NCT04885374

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  1204. Recruiting
    Toripalimab Plus FLOT in Locally Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2021-06
    Registry
    NCT04891016

    Age 18 years to 70 years (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  1205. Recruiting
    Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2021-06
    Registry
    NCT04900818

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Harbin, Hefei, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou

  1206. Recruiting
    Intrathecal Chemotherapy for Central Nervous System Metastasis in Retinoblastoma
    Phase
    N/A
    Started
    2021-05
    Registry
    NCT04903678

    Age not stated (registered criteria)

    Led by Eye & ENT Hospital of Fudan UniversityShanghai

  1207. Recruiting
    Gene Therapy Clinical Trial for the Treatment Of Leber's HereDitary Optic Neuropathy
    Phase
    Phase 2/Phase 3
    Started
    2021-06
    Registry
    NCT04912843

    Age 12 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  1208. Recruiting
    Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
    Phase
    Phase 2
    Started
    2021-08
    Registry
    NCT04924075

    Age 12 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  1209. Recruiting
    Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors
    Phase
    Phase 2
    Started
    2021-09
    Registry
    NCT04933669

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  1210. Recruiting
    Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2021-06
    Registry
    NCT04944914

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  1211. Recruiting
    Genotype-Phenotype Correlations in Patients With Alport Syndrome
    Phase
    Not given
    Started
    2021-01
    Registry
    NCT04947813

    Age not stated (registered criteria)

    Led by Xinhua HospitalShanghai

  1212. Recruiting
    A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
    Phase
    Phase 3
    Started
    2021-07
    Registry
    NCT04951622

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Shanghai, Tianjin, Xi'an

  1213. Recruiting
    Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2021-03
    Registry
    NCT04952272

    Age 18 years to 80 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  1214. Recruiting
    A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2021-09
    Registry
    NCT04973605

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Chongqing, Fuzhou, Hangzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xiamen, Zhengzhou

  1215. Recruiting
    Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma
    Phase
    Phase 3
    Started
    2021-07
    Registry
    NCT04997837

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  1216. Recruiting
    Gastric Cancer Marker Detection and Its Kit Development
    Phase
    Not given
    Started
    2021-01
    Registry
    NCT05010863

    Age not stated (registered criteria)

    Led by Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical UniversityWenzhou

  1217. Recruiting
    A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
    Phase
    Phase 3
    Started
    2021-10
    Registry
    NCT05020236

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Shenzhen, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Xuzhou, Zhengzhou

  1218. Recruiting
    Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-11
    Registry
    NCT05024214

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Bengbu, Changchun, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Shanghai, Shenyang, Tianjin, Zhengzhou, Zhuhai

  1219. Recruiting
    PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer
    Phase
    Phase 2
    Started
    2021-09
    Registry
    NCT05033392

    Age 18 years to 79 years (registered criteria)

    Led by Shenzhen People's HospitalShenzhen

  1220. Recruiting
    The Treatment of Bioartificial Liver With hiHep Cells After Extensive Hepatectomy
    Phase
    Early phase 1
    Started
    2021-09
    Registry
    NCT05035108

    Age 30 years to 80 years (registered criteria)

    Led by Sir Run Run Shaw HospitalHangzhou

  1221. Recruiting
    GPC3 Targeted Fluorescence Image Guided Surgery of Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2021-09
    Registry
    NCT05047510

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesLuzhou, Zhuhai

  1222. Recruiting
    Cryoablation Combined with Tislelizumab Plus Lenvatinib As Second-line or Later Therapy in Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2021-09
    Registry
    NCT05057845

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  1223. Recruiting
    ICCRT vs. CRT for Locally Advanced Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2021-09
    Registry
    NCT05062005

    Age 18 years to 65 years (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  1224. Recruiting
    Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC
    Phase
    Phase 2/Phase 3
    Started
    2021-06
    Registry
    NCT05062837

    Age 18 years to 75 years (registered criteria)

    Led by Guangxi Medical University Cancer HospitalNanning

  1225. Recruiting
    18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor
    Phase
    Early phase 1
    Started
    2021-09
    Registry
    NCT05069220

    Age 1 year to 80 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  1226. Recruiting
    High Medium-chain Triglyceride Nutritional Support in Infants With Biliary Atresia
    Phase
    Not given
    Started
    2021-10
    Registry
    NCT05072626

    Age Not stated to 3 months (registered criteria)

    Led by Children's Hospital of Fudan UniversityShanghai

  1227. Recruiting
    Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen
    Phase
    Phase 2
    Started
    2021-12
    Registry
    NCT05088226

    Age 12 years to 65 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  1228. Recruiting
    Immune Score Based Radiomics in Nasopharyngeal Carcinoma
    Phase
    Not given
    Started
    2021-11
    Registry
    NCT05126160

    Age 18 years to 70 years (registered criteria)

    Led by Zhejiang Cancer Hospital; 4 listed hospitals as study sitesHangzhou, Ningbo, Wenzhou, Wuhan

  1229. Recruiting
    Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
    Phase
    Phase 3
    Started
    2021-11
    Registry
    NCT05145127

    Age 1 year to 74 years; men only (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Guangzhou, Guiyang, Nanchang, Tianjin, Wuhan

  1230. Recruiting
    Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-11
    Registry
    NCT05187338

    Age 18 years to 70 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  1231. Recruiting
    A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
    Phase
    Phase 1
    Started
    2021-11
    Registry
    NCT05194982

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChangsha, Chongqing, Guangzhou, Wuhan

  1232. Recruiting
    A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
    Phase
    Not given
    Started
    2021-07
    Registry
    NCT05283993

    Age not stated (registered criteria)

    Led by Peking University First HospitalBeijing

  1233. Recruiting
    Antiviral Therapy for Patients With Liver Cancer After Surgery
    Phase
    Not given
    Started
    2021-12
    Registry
    NCT05466565

    Age 18 years to 65 years (registered criteria)

    Led by Xiangya HospitalChangsha

  1234. Recruiting
    Multi-parametric MRI and Dual-energy CT in Patients of Gastric Cancer
    Phase
    Not given
    Started
    2021-11
    Registry
    NCT05508126

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  1235. Recruiting
    Proximal Gastrectomy Anterior Anastomosis With Pyloroplasty Versus Esophagogastric Anastomosis for Gastric Cancer
    Phase
    N/A
    Started
    2021-01
    Registry
    NCT05514769

    Age 18 years to 85 years (registered criteria)

    Led by Nanchong Central HospitalNanchong

  1236. Recruiting
    Comparison of Chemoradiotherapy and Chemoradiotherapy Combined With Consolidation Chemotherapy for ESCC
    Phase
    N/A
    Started
    2021-06
    Registry
    NCT05775419

    Age 18 years to 70 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  1237. Recruiting
    Development of Novel Gastric Cancer Screening and Diagnosis Technologies Using Tongue Imaging and Study of Tongue Image Changes Mechanisms
    Phase
    Not given
    Started
    2021-06
    Registry
    NCT06078930

    Age 18 years to 90 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  1238. Recruiting
    Individualized Dynamic Frailty-tailored Therapy (DynaFiT) in Elderly Patients With NDMM
    Phase
    Not given
    Started
    2021-09
    Registry
    NCT06099912

    Age 65 years to Not stated (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  1239. Recruiting
    HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2021-01
    Registry
    NCT06333561

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  1240. Recruiting
    An Observational Study on the Safety and Efficacy of Immunotherapy Combined With Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma
    Phase
    Not given
    Started
    2021-03
    Registry
    NCT07080437

    Age 70 years to Not stated (registered criteria)

    Led by Chongqing University Three Gorges HospitalChongqing

  1241. Recruiting
    A Prospective Multicenter Clinical Study of SCCG Protocol and ctDNA 5hmc in Predicting the Chemotherapy Sensitivity and Monitoring the Recurrence and Metastasis of Hepatoblastoma in Children and Adolescents
    Phase
    Phase 2
    Started
    2021-06
    Registry
    NCT07300449

    Age Not stated to 18 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  1242. Recruiting
    Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2021-03
    Registry
    NCT07320586

    Age 18 years to 75 years (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  1243. Recruiting
    PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
    Phase
    Phase 3
    Started
    2020-03
    Registry
    NCT03907826

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 10 listed hospitals as study sitesChengdu, Fuzhou, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanning, Shanghai, Wuhan, Xi'an, Xiamen

  1244. Recruiting
    Samples Procurement for Colorectal Cancer, Gastric Cancer, and Non-malignant Disease
    Phase
    Not given
    Started
    2020-12
    Registry
    NCT03972956

    Age 18 years to 80 years (registered criteria)

    Led by Renmin Hospital of Wuhan UniversityWuhan

  1245. Recruiting
    Screening Nasopharyngeal Carcinoma With EBV Associated Biomarkers in Zhongshan City
    Phase
    Not given
    Started
    2020-04
    Registry
    NCT04085900

    Age 30 years to 69 years (registered criteria)

    Led by Zhongshan City People's Hospital; 1 listed hospital as study siteWuzhou, Zhongshan

  1246. Recruiting
    RFA Plus Carrizumab vs Carrizumab Alone for HCC
    Phase
    Phase 2
    Started
    2020-08
    Registry
    NCT04150744

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  1247. Recruiting
    A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy
    Phase
    Early phase 1
    Started
    2020-01
    Registry
    NCT04227015

    Age 3 years to 70 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  1248. Recruiting
    Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma
    Phase
    Phase 3
    Started
    2020-04
    Registry
    NCT04280822

    Age 18 years to 75 years (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  1249. Recruiting
    Reduced Port Laparoscopic Gastrectomy for Gastric Cancer
    Phase
    N/A
    Started
    2020-03
    Registry
    NCT04295473

    Age 18 years to 90 years (registered criteria)

    Led by Nanchong Central HospitalNanchong

  1250. Recruiting
    A Pilot Study in Severe Patients With Takayasu Arteritis.
    Phase
    Phase 4
    Started
    2020-03
    Registry
    NCT04300686

    Age 14 years to 100 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  1251. Recruiting
    Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2020-06
    Registry
    NCT04376866

    Age 18 years to 65 years (registered criteria)

    Led by Guangxi Medical University Cancer HospitalNanning

  1252. Recruiting
    Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma
    Phase
    N/A
    Started
    2020-06
    Registry
    NCT04425265

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Zhuhai

  1253. Recruiting
    Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2020-08
    Registry
    NCT04437329

    Age 18 years to 65 years (registered criteria)

    Led by Affiliated Cancer Hospital of Guangzhou Medical UniversityGuangzhou

  1254. Recruiting
    Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2020-08
    Registry
    NCT04448522

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 3 listed hospitals as study sitesGuangzhou, Shaoguan, Wuzhou, Zhongshan

  1255. Recruiting
    Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2020-07
    Registry
    NCT04453813

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesGuangzhou, Shaoguan, Wuzhou, Zhongshan, Zhuhai

  1256. Recruiting
    Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2020-09
    Registry
    NCT04453826

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesGuangzhou, Shaoguan, Wuzhou, Zhongshan, Zhuhai

  1257. Recruiting
    Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases
    Phase
    Early phase 1
    Started
    2020-08
    Registry
    NCT04504526

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou

  1258. Recruiting
    Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)
    Phase
    N/A
    Started
    2020-01
    Registry
    NCT04519905

    Age 76 years to Not stated (registered criteria)

    Led by Huadong Hospital, Fudan University; 1 listed hospital as study siteNanjing, Shanghai

  1259. Recruiting
    Detecting Chemosensitivity and Predicting Treatmemt Efficacy With CTCs in mNPC
    Phase
    Not given
    Started
    2020-04
    Registry
    NCT04544969

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  1260. Recruiting
    To Develop and Validate a Nasoendoscopic Intelligent Diagnostic System for Nasopharyngeal Carcinoma
    Phase
    Not given
    Started
    2020-06
    Registry
    NCT04547673

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen University; 1 listed hospital as study siteGuangzhou

  1261. Recruiting
    Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
    Phase
    Early phase 1
    Started
    2020-09
    Registry
    NCT04561557

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  1262. Recruiting
    Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC
    Phase
    Phase 2
    Started
    2020-12
    Registry
    NCT04615143

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  1263. Recruiting
    National Longitudinal Cohort of Hematological Diseases
    Phase
    Not given
    Started
    2020-12
    Registry
    NCT04645199

    Age not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  1264. Recruiting
    Clinical Research of Tapering UDCA in PBC Patients With a Complete Response
    Phase
    Phase 4
    Started
    2020-01
    Registry
    NCT04650243

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  1265. Recruiting
    Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer
    Phase
    N/A
    Started
    2020-07
    Registry
    NCT04688801

    Age 25 years to 80 years (registered criteria)

    Led by Second Hospital of Shandong UniversityJinan

  1266. Recruiting
    Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs
    Phase
    Phase 2
    Started
    2020-11
    Registry
    NCT04770207

    Age 18 years to 99 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  1267. Recruiting
    Phase Ib Clinical Study of Keynatinib
    Phase
    Phase 1
    Started
    2020-09
    Registry
    NCT04807881

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Chengdu, Shanghai

  1268. Recruiting
    The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA)
    Phase
    Not given
    Started
    2020-12
    Registry
    NCT04858724

    Age not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  1269. Recruiting
    Adjuvant Chemotherapy for High-risk Postenucleation Retinoblastoma
    Phase
    Phase 3
    Started
    2020-11
    Registry
    NCT05080010

    Age not stated (registered criteria)

    Led by Zhongshan Ophthalmic CenterGuangzhou

  1270. Recruiting
    Prediction of Neoadjuvant Chemotherapy Efficacy in Locally Advanced Gastric Cancer
    Phase
    N/A
    Started
    2020-09
    Registry
    NCT05140746

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  1271. Recruiting
    Correlation of Microbiome and Metabonomics With IgA Nephropathy
    Phase
    Not given
    Started
    2020-05
    Registry
    NCT05190848

    Age 16 years to 65 years (registered criteria)

    Led by Guangdong Provincial People's Hospital; 4 listed hospitals as study sitesGuangzhou

  1272. Recruiting
    AutoInflammatory Disease Alliance Registry (AIDA)
    Phase
    Not given
    Started
    2020-08
    Registry
    NCT05200715

    Age not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Chongqing

  1273. Recruiting
    Linear Stapler Versus Circular Stapler in Esophagojejunostomy
    Phase
    N/A
    Started
    2020-01
    Registry
    NCT05360069

    Age 18 years to 90 years (registered criteria)

    Led by Nanchong Central HospitalNanchong

  1274. Recruiting
    Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing
    Phase
    Not given
    Started
    2020-05
    Registry
    NCT05520788

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  1275. Recruiting
    Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2020-05
    Registry
    NCT05713994

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital of Fujian Medical UniversityQuanzhou

  1276. Recruiting
    Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
    Phase
    Not given
    Started
    2020-12
    Registry
    NCT05740995

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  1277. Recruiting
    Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients
    Phase
    Early phase 1
    Started
    2020-12
    Registry
    NCT05745532

    Age 8 years to 16 years (registered criteria)

    Led by Shenzhen Children's HospitalShenzhen

  1278. Recruiting
    Surveillance and Tracking the Outcomes of Chronic Latent EBV Infection
    Phase
    Not given
    Started
    2019-07
    Registry
    NCT03491605

    Age not stated (registered criteria)

    Led by Tongji HospitalWuhan

  1279. Recruiting
    S-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC)
    Phase
    Phase 3
    Started
    2019-01
    Registry
    NCT03941561

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesHefei, Nanchang, Wuhu

  1280. Recruiting
    Infusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular Carcinoma
    Phase
    Phase 3
    Started
    2019-01
    Registry
    NCT03949231

    Age 18 years to 80 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  1281. Recruiting
    Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2019-04
    Registry
    NCT03964753

    Age 18 years to 75 years (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  1282. Recruiting
    A Registered Cohort Study on Amyotrophic Lateral Sclerosis
    Phase
    Not given
    Started
    2019-07
    Registry
    NCT04008329

    Age not stated (registered criteria)

    Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou

  1283. Recruiting
    A Registered Cohort Study on SMA
    Phase
    Not given
    Started
    2019-07
    Registry
    NCT04010604

    Age 1 week to 70 years (registered criteria)

    Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou

  1284. Recruiting
    A Registered Cohort Study on Wilson's Disease
    Phase
    Not given
    Started
    2019-07
    Registry
    NCT04012658

    Age not stated (registered criteria)

    Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou

  1285. Recruiting
    A Registered Cohort Study on Duchenne Muscular Dystrophy
    Phase
    Not given
    Started
    2019-07
    Registry
    NCT04012671

    Age 2 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou

  1286. Recruiting
    Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients
    Phase
    Phase 1/Phase 2
    Started
    2019-07
    Registry
    NCT04025450

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  1287. Recruiting
    Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma
    Phase
    N/A
    Started
    2019-09
    Registry
    NCT04047953

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  1288. Recruiting
    Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)
    Phase
    Not given
    Started
    2019-01
    Registry
    NCT04106830

    Age 16 years to 75 years (registered criteria)

    Led by Beijing Tiantan HospitalBeijing

  1289. Recruiting
    Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma
    Phase
    Phase 3
    Started
    2019-09
    Registry
    NCT04135664

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Chest Hospital; 5 listed hospitals as study sitesNanchang, Shanghai, Tianjin

  1290. Recruiting
    Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903)
    Phase
    Phase 3
    Started
    2019-10
    Registry
    NCT04138212

    Age 18 years to 70 years (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  1291. Recruiting
    Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
    Phase
    Phase 2
    Started
    2019-11
    Registry
    NCT04143724

    Age 6 years to 17 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChengdu, Guangzhou, Nanning, Shenzhen

  1292. Recruiting
    BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma
    Phase
    Phase 1
    Started
    2019-07
    Registry
    NCT04162353

    Age not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

  1293. Recruiting
    Study on Adjuvant Chemotherapy After Total Two-field Lymph Node Dissection of Thoracic Esophageal Squamous Cell Carcinoma
    Phase
    N/A
    Started
    2019-12
    Registry
    NCT04174079

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  1294. Recruiting
    TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study
    Phase
    Not given
    Started
    2019-11
    Registry
    NCT04182984

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu HospitalXi'an

  1295. Recruiting
    Chemoradiotherapy in Unresectable Esophageal Cancer
    Phase
    Phase 1/Phase 2
    Started
    2019-10
    Registry
    NCT04278287

    Age 18 years to 75 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMS; 4 listed hospitals as study sitesAnyang, Beijing, Changsha, Nanjing

  1296. Recruiting
    To Compare the Efficacy of Microwave Ablation and Laparoscopic Hepatectomy for Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2019-12
    Registry
    NCT04365751

    Age 18 years to Not stated (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  1297. Recruiting
    Natural History and Clinical Features of Amyotrophic Lateral Sclerosis (ALS)
    Phase
    Not given
    Started
    2019-11
    Registry
    NCT04454892

    Age not stated (registered criteria)

    Led by Peking University Third HospitalBeijing

  1298. Recruiting
    Liver Volume Metrics for Predicting Immunotherapy Prognosis in Unresectable Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2019-01
    Registry
    NCT07782632

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of USTCHefei

  1299. Recruiting
    A Study of HQP1351 in Patients With GIST or Other Solid Tumors
    Phase
    Phase 1
    Started
    2018-07
    Registry
    NCT03594422

    Age 12 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Guangzhou, Shanghai, Wuhan, Zhengzhou

  1300. Recruiting
    The Overall Survival of Patients With Unresectable HCC in Real-life
    Phase
    Not given
    Started
    2018-07
    Registry
    NCT03612726

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  1301. Recruiting
    Comparison of Tumor Efficacy Safety in Laparoscopic Resection of Gastrointestinal Stromal Tumors Between Favorable and Unfavorable Site
    Phase
    Not given
    Started
    2018-10
    Registry
    NCT03716089

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  1302. Recruiting
    Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
    Phase
    Phase 2/Phase 3
    Started
    2018-11
    Registry
    NCT03755739

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  1303. Recruiting
    Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2018-01
    Registry
    NCT03919552

    Age 18 years to 64 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  1304. Recruiting
    Regional Lymph Node Metastasis and Survival Outcomes in Advanced HCC
    Phase
    Not given
    Started
    2018-06
    Registry
    NCT06876753

    Age 18 years to 80 years (registered criteria)

    Led by Zhongda Hospital, Southeast UniversityNanjing

  1305. Recruiting
    GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
    Phase
    Phase 1
    Started
    2017-07
    Registry
    NCT03198546

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical University; 1 listed hospital as study siteGuangzhou

  1306. Recruiting
    Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer
    Phase
    Phase 2
    Started
    2017-09
    Registry
    NCT03219593

    Age 65 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Bengbu Medical UniversityBengbu

  1307. Recruiting
    Endoscopic Nasopharyngectomy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma Patients
    Phase
    N/A
    Started
    2017-10
    Registry
    NCT03353467

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFoshan, Guangzhou, Nanning, Zhongshan

  1308. Recruiting
    Fenofibrate in Patients With Primary Biliary Cholangitis (PBC)
    Phase
    Phase 2/Phase 3
    Started
    2017-04
    Registry
    NCT06365424

    Age 18 years to 75 years (registered criteria)

    Led by Xijing HospitalXi'an

  1309. Recruiting
    IgA Nephropathy Biomarkers Evaluation Study (INTEREST)
    Phase
    Not given
    Started
    2016-11
    Registry
    NCT02954419

    Age 14 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  1310. Recruiting
    Chemoradiation Versus Esophagectomy for Locally Advanced Esophageal Cancer
    Phase
    N/A
    Started
    2016-11
    Registry
    NCT02972372

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Henan University of Science and Technology; 1 listed hospital as study siteAnyang, Luoyang

  1311. Recruiting
    National Registry of IgG4-RD in China
    Phase
    Not given
    Started
    2016-12
    Registry
    NCT03023371

    Age not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  1312. Recruiting
    Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2016-09
    Registry
    NCT03196414

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  1313. Recruiting
    A Registry Study on Biomarkers of Takayasu's Arteritis (ARSBTA)
    Phase
    Not given
    Started
    2016-01
    Registry
    NCT03372980

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  1314. Recruiting
    Clinical Features and Prognosis of Takayasu's Arteritis With Pulmonary Arteries Involvement
    Phase
    Not given
    Started
    2016-01
    Registry
    NCT07184814

    Age 18 years to Not stated (registered criteria)

    Led by China-Japan Friendship HospitalBeijing

  1315. Recruiting
    China Registry for Genetic / Metabolic Liver Diseases
    Phase
    Not given
    Started
    2015-06
    Registry
    NCT03131427

    Age not stated (registered criteria)

    Led by Beijing Friendship Hospital; 1 listed hospital as study siteBeijing

  1316. Recruiting
    Treatment of Patients With Takayasu Arteritis Complicated With Pulmonary Artery Involvement
    Phase
    Not given
    Started
    2014-01
    Registry
    NCT05388682

    Age not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  1317. Recruiting
    Predicting Gastric Cancer Response to Chemo With Multimodal AI Model
    Phase
    Not given
    Started
    2013-02
    Registry
    NCT06451393

    Age 20 years to 90 years (registered criteria)

    Led by Sixth Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  1318. Recruiting
    A Prospective Cohort Study of IgG4RD in China
    Phase
    Not given
    Started
    2012-01
    Registry
    NCT01670695

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  1319. Recruiting
    IgA Nephropathy Registration Initiative of High Quality (INSIGHT)
    Phase
    Not given
    Started
    2012-11
    Registry
    NCT03001947

    Age 14 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  1320. Recruiting
    Influence of Radiotherapy and Chemotherapy in the Value of Peripheral Blood Lymphocyte Subsets Among Thoracic Cancer
    Phase
    Not given
    Started
    2012-01
    Registry
    NCT04522687

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  1321. Recruiting
    Registry of Multicenter Brain-Heart Comorbidity in China
    Phase
    Not given
    Started
    2012-01
    Registry
    NCT05961748

    Age 18 years to Not stated (registered criteria)

    Led by Beijing Tiantan Hospital; 4 listed hospitals as study sitesBeijing, Harbin, Shanghai, Zhengzhou

  1322. Recruiting
    Precision Diagnosis and Risk Stratification of Rare Cardiomyopathies Based on Novel Cardiac Magnetic Resonance Techniques
    Phase
    Not given
    Started
    2010-01
    Registry
    NCT07336394

    Age not stated (registered criteria)

    Led by Fuwai HospitalBeijing

  1323. Recruiting
    Combination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma
    Phase
    Phase 2/Phase 3
    Started
    2009-12
    Registry
    NCT02851784

    Age not stated (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  1324. Recruiting
    Role for Biochemical Assays and Kayser-Fleischer Rings in Diagnosis of Wilson Disease
    Phase
    Not given
    Started
    2004-01
    Registry
    NCT04965545

    Age 6 years to 65 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  1325. Recruiting
    Clinical Features and Outcome in Patients With Osseomuscular Type of Wilson's Disease
    Phase
    Not given
    Started
    2004-01
    Registry
    NCT04965558

    Age 6 years to 65 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  1326. Not yet recruiting
    NK521 in the Treatment of Advanced Solid Tumors
    Phase
    Early phase 1
    Started
    2027-01
    Registry
    NCT07657416

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHefei

  1327. Not yet recruiting
    Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome
    Phase
    Phase 2
    Started
    2027-09
    Registry
    NCT07691645

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  1328. Not yet recruiting
    Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 2
    Started
    2027-12
    Registry
    NCT07695740

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  1329. Not yet recruiting
    Conditioning Regimen Containing Low-Dose ATG for the Treatment of AA Receiving sUCBT
    Phase
    Phase 2
    Started
    2027-08
    Registry
    NCT07885982

    Age 1 year to 50 years (registered criteria)

    Led by First Affiliated Hospital of USTCHefei

  1330. Not yet recruiting
    Integration of Imaging, Molecular, Pathological, and Clinical Outcome Data in Hepatocellular Carcinoma.
    Phase
    Not given
    Started
    2027-01
    Registry
    NCT07912853

    Age 18 years to Not stated (registered criteria)

    Led by West China HospitalChengdu

  1331. Not yet recruiting
    Sintilimab Plus FOLFIRI as Second-line Therapy for Patients With HER2-negative Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2026-06
    Registry
    NCT06365008

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  1332. Not yet recruiting
    Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma
    Phase
    Phase 3
    Started
    2026-02
    Registry
    NCT06952621

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu HospitalXi'an

  1333. Not yet recruiting
    Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07064902

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 2 listed hospitals as study sitesGuangzhou, Guilin, Xiamen

  1334. Not yet recruiting
    Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD
    Phase
    Phase 2
    Started
    2026-10
    Registry
    NCT07222553

    Age 2 years to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Changsha

  1335. Not yet recruiting
    Risk-Adapted Omission of Level Va Irradiation in Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2026-01
    Registry
    NCT07268690

    Age 18 years to 70 years (registered criteria)

    Led by Fujian Cancer HospitalFuzhou

  1336. Not yet recruiting
    A Study on the Efficacy and Safety of Telitacicept in the Treatment of Children Ocular Myasthenia Gravis
    Phase
    N/A
    Started
    2026-03
    Registry
    NCT07298928

    Age Not stated to 18 years (registered criteria)

    Led by Children's Hospital, Zhejiang University School of MedicineHangzhou

  1337. Not yet recruiting
    Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07303283

    Age 18 years to 65 years (registered criteria)

    Led by First Affiliated Hospital of Guangxi Medical UniversityNanning

  1338. Not yet recruiting
    Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing
    Phase
    Phase 4
    Started
    2026-04
    Registry
    NCT07312370

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteLanzhou

  1339. Not yet recruiting
    Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer
    Phase
    Phase 3
    Started
    2026-12
    Registry
    NCT07314203

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  1340. Not yet recruiting
    FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2026-02
    Registry
    NCT07314372

    Age 18 years to Not stated (registered criteria)

    Led by Nanjing Drum Tower HospitalNanjing

  1341. Not yet recruiting
    Recurrence After Gastric and Intestinal Polyp Resection
    Phase
    Not given
    Started
    2026-07
    Registry
    NCT07314554

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteLanzhou

  1342. Not yet recruiting
    QL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric Cancer
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07315035

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  1343. Not yet recruiting
    Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07324473

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Chongqing Medical UniversityChongqing

  1344. Not yet recruiting
    Exploration of Sintilimab + Bevacizumab + AG Chemotherapy as First-Line Treatment for Unresectable Advanced/Metastatic Cholangiocarcinoma
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07328802

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  1345. Not yet recruiting
    Robotic vs Laparoscopic Gastrectomy for cT4a Gastric Cancer
    Phase
    Phase 3
    Started
    2026-02
    Registry
    NCT07331454

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  1346. Not yet recruiting
    Tongji NADs Cohort
    Phase
    Not given
    Started
    2026-03
    Registry
    NCT07333196

    Age 18 years to 80 years (registered criteria)

    Led by Tongji HospitalWuhan

  1347. Not yet recruiting
    A Hypoxia-Inducible CAR-T Cell Targeting AXL and CD73 for Advanced Gastric Cancer
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Registry
    NCT07333573

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  1348. Not yet recruiting
    Isa-VRD in TIE HRMM
    Phase
    Phase 4
    Started
    2026-01
    Registry
    NCT07334535

    Age 18 years to 80 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  1349. Not yet recruiting
    A Trial of Behavioral Intervention on Prognostic Survival of Patients With Unresectable Liver Cancer
    Phase
    N/A
    Started
    2026-01
    Registry
    NCT07337031

    Age 18 years to 75 years (registered criteria)

    Led by Eastern Hepatobiliary Surgery HospitalShanghai

  1350. Not yet recruiting
    Head to Head, Prospective, Open Label Multicenter Study on the Diagnostic Efficacy of GPC3 Targeted PET Imaging and Enhanced Magnetic Resonance Imaging for Hepatocellular Carcinoma
    Phase
    Early phase 1
    Started
    2026-01
    Registry
    NCT07352345

    Age 18 years to Not stated (registered criteria)

    Led by Union HospitalWuhan

  1351. Not yet recruiting
    Application Study of 68Ga-NOTA-BCMA Nanoantibody Imaging in Multiple Myeloma
    Phase
    N/A
    Started
    2026-02
    Registry
    NCT07353554

    Age 18 years to 85 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  1352. Not yet recruiting
    Nanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma
    Phase
    Phase 3
    Started
    2026-01
    Registry
    NCT07356037

    Age 18 years to 85 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteChengdu

  1353. Not yet recruiting
    IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric Cancer
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Registry
    NCT07361991

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  1354. Not yet recruiting
    Drug Sensitivity Testing-Based Tumor Organoids to Guide Adjuvant Therapy After Hepatectomy for Primary Liver Cancer
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07363356

    Age 18 years to 70 years (registered criteria)

    Led by Eastern Hepatobiliary Surgery HospitalShanghai

  1355. Not yet recruiting
    A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Unresectable Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2026-01
    Registry
    NCT07368023

    Age 16 years to Not stated (registered criteria)

    Led by Ningbo Medical Center Lihuili HospitalNingbo

  1356. Not yet recruiting
    Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma
    Phase
    Phase 2
    Started
    2026-02
    Registry
    NCT07374250

    Age 18 years to 75 years (registered criteria)

    Led by West China HospitalChengdu

  1357. Not yet recruiting
    A Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of Treatment
    Phase
    N/A
    Started
    2026-02
    Registry
    NCT07376720

    Age 18 years to 78 years (registered criteria)

    Led by Tongji HospitalWuhan

  1358. Not yet recruiting
    Indocyanine Green-guided Omental Shield Anastomosis for Cervical Esophagogastric Anastomosis in Minimally Invasive McKeown Esophagectomy
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07376876

    Age 18 years to 80 years (registered criteria)

    Led by Daping Hospital, Army Medical UniversityChongqing

  1359. Not yet recruiting
    Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2026-02
    Registry
    NCT07388758

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  1360. Not yet recruiting
    Megestrol Acetate Oral Suspension for Cachexia in Patients With cStage III Gastric/Gastroesophageal Junction Adenocarcinoma Receiving Neoadjuvant Therapy With Serplulimab Combined With SOX
    Phase
    Phase 2
    Started
    2026-02
    Registry
    NCT07391826

    Age 18 years to 80 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  1361. Not yet recruiting
    Universal Chimeric Antigen Receptor T-Cell (UCAR T-cell) Therapy Targeting CD19/ BCMA(QT-019C) in Patients With r/ r Neurological Autoimmune Diseases
    Phase
    Early phase 1
    Started
    2026-03
    Registry
    NCT07392528

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Huanhu HospitalTianjin

  1362. Not yet recruiting
    A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma
    Phase
    Phase 2/Phase 3
    Started
    2026-03
    Registry
    NCT07392866

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai

  1363. Not yet recruiting
    Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Cancer
    Phase
    Early phase 1
    Started
    2026-09
    Registry
    NCT07394205

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of Wenzhou Medical UniversityWenzhou

  1364. Not yet recruiting
    A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma(LB2505-0001)
    Phase
    Early phase 1
    Started
    2026-01
    Registry
    NCT07399444

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 4 listed hospitals as study sitesNanchang, Tianjin, Wuhan, Xuzhou, Zhengzhou

  1365. Not yet recruiting
    Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC
    Phase
    Phase 2
    Started
    2026-02
    Registry
    NCT07403435

    Age 18 years to 75 years (registered criteria)

    Led by Union HospitalWuhan

  1366. Not yet recruiting
    A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07446335

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  1367. Not yet recruiting
    LDRT Sequential NIPS Immunochemotherapy for Peritoneal Metastasis of Gastric and Colorectal Cancer
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07453875

    Age 18 years to 75 years (registered criteria)

    Led by Daping Hospital, Army Medical UniversityChongqing

  1368. Not yet recruiting
    Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC
    Phase
    N/A
    Started
    2026-04
    Registry
    NCT07480382

    Age 18 years to 80 years (registered criteria)

    Led by West China HospitalChengdu

  1369. Not yet recruiting
    Evaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advanced Gastric Cancer and PeritonealMetastasis: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial
    Phase
    Phase 2
    Started
    2026-03
    Registry
    NCT07486310

    Age 18 years to 75 years (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  1370. Not yet recruiting
    Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma
    Phase
    Early phase 1
    Started
    2026-03
    Registry
    NCT07487402

    Age 19 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  1371. Not yet recruiting
    Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Leukemia
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07491263

    Age 14 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou

  1372. Not yet recruiting
    Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-06
    Registry
    NCT07493993

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  1373. Not yet recruiting
    Comparison of the Sensitivity of pCLE and Pathological Biopsy for Gastric Mucosal Lesions
    Phase
    Not given
    Started
    2026-03
    Registry
    NCT07507071

    Age 18 years to 75 years (registered criteria)

    Led by Changhai HospitalShanghai

  1374. Not yet recruiting
    A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2026-04
    Registry
    NCT07507526

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  1375. Not yet recruiting
    Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07508956

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  1376. Not yet recruiting
    18F-FAPI PET/CT and MRI in Gastric Cancer
    Phase
    Not given
    Started
    2026-05
    Registry
    NCT07510867

    Age 20 years to 80 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  1377. Not yet recruiting
    U96-CAR-T-Cells For R/R B-ALL
    Phase
    Phase 1
    Started
    2026-07
    Registry
    NCT07511426

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  1378. Not yet recruiting
    Beta-Blockers on the Efficacy of Neoadjuvant Immunotherapy for Gastric Cancer
    Phase
    Phase 2
    Started
    2026-05
    Registry
    NCT07511894

    Age 18 years to 75 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  1379. Not yet recruiting
    SHR-1701 in Combination With Irinotecan Liposome (II) for Second-line Treatment of ESCC After Immunotherapy
    Phase
    Phase 2
    Started
    2026-03
    Registry
    NCT07524374

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  1380. Not yet recruiting
    Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2
    Phase
    Phase 2
    Started
    2026-04
    Registry
    NCT07531979

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  1381. Not yet recruiting
    Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy
    Phase
    Phase 2
    Started
    2026-04
    Registry
    NCT07537777

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang HospitalGuangzhou

  1382. Not yet recruiting
    Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT07537946

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  1383. Not yet recruiting
    Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases
    Phase
    N/A
    Started
    2026-04
    Registry
    NCT07537959

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  1384. Not yet recruiting
    Denosumab Strategy for Liver Cancer With Bone Metastases
    Phase
    Phase 2
    Started
    2026-05
    Registry
    NCT07537972

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  1385. Not yet recruiting
    A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma.
    Phase
    Early phase 1
    Started
    2026-04
    Registry
    NCT07539233

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  1386. Not yet recruiting
    Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors
    Phase
    Phase 1
    Started
    2026-04
    Registry
    NCT07539610

    Age 18 years to 69 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  1387. Not yet recruiting
    GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT07540390

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  1388. Not yet recruiting
    Clinical Study on the Preservation of Ovarian Function in Patients With Aplastic Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation Using Goserelin
    Phase
    N/A
    Started
    2026-05
    Registry
    NCT07552506

    Age 14 years to 50 years; women only (registered criteria)

    Led by Union Hospital; 3 listed hospitals as study sitesHangzhou, Wuhan, Zhengzhou

  1389. Not yet recruiting
    Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection
    Phase
    Early phase 1
    Started
    2026-03
    Registry
    NCT07553767

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteNingbo

  1390. Not yet recruiting
    Non-Invasive Detection of claudin18.2 in Pancreatic and Gastric/Gastroesophageal Junction Cancer by [68Ga]Ga-NODAGA-SNA014 PET Imaging
    Phase
    Not given
    Started
    2026-04
    Registry
    NCT07554742

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  1391. Not yet recruiting
    Efficacy and Safety of HN2301 in Patients With Generalized Myasthenia Gravis (MG)
    Phase
    Phase 1
    Started
    2026-12
    Registry
    NCT07556120

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHefei

  1392. Not yet recruiting
    Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes
    Phase
    Phase 2
    Started
    2026-10
    Registry
    NCT07557914

    Age 18 years to 80 years (registered criteria)

    Led by First Hospital of China Medical UniversityShenyang

  1393. Not yet recruiting
    Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07558200

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  1394. Not yet recruiting
    Stomach-Partitioning Versus Conventional Gastrojejunostomy for Malignant Gastric Outlet Obstruction: A Multicenter Randomized Controlled Trial
    Phase
    N/A
    Started
    2026-10
    Registry
    NCT07561073

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanning

  1395. Not yet recruiting
    Nanocrystalline Megestrol Acetate Versus Placebo for Anorexia in Patients With Unresectable Hepatocellular Carcinoma Receiving TACE Combined With Targeted and Immunotherapy
    Phase
    Phase 2
    Started
    2026-06
    Registry
    NCT07565415

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang HospitalGuangzhou

  1396. Not yet recruiting
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07569757

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou

  1397. Not yet recruiting
    YMN-A02 for Advanced Primary Hepatocellular Carcinoma.
    Phase
    Phase 1
    Started
    2026-07
    Registry
    NCT07580261

    Age 18 years to 70 years (registered criteria)

    Led by West China HospitalChengdu

  1398. Not yet recruiting
    Hybrid Deep Learning Integrating Multimodal CEUS and Enhanced MRI to Optimize Early-Stage HCC Treatment Decisions
    Phase
    Not given
    Started
    2026-04
    Registry
    NCT07582419

    Age 18 years to 85 years (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  1399. Not yet recruiting
    A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07583316

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  1400. Not yet recruiting
    The Safety and Efficacy of KSVCBD Injection in Neuromyelitis Optica Spectrum Disorder.
    Phase
    Early phase 1
    Started
    2026-05
    Registry
    NCT07592754

    Age 18 years to 65 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  1401. Not yet recruiting
    A Study to Evaluate MTM-H-001 Injection in Adult Patients With B-Cell-Related Autoimmune Diseases
    Phase
    N/A
    Started
    2026-06
    Registry
    NCT07593911

    Age 18 years to 75 years (registered criteria)

    Led by Beijing GoBroad HospitalBeijing

  1402. Not yet recruiting
    Multimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCC
    Phase
    N/A
    Started
    2026-10
    Registry
    NCT07596134

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHangzhou, Nanchang, Taizhou

  1403. Not yet recruiting
    Adaptive Adjuvant Therapy After Neoadjuvant Therapy and Gastrectomy for Gastric or Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 2/Phase 3
    Started
    2026-06
    Registry
    NCT07603349

    Age 18 years to 75 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  1404. Not yet recruiting
    Retlirafusp Alfa Combined With Apatinib and Nab-Paclitaxel as Second-line Treatment for Gastric or Gastroesophageal Junction Cancer
    Phase
    Phase 2
    Started
    2026-05
    Registry
    NCT07610629

    Age 18 years to Not stated (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  1405. Not yet recruiting
    A Study on the Efficacy of Sodium Propionate Combined With Anti-PD-1 Immunotherapy in Gastric Cancer
    Phase
    N/A
    Started
    2026-05
    Registry
    NCT07615907

    Age 18 years to 80 years (registered criteria)

    Led by Jinling HospitalNanjing

  1406. Not yet recruiting
    Retlirafusp Alfa Plus Chemotherapy as Neoadjuvant Therapy for Thoracic ESCC
    Phase
    Phase 2
    Started
    2026-05
    Registry
    NCT07618910

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu HospitalXi'an

  1407. Not yet recruiting
    Tafolecimab Combined With Sintilimab and SOX in the Treatment of pMMR/MSS Gastric Cancer
    Phase
    Phase 2
    Started
    2026-06
    Registry
    NCT07621562

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  1408. Not yet recruiting
    A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
    Phase
    Phase 2
    Started
    2026-06
    Registry
    NCT07623642

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Harbin

  1409. Not yet recruiting
    Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma
    Phase
    Early phase 1
    Started
    2026-07
    Registry
    NCT07628595

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  1410. Not yet recruiting
    Phase I/II Clinical Study to Evaluate the Safety, Tolerability and Efficacy of LY-M003 Injection in Adult Patients With Wilson's Disease
    Phase
    Phase 1/Phase 2
    Started
    2026-06
    Registry
    NCT07641140

    Age 18 years to 60 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou

  1411. Not yet recruiting
    Mannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer.
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07655661

    Age 18 years to 75 years (registered criteria)

    Led by West China HospitalChengdu

  1412. Not yet recruiting
    Non-Operative Management and Following Immunotherapy for Colorectal Cancer and Other GI Cancers
    Phase
    Not given
    Started
    2026-06
    Registry
    NCT07656740

    Age not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  1413. Not yet recruiting
    Yttrium-90 Carbon Microsphere Radioembolization in Previously Treated Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2026-06
    Registry
    NCT07657273

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  1414. Not yet recruiting
    One-Click Autofocus Versus Segmented Focus in Gastric Endoscopy
    Phase
    N/A
    Started
    2026-06
    Registry
    NCT07664813

    Age 18 years to Not stated (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  1415. Not yet recruiting
    A Study on the Efficacy and Safety of Sintilimab Combined With Ramucirumab and Paclitaxel in the Treatment of Gastric Cancer Patients With Short-term Recurrence After Adjuvant Therapy
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07669740

    Age 15 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  1416. Not yet recruiting
    A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
    Phase
    Phase 1
    Started
    2026-07
    Registry
    NCT07676266

    Age 18 years to 70 years (registered criteria)

    Led by Affiliated Hospital of Qingdao UniversityQingdao

  1417. Not yet recruiting
    Neoadjuvant Short-Course Radiotherapy Plus Tislelizumab and Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07678580

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu HospitalXi'an

  1418. Not yet recruiting
    A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07682272

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  1419. Not yet recruiting
    A Study of Combination Therapy in Patients With Resectable Liver Cancer
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07684040

    Age 18 years to Not stated (registered criteria)

    Led by Affiliated Hospital of Guangdong Medical UniversityZhanjiang

  1420. Not yet recruiting
    Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07685704

    Age 18 years to 75 years (registered criteria)

    Led by Xijing HospitalXi'an

  1421. Not yet recruiting
    Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification
    Phase
    Phase 1/Phase 2
    Started
    2026-08
    Registry
    NCT07687004

    Age 18 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  1422. Not yet recruiting
    A Phase II Study of PD-1/IL-2α-bias Bispecific Antibody Fusion Protein Monotherapy in Advanced Esophageal Squamous Cell Carcinoma After Failure of Prior ICI Plus Platinum-Based Chemotherapy
    Phase
    Phase 2
    Started
    2026-06
    Registry
    NCT07688291

    Age 18 years to 75 years (registered criteria)

    Led by Beijing GoBroad HospitalBeijing

  1423. Not yet recruiting
    A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma
    Phase
    Phase 3
    Started
    2026-11
    Registry
    NCT07691762

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai

  1424. Not yet recruiting
    Clinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia
    Phase
    Early phase 1
    Started
    2026-08
    Registry
    NCT07696481

    Age 3 years to 75 years (registered criteria)

    Led by Zhujiang HospitalGuangzhou

  1425. Not yet recruiting
    Becotatug Vedotin Plus Cisplatin and Radiotherapy in LA-ESCC
    Phase
    Phase 1
    Started
    2026-07
    Registry
    NCT07697040

    Age 18 years to 75 years (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  1426. Not yet recruiting
    Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial
    Phase
    Phase 4
    Started
    2026-06
    Registry
    NCT07699770

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu Hospital; 5 listed hospitals as study sitesBeijing, Changchun, Chongqing, Kunming, Shenyang, Xi'an

  1427. Not yet recruiting
    Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07701681

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  1428. Not yet recruiting
    A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd Regimen
    Phase
    Phase 4
    Started
    2026-07
    Registry
    NCT07709884

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  1429. Not yet recruiting
    Universal STAR-T Cell Injection in Generalized Myasthenia Gravis
    Phase
    Phase 1
    Started
    2026-07
    Registry
    NCT07714798

    Age 18 years to 65 years (registered criteria)

    Led by Tongji HospitalWuhan

  1430. Not yet recruiting
    Efficacy and Safety of Lenalidomide in Patients With IgG4-Related Disease
    Phase
    Phase 3
    Started
    2026-08
    Registry
    NCT07719543

    Age 18 years to 75 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  1431. Not yet recruiting
    Early Response-guided Sequential Radiotherapy After Chemoimmunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07721103

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  1432. Not yet recruiting
    The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
    Phase
    Not given
    Started
    2026-07
    Registry
    NCT07724951

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan University; 6 listed hospitals as study sitesGuangzhou, Harbin, Nanning, Qingdao, Shanghai

  1433. Not yet recruiting
    A Study of KIV-318 Injection in Patients With BCMA-Positive Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-07
    Registry
    NCT07726160

    Age 18 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  1434. Not yet recruiting
    AI-Guided First-Line Immunotherapy Selection in Unresectable Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2026-10
    Registry
    NCT07729618

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  1435. Not yet recruiting
    AI-Guided Surveillance and Curative Salvage of Recurrence After Hepatocellular Carcinoma Resection or Ablation
    Phase
    N/A
    Started
    2026-10
    Registry
    NCT07732504

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  1436. Not yet recruiting
    Prospective Assessment of Alignment Between Multimodal Artificial Intelligence and Multidisciplinary Team Decisions in Gastrointestinal Oncology
    Phase
    Not given
    Started
    2026-08
    Registry
    NCT07746830

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  1437. Not yet recruiting
    SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07749859

    Age 18 years to 75 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  1438. Not yet recruiting
    Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II Study
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07756190

    Age 18 years to 80 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  1439. Not yet recruiting
    Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma
    Phase
    Phase 1/Phase 2
    Started
    2026-09
    Registry
    NCT07761286

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHarbin

  1440. Not yet recruiting
    Evaluating Antiplatelet and Physical Therapy for Slowing Progression in Mild Moyamoya Disease.
    Phase
    N/A
    Started
    2026-07
    Registry
    NCT07762547

    Age 18 years to 70 years (registered criteria)

    Led by Beijing Tiantan HospitalBeijing

  1441. Not yet recruiting
    Home-based Whole Course Multimodal Prehabilitation Based on 5G + Artificial Intelligence Mobile Health
    Phase
    N/A
    Started
    2026-08
    Registry
    NCT07764523

    Age 18 years to Not stated (registered criteria)

    Led by Affiliated Hospital of Qingdao UniversityQingdao

  1442. Not yet recruiting
    A Open-Label Phase in Participants With Multiple Myeloma
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07764861

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  1443. Not yet recruiting
    Impacted Tooth Management and Osteoradionecrosis Risk in NPC
    Phase
    N/A
    Started
    2026-08
    Registry
    NCT07764887

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Guangxi Medical University; 6 listed hospitals as study sitesGuilin, Liuzhou, Nanning, Wuzhou, Zhongshan

  1444. Not yet recruiting
    Pragmatic RCT of AI-Assisted Reading for Malignant Hepatic Lesions on CE-CT
    Phase
    N/A
    Started
    2026-08
    Registry
    NCT07768085

    Age 18 years to Not stated (registered criteria)

    Led by Shengjing Hospital of China Medical UniversityShenyang

  1445. Not yet recruiting
    Standardized MRI and Structured Reporting for Esophageal Squamous Cell Carcinoma
    Phase
    Not given
    Started
    2026-09
    Registry
    NCT07769658

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou University; 5 listed hospitals as study sitesChengdu, Guangzhou, Kunming, Shanghai, Tianjin, Zhengzhou

  1446. Not yet recruiting
    Retlirafusp Alfa Combined With Chemoradiotherapy in Unresectable ESCC
    Phase
    N/A
    Started
    2026-09
    Registry
    NCT07769866

    Age 18 years to 75 years (registered criteria)

    Led by Renji HospitalShanghai

  1447. Not yet recruiting
    An Exploratory Clinical Study of Accurate Efficacy Assessment of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma Based on 68Ga-FAPI ([68Ga] Fibroblast Activation Protein Inhibitor)/¹⁸F-FDG (2-Deoxy-2-[¹⁸F]Fluoro-D-glucose) Dual Imaging
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07770672

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  1448. Not yet recruiting
    HCC Risk Prediction Model Based on Multimodal Data in Chronic Hepatitis B
    Phase
    Not given
    Started
    2026-08
    Registry
    NCT07780357

    Age 18 years to Not stated (registered criteria)

    Led by Beijing Friendship HospitalBeijing

  1449. Not yet recruiting
    Study of Adebrelimab Combined With Thymalfasin and Chemotherapy for Neoadjuvant Treatment of Esophageal Cancer
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07780721

    Age 18 years to 80 years (registered criteria)

    Led by Affiliated Hospital of Putian UniversityPutian

  1450. Not yet recruiting
    AI-Assisted Novel rbcDNA Detection for Early Gastric Cancer Diagnosis
    Phase
    Not given
    Started
    2026-09
    Registry
    NCT07782294

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang University; 2 listed hospitals as study sitesAnyang, Hangzhou, Shanghai

  1451. Not yet recruiting
    A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02)
    Phase
    Phase 3
    Started
    2026-09
    Registry
    NCT07783321

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  1452. Not yet recruiting
    A Sequential Trial of Low-Dose Radiotherapy Followed by Concurrent Immunotherapy, Systemic Chemotherapy, and Intraperitoneal Perfusion in Gastric Cancer With Peritoneal Carcinomatosis
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07784413

    Age 18 years to Not stated (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  1453. Not yet recruiting
    A Non-inferiority Study of Indocyanine Green-guided Sentinel Lymph Node Mapping Versus Conventional Lymph Node Dissection in Esophageal Cancer
    Phase
    Phase 3
    Started
    2026-10
    Registry
    NCT07788001

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  1454. Not yet recruiting
    A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular Invasion
    Phase
    Phase 4
    Started
    2026-08
    Registry
    NCT07790419

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  1455. Not yet recruiting
    High-Flow Nasal Cannula Oxygenation During Sedated Gastrointestinal Endoscopy in Patients With Chronic Obstructive Pulmonary Disease
    Phase
    N/A
    Started
    2026-08
    Registry
    NCT07791979

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  1456. Not yet recruiting
    TR115 in ARID1A-Mutated Advanced Solid Tumors
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07793318

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  1457. Not yet recruiting
    Platinum-Free Regimen in Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07794488

    Age 18 years to 70 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  1458. Not yet recruiting
    A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07797881

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  1459. Not yet recruiting
    Paclitaxel Polymeric Micelles and Cisplatin Plus Sintilimab as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07799077

    Age 18 years to 75 years (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  1460. Not yet recruiting
    ctDNA-MRD Monitoring After Neoadjuvant Therapy in Gastric Cancer With pCR or MPR
    Phase
    Not given
    Started
    2026-09
    Registry
    NCT07799649

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  1461. Not yet recruiting
    Nebulized UC-EVs for Recurrent or Refractory IMIDs With Lung Involvement
    Phase
    Early phase 1
    Started
    2026-10
    Registry
    NCT07806045

    Age 18 years to 80 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  1462. Not yet recruiting
    Efficacy and Safety of Low-Dose IL-2 in Neuromyelitis Optica Spectrum Disorder
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07809724

    Age 18 years to 74 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  1463. Not yet recruiting
    HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07811986

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  1464. Not yet recruiting
    ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular
    Phase
    Phase 3
    Started
    2026-09
    Registry
    NCT07813572

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanjing

  1465. Not yet recruiting
    An Open-label, Dose-escalation Phase Ib Study of EA5 Injection in Adults With Anti-AChR Antibody-Positive Generalized Myasthenia Gravis
    Phase
    Phase 1
    Started
    2026-09
    Registry
    NCT07818291

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Shanghai

  1466. Not yet recruiting
    A Study of BL-M08D1 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma and Other Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2026-09
    Registry
    NCT07818486

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChongqing, Guangzhou

  1467. Not yet recruiting
    Risk of Esophageal Cancer Returning After Immunotherapy, Chemotherapy, and Surgery
    Phase
    Not given
    Started
    2026-10
    Registry
    NCT07822906

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  1468. Not yet recruiting
    Neoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-10
    Registry
    NCT07823270

    Age 18 years to Not stated (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  1469. Not yet recruiting
    JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer
    Phase
    Phase 3
    Started
    2026-10
    Registry
    NCT07823348

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHarbin, Shanghai

  1470. Not yet recruiting
    Heterogeneity of Treatment Effects of Adding Locoregional Therapies to Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma (ISMIO-026)
    Phase
    Not given
    Started
    2026-09
    Registry
    NCT07824765

    Age 18 years to Not stated (registered criteria)

    Led by Zhongda Hospital, Southeast UniversityNanjing

  1471. Not yet recruiting
    Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2026-10
    Registry
    NCT07824856

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  1472. Not yet recruiting
    Safety and Efficacy Evaluation of Single-Port Versus Multi-Port Robotic-Assisted Radical Distal Gastrectomy for Gastric Cancer
    Phase
    N/A
    Started
    2026-10
    Registry
    NCT07828899

    Age 18 years to 85 years (registered criteria)

    Led by First Affiliated Hospital of Wenzhou Medical University; 2 listed hospitals as study sitesJinan, Shijiazhuang, Wenzhou

  1473. Not yet recruiting
    SNC116 Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
    Phase
    Early phase 1
    Started
    2026-09
    Registry
    NCT07830238

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangchun

  1474. Not yet recruiting
    CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
    Phase
    Phase 2
    Started
    2026-10
    Registry
    NCT07830485

    Age 18 years to 75 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  1475. Not yet recruiting
    TACE in Combination With Tislelizumab and Lenvatinib for Advanced HCC (CHANCE2602)
    Phase
    Not given
    Started
    2026-09
    Registry
    NCT07836309

    Age 16 years to Not stated (registered criteria)

    Led by Zhongda Hospital, Southeast UniversityNanjing

  1476. Not yet recruiting
    Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL
    Phase
    Phase 2
    Started
    2026-10
    Registry
    NCT07840976

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  1477. Not yet recruiting
    Fecal Microbiota Transplantation Combined With QL1706 Plus Bevacizumab for Advanced HCC
    Phase
    Phase 2
    Started
    2026-10
    Registry
    NCT07847671

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  1478. Not yet recruiting
    Phase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard Systemic Therapy Containing ICIs
    Phase
    Phase 1
    Started
    2026-11
    Registry
    NCT07861425

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai

  1479. Not yet recruiting
    Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2026-12
    Registry
    NCT07866612

    Age 18 years to 80 years (registered criteria)

    Led by West China Hospital; 8 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanjing, Shanghai

  1480. Not yet recruiting
    Lenvatinib Plus Bevacizumab and PD-1 Inhibition Versus Bevacizumab Plus PD-1 Inhibition After Progression on Bevacizumab Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Prospective, Randomized, Two-Cohort, Phase II Study
    Phase
    Phase 2
    Started
    2026-10
    Registry
    NCT07870772

    Age 18 years to 80 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  1481. Not yet recruiting
    Exploring the Efficacy of Ferrous Sulfate/Ferrous Succinate Combined With Serplulimab and SOX Regimen in Neoadjuvant Therapy for Gastric Cancer: A Prospective Cohort Study
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07872696

    Age 18 years to 75 years (registered criteria)

    Led by Union HospitalWuhan

  1482. Not yet recruiting
    A Phase II Study of Ipilimumab N01 Plus Sintilimab for MSI-H or dMMR Gastric and Gastroesophageal Junction Cancer
    Phase
    Phase 2
    Started
    2026-10
    Registry
    NCT07878221

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  1483. Not yet recruiting
    Tripterygium Wilfordii Plus Prednisone for Active IgG4-Related Disease
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07878585

    Age 45 years to 79 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  1484. Not yet recruiting
    Multimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer
    Phase
    Not given
    Started
    2026-10
    Registry
    NCT07880106

    Age 18 years to 80 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  1485. Not yet recruiting
    SBRT Combined With Iparomlimab and Tuvonralimab (QL1706) and Bevacizumab for Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2026-10
    Registry
    NCT07882056

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  1486. Not yet recruiting
    Lymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ Adenocarcinoma
    Phase
    Not given
    Started
    2026-10
    Registry
    NCT07902596

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province Hospital; 6 listed hospitals as study sitesNanjing, Qingdao, Shanghai, Shijiazhuang, Suzhou

  1487. Not yet recruiting
    Becotatug Vedotin Plus Gemcitabine and a PD-1 Inhibitor in Recurrent or Metastatic Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2026-11
    Registry
    NCT07902713

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  1488. Not yet recruiting
    QLS4131 for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
    Phase
    Phase 2
    Started
    2026-12
    Registry
    NCT07903636

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  1489. Not yet recruiting
    SND002 Cell Injection in Participants With Advanced Malignant Solid Tumors
    Phase
    Phase 1
    Started
    2026-12
    Registry
    NCT07903857

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou

  1490. Not yet recruiting
    Effect of High-flow Nasal Cannula Oxygenation on the Incidence of Hypoxemia During Painless Gastrointestinal Endoscopy in Patients at High Risk for Obstructive Sleep Apnea Syndrome in High-altitude Regions
    Phase
    N/A
    Started
    2026-11
    Registry
    NCT07904260

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou

  1491. Not yet recruiting
    Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-12
    Registry
    NCT07910903

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  1492. Not yet recruiting
    D2 Gastrectomy With or Without Para-Aortic Lymph Node Dissection After Chemoimmunotherapy for Gastric Cancer
    Phase
    Phase 2
    Started
    2026-11
    Registry
    NCT07912606

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  1493. Not yet recruiting
    Neoadjuvant SHR-A1811 ± Adebrelimab in GC/GEJ
    Phase
    Phase 2
    Started
    2026-11
    Registry
    NCT07912957

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  1494. Not yet recruiting
    Multi-center Prospective Validation of Real-Time AI-EGGIM System
    Phase
    Not given
    Started
    2026-11
    Registry
    NCT07915843

    Age not stated (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  1495. Not yet recruiting
    A Clinical Study to Evaluate the Safety and Efficacy of GT802 Injection in the Treatment of Refractory Generalized Myasthenia Gravis
    Phase
    Early phase 1
    Started
    2026-12
    Registry
    NCT07917923

    Age 18 years to 65 years (registered criteria)

    Led by Tongji HospitalWuhan

  1496. Not yet recruiting
    Development and Validation of a Biopsy Decision Model for Nasopharyngeal Carcinoma Based on Serological Markers and Endoscopic Features
    Phase
    Not given
    Started
    2026-11
    Registry
    NCT07918755

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan City People's Hospital; 1 listed hospital as study siteNanning, Zhongshan

  1497. Not yet recruiting
    Busulfan-Based Versus TBI-Based Conditioning for Adult ALL-CR2 Allo-HSCT
    Phase
    N/A
    Started
    2026-11
    Registry
    NCT07919470

    Age 14 years to 65 years (registered criteria)

    Led by Peking University People's Hospital; 1 listed hospital as study siteBeijing, Langfang

  1498. Not yet recruiting
    NIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCC
    Phase
    Phase 2
    Started
    2026-11
    Registry
    NCT07919717

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  1499. Not yet recruiting
    GK01 Cell Therapy in Gastric Cancer With Peritoneal Metastasis
    Phase
    Phase 1
    Started
    2026-11
    Registry
    NCT07923396

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  1500. Not yet recruiting
    Prospective Study for Molecular Biomarkers and Spatial Transcriptomics of Nasopharyngeal Carcinoma
    Phase
    Not given
    Started
    2025-12
    Registry
    NCT05912582

    Age 18 years to 80 years (registered criteria)

    Led by Jiangsu Cancer HospitalNanjing

  1501. Not yet recruiting
    FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation
    Phase
    Phase 1/Phase 2
    Started
    2025-01
    Registry
    NCT06409637

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  1502. Not yet recruiting
    A Real-World Study of Neoadjuvant/Conversion Therapy for Locally Advanced or Metastatic Gastric Cancer
    Phase
    Not given
    Started
    2025-04
    Registry
    NCT06464601

    Age 18 years to 75 years (registered criteria)

    Led by Zhongnan Hospital of Wuhan UniversityWuhan

  1503. Not yet recruiting
    Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.
    Phase
    Early phase 1
    Started
    2025-02
    Registry
    NCT06485232

    Age 18 years to 75 years (registered criteria)

    Led by Xuanwu HospitalBeijing

  1504. Not yet recruiting
    Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma
    Phase
    Phase 3
    Started
    2025-09
    Registry
    NCT06580223

    Age 18 years to 90 years (registered criteria)

    Led by Union HospitalWuhan

  1505. Not yet recruiting
    GP Combined with Toripalimab Versus GP Induction Chemotherapy for Advanced Childhood Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06605131

    Age 6 years to 18 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  1506. Not yet recruiting
    Liver Cancer Prognosis Investigation Study
    Phase
    Not given
    Started
    2025-04
    Registry
    NCT06623734

    Age 18 years to 80 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  1507. Not yet recruiting
    Combination of SFRT, PD-L1 Inhibitor, and Anti-VEGF in Advanced Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2025-01
    Registry
    NCT06708650

    Age 18 years to 75 years (registered criteria)

    Led by Guiping People's HospitalGuigang

  1508. Not yet recruiting
    SBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.
    Phase
    Phase 2/Phase 3
    Started
    2025-01
    Registry
    NCT06739317

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  1509. Not yet recruiting
    Preliminary Efficacy Analysis of "C" Single Flap Plasty Reconstruction After Laparoscopic Proximal Gastrectomy
    Phase
    N/A
    Started
    2025-01
    Registry
    NCT06741501

    Age 18 years to 80 years (registered criteria)

    Led by Northern Jiangsu People's HospitalYangzhou

  1510. Not yet recruiting
    Effect of Prehabilitation During the Conversion Therapy on Postoperative Outcomes in Unresectable Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2025-01
    Registry
    NCT06749678

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  1511. Not yet recruiting
    Endoscopic Cryoablation Combined With PD-1 in Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2025-05
    Registry
    NCT06759233

    Age 18 years to 80 years (registered criteria)

    Led by Huashan HospitalShanghai

  1512. Not yet recruiting
    An Early Exploratory Clinical Study of GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis
    Phase
    Phase 1
    Started
    2025-02
    Registry
    NCT06759948

    Age 18 years to 75 years (registered criteria)

    Led by Huashan HospitalShanghai

  1513. Not yet recruiting
    A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma
    Phase
    Phase 3
    Started
    2025-01
    Registry
    NCT06779461

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBengbu, Guangzhou, Lanzhou, Nanjing, Shanghai, Tianjin, Zhengzhou

  1514. Not yet recruiting
    Study of CM313(SC) Injection in Subjects With Relapsed/Refractory Aplastic Anemia
    Phase
    Phase 1/Phase 2
    Started
    2025-03
    Registry
    NCT06791824

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  1515. Not yet recruiting
    Fusing Ultrasound and Magnetic Resonance Imaging to Intelligently Plan Highly Conformal Ablation Thermal Field for Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2025-01
    Registry
    NCT06798194

    Age 18 years to Not stated (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  1516. Not yet recruiting
    A Phase Ib/II Clinical Study on the Application of Linperlisib Combined with the VRD Regimen in Newly Diagnosed Patients with Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2025-02
    Registry
    NCT06799676

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesWuhan, Zhengzhou

  1517. Not yet recruiting
    Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer
    Phase
    Phase 2
    Started
    2025-03
    Registry
    NCT06814158

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  1518. Not yet recruiting
    QL1706 As Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2025-02
    Registry
    NCT06822985

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  1519. Not yet recruiting
    A Prospective, Multicenter, Phase II Clinical Study on the Treatment of Unresectable Advanced HCC with DEB-TACE Combined with SALOX-HAIC
    Phase
    Not given
    Started
    2025-03
    Registry
    NCT06823050

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou

  1520. Not yet recruiting
    Predicting Gastric Neoplasia in Patients with High-risk Endoscopic Features
    Phase
    Not given
    Started
    2025-03
    Registry
    NCT06853509

    Age 45 years to Not stated (registered criteria)

    Led by Huadong Hospital, Fudan UniversityShanghai

  1521. Not yet recruiting
    Effectiveness and Safety of InO±DLI for Relapsed B-ALL/LBL After Allo-HSCT
    Phase
    Phase 2
    Started
    2025-03
    Registry
    NCT06861348

    Age 14 years to 65 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  1522. Not yet recruiting
    Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC
    Phase
    Phase 2/Phase 3
    Started
    2025-03
    Registry
    NCT06861777

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  1523. Not yet recruiting
    Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC
    Phase
    Phase 2
    Started
    2025-07
    Registry
    NCT06861894

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  1524. Not yet recruiting
    Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer
    Phase
    Phase 1/Phase 2
    Started
    2025-03
    Registry
    NCT06871527

    Age 18 years to 75 years (registered criteria)

    Led by Sixth Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  1525. Not yet recruiting
    Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2025-03
    Registry
    NCT06888037

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  1526. Not yet recruiting
    Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy
    Phase
    Not given
    Started
    2025-04
    Registry
    NCT06889402

    Age 18 years to 85 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  1527. Not yet recruiting
    A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma
    Phase
    Phase 3
    Started
    2025-04
    Registry
    NCT06895512

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  1528. Not yet recruiting
    Icaritin Soft Capsules+TACE+Immunotherapy+Targeted Therapy Versus TACE+Immunotherapy+Targeted Therapy for Unresectable Hepatocellular Carcinoma
    Phase
    Phase 1/Phase 2
    Started
    2025-04
    Registry
    NCT06896396

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  1529. Not yet recruiting
    PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06900218

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  1530. Not yet recruiting
    Icariin Soft Capsules Combined With TACE as Adjuvant Therapy for HCC
    Phase
    Phase 2
    Started
    2025-03
    Registry
    NCT06900478

    Age 18 years to 80 years (registered criteria)

    Led by Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  1531. Not yet recruiting
    JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Leukemia
    Phase
    N/A
    Started
    2025-03
    Registry
    NCT06902025

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  1532. Not yet recruiting
    Toripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR)
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06903871

    Age 18 years to Not stated (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  1533. Not yet recruiting
    UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Myasthenia Gravis
    Phase
    Early phase 1
    Started
    2025-04
    Registry
    NCT06933563

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  1534. Not yet recruiting
    A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer
    Phase
    Phase 2
    Started
    2025-05
    Registry
    NCT06935175

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  1535. Not yet recruiting
    Relationship Between FGF19 Overexpression and Disease Prognosis
    Phase
    Not given
    Started
    2025-05
    Registry
    NCT06938451

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  1536. Not yet recruiting
    A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06944496

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  1537. Not yet recruiting
    Dose-modified Emapalumab and Ruxolitinib (E-Ru) Regimens for Hemophagocytic Lymphohistiocytosis
    Phase
    Phase 2/Phase 3
    Started
    2025-06
    Registry
    NCT06951971

    Age 1 year to 70 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  1538. Not yet recruiting
    A Randomized Controlled Study of Endoscopic Cryoablation Combined With PD-1 Inhibitor for Maintenance Therapy in Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2025-05
    Registry
    NCT06957977

    Age 18 years to Not stated (registered criteria)

    Led by Huashan HospitalShanghai

  1539. Not yet recruiting
    Comparing ASCT Followed by Anti-BCMA CAR-T vs. ASCT Alone in NDMM Patients Eligible for ASCT
    Phase
    Phase 2
    Started
    2025-05
    Registry
    NCT06963866

    Age 18 years to 70 years (registered criteria)

    Led by Affiliated Hospital of Xuzhou Medical UniversityXuzhou

  1540. Not yet recruiting
    Treatment of Transfusion-dependent Nonsevere Aplastic Anemia With Luspatercept: a Multicenter Prospective Clinical Study
    Phase
    N/A
    Started
    2025-05
    Registry
    NCT06964971

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Zhejiang Chinese Medical UniversityHangzhou

  1541. Not yet recruiting
    The Application Value of Spectral CT in the Accurate Staging of Gastric Cancer
    Phase
    N/A
    Started
    2025-06
    Registry
    NCT06977386

    Age 18 years to 80 years (registered criteria)

    Led by Yunnan Cancer HospitalKunming

  1542. Not yet recruiting
    UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
    Phase
    Phase 1
    Started
    2025-05
    Registry
    NCT06978738

    Age 18 years to Not stated (registered criteria)

    Led by Changzhou No.2 People's HospitalChangzhou

  1543. Not yet recruiting
    Node-Sparing Short-Course Radiotherapy Plus First-Line Therapy and PD-1 Inhibitor in Unresectable/Metastastic pMMR/MSS Gastric Cancer (MODIFI-GC)
    Phase
    Phase 2
    Started
    2025-05
    Registry
    NCT06980389

    Age 18 years to 75 years (registered criteria)

    Led by Sixth Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  1544. Not yet recruiting
    Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk
    Phase
    N/A
    Started
    2025-06
    Registry
    NCT07010588

    Age 18 years to 75 years (registered criteria)

    Led by Peking University People's Hospital; 8 listed hospitals as study sitesBeijing, Changchun, Chongqing, Harbin, Jinan, Qingdao, Wuhan, Xi'an

  1545. Not yet recruiting
    Therapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies
    Phase
    N/A
    Started
    2025-06
    Registry
    NCT07014254

    Age 18 years to 80 years (registered criteria)

    Led by Xijing HospitalXi'an

  1546. Not yet recruiting
    Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer
    Phase
    Phase 2
    Started
    2025-10
    Registry
    NCT07018063

    Age 16 years to 45 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  1547. Not yet recruiting
    PD-1-M1-NK Cells in the Treatment of Advanced Gastric or Colorectal Cancer
    Phase
    Phase 1
    Started
    2025-06
    Registry
    NCT07031011

    Age 18 years to 75 years (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  1548. Not yet recruiting
    Definitive Proton Radiotherapy Combined With Chemotherapy and Immunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase I Clinical Study
    Phase
    Phase 1
    Started
    2025-08
    Registry
    NCT07034118

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of USTCHefei

  1549. Not yet recruiting
    Phase II Clinical Study on the Safety and Efficacy of Combined CAR-T Therapy Following Autologous Stem Cell Transplantation in Multiple Myeloma
    Phase
    N/A
    Started
    2025-07
    Registry
    NCT07034755

    Age 18 years to 70 years (registered criteria)

    Led by Affiliated Hospital of Xuzhou Medical UniversityXuzhou

  1550. Not yet recruiting
    A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors
    Phase
    Phase 1
    Started
    2025-06
    Registry
    NCT07036185

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  1551. Not yet recruiting
    A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
    Phase
    Phase 1
    Started
    2025-07
    Registry
    NCT07043218

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalShanghai

  1552. Not yet recruiting
    Risk-adapted Therapeutic Strategy in +1q NDMM
    Phase
    Not given
    Started
    2025-09
    Registry
    NCT07045168

    Age not stated (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  1553. Not yet recruiting
    HAIC + Atezolizumab Plus Bevacizumab in Unresectable HCC
    Phase
    Not given
    Started
    2025-08
    Registry
    NCT07045558

    Age 18 years to 75 years (registered criteria)

    Led by Renji HospitalShanghai

  1554. Not yet recruiting
    Omega-3 Supplementation and Immunotherapy in Gastric Cancer: A Phase II Trial
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07050524

    Age 18 years to 80 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  1555. Not yet recruiting
    A Real-world Study of the Efficacy and Safety of PD-1 Inhibitors Combined With Chemoradiotherapy in Lung Metastatic Nasopharyngeal Carcinoma
    Phase
    N/A
    Started
    2025-07
    Registry
    NCT07062484

    Age 18 years to Not stated (registered criteria)

    Led by Sichuan Cancer HospitalChengdu

  1556. Not yet recruiting
    Tauroursodeoxycholic Acid Combined With PD-1/PD-L1 Immunotherapy in Advanced Hepatocellular Carcinoma: A Prospective Study
    Phase
    Phase 2
    Started
    2025-07
    Registry
    NCT07064668

    Age 18 years to 80 years (registered criteria)

    Led by Tongji HospitalWuhan

  1557. Not yet recruiting
    Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer
    Phase
    Phase 3
    Started
    2025-07
    Registry
    NCT07068516

    Age 18 years to 80 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  1558. Not yet recruiting
    Shrinking the Anterior Border of CTV2 for Nasopharyngeal Carcinoma to Reduce the Radiation of Nasal Cavity
    Phase
    Phase 3
    Started
    2025-08
    Registry
    NCT07072000

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFoshan, Guangzhou, Liuzhou, Wuzhou, Zhanjiang

  1559. Not yet recruiting
    Efficacy and Safety of UCBT With TMI -Based Conditioning Regimen for Adults With Refractory/Relapsed Aplastic Anemia
    Phase
    Phase 2
    Started
    2025-07
    Registry
    NCT07078721

    Age 18 years to 50 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  1560. Not yet recruiting
    Ex Vivo T-Cell-Depleted Haploidentical Transplantation Bridging With Chimeric Antigen Receptor T-cell Therapy and Prophylactic Memory T Cell Infusion for Acute Leukemia
    Phase
    N/A
    Started
    2025-09
    Registry
    NCT07087847

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  1561. Not yet recruiting
    Comparison of the Sensitivity of pCLE and Pathological Biopsy Before ESD
    Phase
    Not given
    Started
    2025-07
    Registry
    NCT07088744

    Age 18 years to 80 years (registered criteria)

    Led by Changhai Hospital; 1 listed hospital as study siteChengdu, Shanghai

  1562. Not yet recruiting
    A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2025-08
    Registry
    NCT07090954

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Xi'an

  1563. Not yet recruiting
    Acupuncture Combined With Chemotherapy for Gastric Cancer After Surgery
    Phase
    N/A
    Started
    2025-08
    Registry
    NCT07098949

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou

  1564. Not yet recruiting
    29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
    Phase
    Not given
    Started
    2025-08
    Registry
    NCT07100236

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Hefei, Shanghai, Wenzhou, Zhengzhou

  1565. Not yet recruiting
    A Phase II Clinical Study of Induction Adebrelimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)
    Phase
    Phase 2
    Started
    2025-08
    Registry
    NCT07112833

    Age 18 years to 75 years (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  1566. Not yet recruiting
    RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
    Phase
    Phase 1
    Started
    2025-08
    Registry
    NCT07113496

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  1567. Not yet recruiting
    RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma
    Phase
    Phase 1
    Started
    2025-08
    Registry
    NCT07114432

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  1568. Not yet recruiting
    A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-08
    Registry
    NCT07131501

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  1569. Not yet recruiting
    The Efficacy and Safety of Iparomlimab/Tuvonralimab (Anti PD-1/CTLA-4) Combined With Albumin-bound Paclitaxel in Second-line Treatment of Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
    Phase
    N/A
    Started
    2025-09
    Registry
    NCT07139587

    Age 18 years to 75 years (registered criteria)

    Led by Hebei General HospitalShijiazhuang

  1570. Not yet recruiting
    Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer
    Phase
    Phase 1
    Started
    2025-09
    Registry
    NCT07154108

    Age 18 years to 75 years (registered criteria)

    Led by West China HospitalChengdu

  1571. Not yet recruiting
    A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world Data
    Phase
    Not given
    Started
    2025-10
    Registry
    NCT07156617

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesHaikou, Nanchang, Zhengzhou

  1572. Not yet recruiting
    Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07157306

    Age 18 years to 80 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  1573. Not yet recruiting
    Clinical Application of PET Imaging Targeting GPA33 in Malignant Tumors
    Phase
    N/A
    Started
    2025-10
    Registry
    NCT07172503

    Age 18 years to 70 years (registered criteria)

    Led by Union HospitalWuhan

  1574. Not yet recruiting
    The Treatment of Unresectable Liver Cancer With E-TACE Combined With Donafenib:A Prospective, Single-arm, Multicenter, Observational Study
    Phase
    Not given
    Started
    2025-10
    Registry
    NCT07180459

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHaikou

  1575. Not yet recruiting
    Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients
    Phase
    Phase 3
    Started
    2025-09
    Registry
    NCT07181239

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  1576. Not yet recruiting
    Family-Supervised Prehabilitation to Reduce Postoperative Complications After Neoadjuvant Chemotherapy in Gastric Cancer
    Phase
    N/A
    Started
    2025-09
    Registry
    NCT07183358

    Age 18 years to 80 years (registered criteria)

    Led by Affiliated Hospital of Qingdao UniversityQingdao

  1577. Not yet recruiting
    EDN Combined With TACE/HAIC and Second-Line Immune-Targeted Treatment Versus TACE/HAIC Alone in Locally Advanced HCC With Portal Vein Tumor Thrombosis After First-Line Therapy Failure: A Prospective, Multicenter, Randomized Controlled Trial
    Phase
    Phase 1/Phase 2
    Started
    2025-09
    Registry
    NCT07187284

    Age 18 years to 75 years (registered criteria)

    Led by Zhongda Hospital, Southeast UniversityNanjing

  1578. Not yet recruiting
    Adebrelimab + Apatinib in Advanced HCC Post-Systemic Therapy
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07192848

    Age 18 years to Not stated (registered criteria)

    Led by Cancer Hospital CAMS – ShenzhenShenzhen

  1579. Not yet recruiting
    EFG vs IVIG in TAMG
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07231523

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  1580. Not yet recruiting
    A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07233850

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan

  1581. Not yet recruiting
    A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms
    Phase
    Phase 1
    Started
    2025-11
    Registry
    NCT07234045

    Age 18 years to 75 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  1582. Not yet recruiting
    A Phase 2 Study of BB102 in Patients With Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07239986

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHefei, Shanghai

  1583. Not yet recruiting
    Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment: An Adaptive Trial (MRD-ATLAS)
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07257380

    Age 18 years to 79 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  1584. Not yet recruiting
    Prospective Cohort Study of Neuromyelitis Optica Spectrum Disorders (NMOSD)
    Phase
    Not given
    Started
    2025-12
    Registry
    NCT07266051

    Age 18 years to Not stated (registered criteria)

    Led by Xiamen Hospital; 3 listed hospitals as study sitesShanghai, Xiamen

  1585. Not yet recruiting
    Novel Humanized Ferritin-based NIR Fluorescent Molecular Probe for Identifying Tumor Margins in Gastric Tissue
    Phase
    Not given
    Started
    2025-12
    Registry
    NCT07276854

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang HospitalGuangzhou

  1586. Not yet recruiting
    An Exploratory Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-NK in the Treatment of Relapsed and Refractory IgG4-related Disease
    Phase
    Early phase 1
    Started
    2025-12
    Registry
    NCT07298590

    Age 18 years to 70 years (registered criteria)

    Led by Changhai HospitalShanghai

  1587. Not yet recruiting
    BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07301138

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  1588. Not yet recruiting
    A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07304258

    Age 18 years to 75 years (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  1589. Not yet recruiting
    ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab
    Phase
    Not given
    Started
    2025-12
    Registry
    NCT07320326

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  1590. Not yet recruiting
    TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07350070

    Age 18 years to 75 years (registered criteria)

    Led by Tongji Hospital; 4 listed hospitals as study sitesFuzhou, Jinan, Nanning, Qingdao, Wuhan

  1591. Not yet recruiting
    Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC
    Phase
    N/A
    Started
    2025-12
    Registry
    NCT07350824

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  1592. Not yet recruiting
    Sintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable Hepatocellular
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07352007

    Age 18 years to 75 years (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  1593. Not yet recruiting
    Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients
    Phase
    Phase 4
    Started
    2024-07
    Registry
    NCT05498766

    Age 18 years to 75 years (registered criteria)

    Led by Union Hospital; 1 listed hospital as study siteQingdao, Wuhan

  1594. Not yet recruiting
    RAE Versus MIE in Patients With Esophageal Cancer After Neoadjuvant Therapy
    Phase
    N/A
    Started
    2024-01
    Registry
    NCT06012214

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  1595. Not yet recruiting
    Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion
    Phase
    Phase 3
    Started
    2024-06
    Registry
    NCT06089369

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  1596. Not yet recruiting
    Induction Chemotherapy and Immunotherapy Combined Radiotherapy With or Without Concurrent Chemotherapy for Stage III-IVa NPC
    Phase
    Phase 3
    Started
    2024-01
    Registry
    NCT06095167

    Age 18 years to 70 years (registered criteria)

    Led by Fujian Cancer HospitalFuzhou

  1597. Not yet recruiting
    A Study of Cadonilimab Combined With AK112 as Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2024-01
    Registry
    NCT06196775

    Age 18 years to 75 years (registered criteria)

    Led by Harbin Medical University HospitalHarbin

  1598. Not yet recruiting
    Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction,a Phase II Clinical Study
    Phase
    Phase 2
    Started
    2024-02
    Registry
    NCT06241469

    Age 18 years to 80 years (registered criteria)

    Led by Third Affiliated Hospital of Soochow UniversityChangzhou

  1599. Not yet recruiting
    To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma
    Phase
    Early phase 1
    Started
    2024-03
    Registry
    NCT06298266

    Age 18 years to 75 years (registered criteria)

    Led by Guangdong Second Provincial General HospitalGuangzhou

  1600. Not yet recruiting
    Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial
    Phase
    Phase 2
    Started
    2024-03
    Registry
    NCT06310473

    Age 18 years to 75 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  1601. Not yet recruiting
    Value of Dynamic Monitoring of Early Recurrence of Hepatocellular Carcinoma After Radical Resection Based on CTCS
    Phase
    Not given
    Started
    2024-04
    Registry
    NCT06317896

    Age 18 years to 75 years (registered criteria)

    Led by Zhujiang Hospital; 1 listed hospital as study siteGuangzhou

  1602. Not yet recruiting
    A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.
    Phase
    Not given
    Started
    2024-06
    Registry
    NCT06369935

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  1603. Not yet recruiting
    KSD-101 Therapy for Standard Treatment Failed EBV-associated NPC: an Exploratory Clinical Trial
    Phase
    Early phase 1
    Started
    2024-05
    Registry
    NCT06370026

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  1604. Not yet recruiting
    Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment.
    Phase
    Phase 2
    Started
    2024-04
    Registry
    NCT06374901

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  1605. Not yet recruiting
    Evaluation of the Efficacy and Safety of Indocyanine Green Tracing in 3D Fluorescent Laparoscopic Lymph Node Dissection for Gastric Cancer
    Phase
    N/A
    Started
    2024-05
    Registry
    NCT06421220

    Age 18 years to 75 years (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  1606. Not yet recruiting
    Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2024-06
    Registry
    NCT06449846

    Age 18 years to 75 years (registered criteria)

    Led by Zhujiang Hospital; 1 listed hospital as study siteGuangzhou

  1607. Not yet recruiting
    Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer
    Phase
    Phase 2
    Started
    2024-06
    Registry
    NCT06454435

    Age 18 years to 70 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  1608. Not yet recruiting
    LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma
    Phase
    N/A
    Started
    2024-07
    Registry
    NCT06472479

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province Hospital; 2 listed hospitals as study sitesHefei, Nanjing, Zhengzhou

  1609. Not yet recruiting
    A Phase lb/lI Clinical Study in Advanced or Metastatic Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2024-07
    Registry
    NCT06487702

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  1610. Not yet recruiting
    RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2024-07
    Registry
    NCT06492317

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  1611. Not yet recruiting
    Prospective Observational Cohort Study
    Phase
    Not given
    Started
    2024-07
    Registry
    NCT06493448

    Age 18 years to Not stated (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  1612. Not yet recruiting
    A Real-world Research on the Prevention and Treatment of Peritoneal Metastasis and Malignant Ascites by Intraperitoneal Infusion of rmhTNF in Gastric and Colorectal Malignant Tumors
    Phase
    Not given
    Started
    2024-08
    Registry
    NCT06496919

    Age 18 years to 80 years (registered criteria)

    Led by Zhongnan Hospital of Wuhan UniversityWuhan

  1613. Not yet recruiting
    Clinical Study of Irinotecan Liposome Combination Therapy for Advanced Gastric Cancer
    Phase
    Phase 4
    Started
    2024-07
    Registry
    NCT06499610

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Xi'an Jiaotong UniversityXi'an

  1614. Not yet recruiting
    A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma
    Phase
    Phase 1
    Started
    2024-08
    Registry
    NCT06500507

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  1615. Not yet recruiting
    Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation
    Phase
    Phase 2
    Started
    2024-08
    Registry
    NCT06531291

    Age 18 years to 75 years (registered criteria)

    Led by Renji HospitalShanghai

  1616. Not yet recruiting
    Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia
    Phase
    Early phase 1
    Started
    2024-09
    Registry
    NCT06559644

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  1617. Not yet recruiting
    Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractorymultiple Myeloma
    Phase
    N/A
    Started
    2024-10
    Registry
    NCT06594211

    Age 18 years to 75 years (registered criteria)

    Led by Renji HospitalShanghai

  1618. Not yet recruiting
    A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway
    Phase
    Phase 1
    Started
    2024-11
    Registry
    NCT06614751

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing

  1619. Not yet recruiting
    Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL
    Phase
    Phase 1
    Started
    2024-11
    Registry
    NCT06641024

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  1620. Not yet recruiting
    CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma
    Phase
    Phase 1/Phase 2
    Started
    2024-11
    Registry
    NCT06641453

    Age 18 years to 70 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  1621. Not yet recruiting
    SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer
    Phase
    Phase 2
    Started
    2024-12
    Registry
    NCT06666166

    Age 18 years to 75 years (registered criteria)

    Led by First Hospital of China Medical UniversityShenyang

  1622. Not yet recruiting
    Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06680115

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Guangxi Medical UniversityNanning

  1623. Not yet recruiting
    Cadonilimab Combined With Anlotinib Followed by Radiotherapy in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (CAR-RMEC)
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06681285

    Age 18 years to Not stated (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  1624. Not yet recruiting
    A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
    Phase
    Phase 2
    Started
    2024-12
    Registry
    NCT06724263

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  1625. Not yet recruiting
    Comparing the Efficacy of Sintilimab Plus Nab-POF Regimen, Sintilimab Plus XELOX Chemotherapy, and Lenvatinib, Sintilimab Plus XELOX Chemotherapy in the Treatment of HER2-negative, Metastatic Gastric Cancer
    Phase
    Phase 2
    Started
    2024-12
    Registry
    NCT06748508

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  1626. Not yet recruiting
    Sintilimab Combined With Bevacizumab and TP Chemotherapy in the Treatment of High Risk Locally-advanced NPC
    Phase
    Phase 2
    Started
    2024-12
    Registry
    NCT06752382

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  1627. Not yet recruiting
    Safety and Efficacy Study of Pulsed Electric Field (PEF) Therapy in Patients With Advanced or Unresectable Esophageal Squamous Cell Carcinoma
    Phase
    N/A
    Started
    2024-12
    Registry
    NCT06756841

    Age 20 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  1628. Not yet recruiting
    Adjuvant Stereotactic Body Radiotherapy (SBRT) for Hepatocellular Carcinoma After Hepatectomy With Narrow Margin: a Prospective, Multi-center, Randomized Controlled, Open-labelled, Phase III Study
    Phase
    N/A
    Started
    2023-03
    Registry
    NCT05602974

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  1629. Not yet recruiting
    SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH)
    Phase
    Phase 3
    Started
    2023-03
    Registry
    NCT05718232

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  1630. Not yet recruiting
    A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC
    Phase
    Phase 3
    Started
    2023-04
    Registry
    NCT05780294

    Age 18 years to 60 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  1631. Not yet recruiting
    Laparoscopic Proximal Gastrectomy With Double-flap Technique Versus Laparoscopic Total Gastrectomy With Roux-en-Y Reconstruction for Proximal Early Gastric Cancer
    Phase
    N/A
    Started
    2023-06
    Registry
    NCT05890339

    Age 20 years to 80 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  1632. Not yet recruiting
    Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
    Phase
    Phase 2
    Started
    2023-07
    Registry
    NCT05970627

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHangzhou, Ningbo

  1633. Not yet recruiting
    A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
    Phase
    Phase 2/Phase 3
    Started
    2023-09
    Registry
    NCT05976568

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai

  1634. Not yet recruiting
    Efficacy and Safety of Carrimycin Tablets in HLH Patients With Carbapenem-resistant Infections
    Phase
    N/A
    Started
    2023-08
    Registry
    NCT05988177

    Age 18 years to Not stated (registered criteria)

    Led by Beijing Friendship HospitalBeijing

  1635. Not yet recruiting
    Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation
    Phase
    Phase 2
    Started
    2023-09
    Registry
    NCT06041490

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  1636. Not yet recruiting
    Segmental Resection Combined With DEP Regimen for EBV-HLH Patients With Intestinal Involvement
    Phase
    Not given
    Started
    2023-12
    Registry
    NCT06131489

    Age 18 years to Not stated (registered criteria)

    Led by Beijing Friendship HospitalBeijing

  1637. Not yet recruiting
    A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.
    Phase
    Phase 1/Phase 2
    Started
    2023-12
    Registry
    NCT06136988

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  1638. Not yet recruiting
    A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2023-12
    Registry
    NCT06152978

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  1639. Not yet recruiting
    Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial
    Phase
    Phase 2
    Started
    2023-12
    Registry
    NCT06178211

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  1640. Not yet recruiting
    Umbrella Biomarker-Guided Therapy in NPC
    Phase
    Phase 2
    Started
    2022-06
    Registry
    NCT04605562

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  1641. Not yet recruiting
    A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)
    Phase
    Phase 1
    Started
    2022-04
    Registry
    NCT05181501

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesChangzhou, Hefei, Nanjing

  1642. Not yet recruiting
    the Clinical Efficacy of Robotic and Laparoscopic Radical Total Gastrectomy in Locally Advanced Middle and Upper Gastric Cancer
    Phase
    N/A
    Started
    2022-02
    Registry
    NCT05235932

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  1643. Not yet recruiting
    Sintilimab Plus NCT or NCRT Versus NCRT for ESCC
    Phase
    Phase 3
    Started
    2022-11
    Registry
    NCT05244798

    Age 18 years to 75 years (registered criteria)

    Led by Sichuan Cancer HospitalChengdu

  1644. Not yet recruiting
    The Safe Study of Routine Closure of Mesenteric Defects Versus Non-closure After Radical Gastrectomy
    Phase
    N/A
    Started
    2022-04
    Registry
    NCT05356156

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  1645. Not yet recruiting
    Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2022-12
    Registry
    NCT05386056

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  1646. Not yet recruiting
    Two-field Versus Three-field Lymph Node Dissection in ESCC After Neoadjuvant Therapy
    Phase
    N/A
    Started
    2022-07
    Registry
    NCT05420480

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  1647. Not yet recruiting
    Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes
    Phase
    Phase 2
    Started
    2022-09
    Registry
    NCT05524974

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  1648. Not yet recruiting
    Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes
    Phase
    Phase 3
    Started
    2022-11
    Registry
    NCT05610332

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  1649. Not yet recruiting
    A Multicenter Randomized Controlled Clinical Study on the Treatment of T3N1M0 High Risk Nasopharyngeal Carcinoma With or Without Induction Chemotherapy Before Concurrent Radiotherapy and Chemotherapy
    Phase
    N/A
    Started
    2022-11
    Registry
    NCT05622474

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  1650. Not yet recruiting
    Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT
    Phase
    Phase 3
    Started
    2021-03
    Registry
    NCT04215510

    Age 18 years to 70 years (registered criteria)

    Led by Eye & ENT Hospital of Fudan University; 3 listed hospitals as study sitesFuzhou, Nanchang, Shanghai

  1651. Not yet recruiting
    Dragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer
    Phase
    Phase 3
    Started
    2021-09
    Registry
    NCT04384601

    Age 18 years to 80 years (registered criteria)

    Led by Ruijin HospitalShanghai

  1652. Not yet recruiting
    A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma
    Phase
    Early phase 1
    Started
    2021-01
    Registry
    NCT04670055

    Age 30 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  1653. Not yet recruiting
    Total Robotic Versus Robotic Assisted Distal Gastrectomy for Gastric Cancer
    Phase
    N/A
    Started
    2021-03
    Registry
    NCT04795063

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  1654. Not yet recruiting
    An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC
    Phase
    Phase 2/Phase 3
    Started
    2021-07
    Registry
    NCT04890522

    Age 18 years to 60 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  1655. Not yet recruiting
    A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy
    Phase
    Early phase 1
    Started
    2020-12
    Registry
    NCT04541368

    Age 30 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  1656. Not yet recruiting
    CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma
    Phase
    Early phase 1
    Started
    2020-11
    Registry
    NCT04609241

    Age not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  1657. Not yet recruiting
    Endoscopic Submucosal Dissection Versus Surgery in the Treatment of Early Gastric Cancer
    Phase
    N/A
    Started
    2019-03
    Registry
    NCT03857737

    Age not stated (registered criteria)

    Led by Peking University Third HospitalBeijing

  1658. Enrolling by invitation
    Early Postoperative Intervention in Gastric Cancer Patients
    Phase
    N/A
    Started
    2026-02
    Registry
    NCT07444099

    Age 18 years to 80 years (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  1659. Enrolling by invitation
    Anemia on Sublingual Microcirculation in GDFT
    Phase
    Not given
    Started
    2026-05
    Registry
    NCT07583927

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  1660. Enrolling by invitation
    Non-surgical Management After NIT for dMMR/MSI-H GC
    Phase
    Not given
    Started
    2026-07
    Registry
    NCT07646574

    Age 18 years to Not stated (registered criteria)

    Led by West China HospitalChengdu

  1661. Enrolling by invitation
    Long-term Follow-up Study in Subjects With Multiple Myeloma Previously Treated With GC012F Injection
    Phase
    Not given
    Started
    2026-11
    Registry
    NCT07833046

    Age not stated (registered criteria)

    Led by Renji HospitalShanghai

  1662. Enrolling by invitation
    Prognostic Value of TIL in Nasopharyngeal Carcinoma
    Phase
    Not given
    Started
    2025-01
    Registry
    NCT06763640

    Age 18 years to 70 years (registered criteria)

    Led by Jiangxi Cancer HospitalNanchang

  1663. Enrolling by invitation
    JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study
    Phase
    Phase 1
    Started
    2025-07
    Registry
    NCT06882876

    Age 18 years to 75 years (registered criteria)

    Led by Xiangya HospitalChangsha

  1664. Enrolling by invitation
    Radiomics-Based AI Model for Predicting Para-Aortic Lymph Node Metastasis in Gastric Cancer Patients
    Phase
    Not given
    Started
    2025-01
    Registry
    NCT06947096

    Age 18 years to 80 years (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  1665. Enrolling by invitation
    AI-Based Prediction of Lymph Node Metastasis in Gastric Cancer Using Preoperative Multimodal Data
    Phase
    Not given
    Started
    2025-01
    Registry
    NCT06957678

    Age 18 years to 80 years (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  1666. Enrolling by invitation
    Diagnostic Accuracy of Endocytoscopy for Superficial Esophageal Neoplasia
    Phase
    Not given
    Started
    2025-03
    Registry
    NCT06984055

    Age 18 years to 85 years (registered criteria)

    Led by Changhai HospitalShanghai

  1667. Enrolling by invitation
    PET Image Exploration of 89Zr-labeled Antibody Fragments Targeting HER2 in Patients With Malignant Tumors
    Phase
    Early phase 1
    Started
    2025-07
    Registry
    NCT07023848

    Age 18 years to 75 years (registered criteria)

    Led by Affiliated Hospital of Jiangnan UniversityWuxi

  1668. Enrolling by invitation
    The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies
    Phase
    Early phase 1
    Started
    2025-07
    Registry
    NCT07023861

    Age 15 years to 75 years (registered criteria)

    Led by Affiliated Hospital of Jiangnan UniversityWuxi

  1669. Enrolling by invitation
    Explainable Machine Learning for Predicting Early Gastric Cancer
    Phase
    Not given
    Started
    2025-06
    Registry
    NCT07047937

    Age not stated (registered criteria)

    Led by Wenzhou Central HospitalWenzhou

  1670. Enrolling by invitation
    An Artificial Intelligence Model for Aiding Claudin18.2 Expression Diagnosis in Gastric Adenocarcinoma
    Phase
    Not given
    Started
    2025-10
    Registry
    NCT07274579

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang Hospital; 1 listed hospital as study siteGuangzhou, Jinan

  1671. Enrolling by invitation
    Survival Analysis of Surgical Resection Versus Observation in Patients With Initially uHCC Achieving CR After Systemic Therapy
    Phase
    Not given
    Started
    2025-12
    Registry
    NCT07290764

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Provincial HospitalFuzhou

  1672. Enrolling by invitation
    Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy(nCT) in the Treatment of Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07312578

    Age 18 years to 70 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  1673. Enrolling by invitation
    Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
    Phase
    Early phase 1
    Started
    2025-05
    Registry
    NCT07356466

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  1674. Enrolling by invitation
    Based on ctDNA-MRD Guided Adjuvant Treatment Escalation After Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Study on Safety and Efficacy
    Phase
    Early phase 1
    Started
    2025-12
    Registry
    NCT07371247

    Age 18 years to 80 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  1675. Enrolling by invitation
    Safety and Efficacy of Leucine-Restricted Diet in Gastric Cancer
    Phase
    Phase 1
    Started
    2025-10
    Registry
    NCT07488312

    Age 18 years to 70 years (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  1676. Enrolling by invitation
    Laparoscopic Staging for Stage III Gastric Cancer
    Phase
    N/A
    Started
    2025-02
    Registry
    NCT07533825

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  1677. Enrolling by invitation
    Infiltration Pattern of Locally Advanced ESCC
    Phase
    Not given
    Started
    2025-10
    Registry
    NCT07567716

    Age not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  1678. Enrolling by invitation
    A Multicenter Prospective Observational Study of Computer-aided Risk Perception and Prognosis Prediction in the Whole Process of Laparoscopic Hepatobiliary and Pancreatic Surgery
    Phase
    Not given
    Started
    2024-09
    Registry
    NCT06647264

    Age 18 years to 80 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  1679. Enrolling by invitation
    IMRT Combined With Lobaplatin-based CCRT in Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06688175

    Age 65 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Xiamen UniversityXiamen

  1680. Enrolling by invitation
    Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-03
    Registry
    NCT06690216

    Age 18 years to Not stated (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  1681. Enrolling by invitation
    Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China
    Phase
    Not given
    Started
    2024-08
    Registry
    NCT06712017

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Shanghai

  1682. Enrolling by invitation
    Efficacy and Safety of Cadonilimab and Chemoradiotherapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
    Phase
    N/A
    Started
    2024-12
    Registry
    NCT06715501

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Ningbo UniversityNingbo

  1683. Enrolling by invitation
    A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for EC
    Phase
    N/A
    Started
    2024-08
    Registry
    NCT06863831

    Age 18 years to 80 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  1684. Enrolling by invitation
    Immunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy
    Phase
    Phase 3
    Started
    2024-08
    Registry
    NCT07016737

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Cancer HospitalNanjing

  1685. Enrolling by invitation
    EGPSS for Weight Management in an in Vivo Human Model
    Phase
    N/A
    Started
    2024-07
    Registry
    NCT07186959

    Age 18 years to 70 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  1686. Enrolling by invitation
    Fufang Tongluo Decoction as an Adjunct to Aspirin and Atorvastatin for Ischemic Moyamoya Disease
    Phase
    N/A
    Started
    2024-12
    Registry
    NCT07875335

    Age 18 years to 60 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  1687. Enrolling by invitation
    Clinical Safety and Efficacy Evaluation of the Blood-cooling and Stasis-removing Formula as an Adjunct to Atorvastatin in the Treatment of Hemorrhagic Moyamoya Disease.
    Phase
    Early phase 1
    Started
    2024-12
    Registry
    NCT07894640

    Age 18 years to 60 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  1688. Enrolling by invitation
    Clinical Evaluation of the Safety and Efficacy of "Buyan Huan Wu Tang" Combined With Atorvastatin in the Treatment of Atypical Pneumonia
    Phase
    Early phase 1
    Started
    2024-12
    Registry
    NCT07906652

    Age 18 years to 60 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  1689. Enrolling by invitation
    A Clinical Study of Non-curative Resection Plus Radiotherapy After Endoscopic ESD for Superficial Esophageal Squamous Cell Carcinoma
    Phase
    Not given
    Started
    2023-11
    Registry
    NCT06160557

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Provincial HospitalFuzhou

  1690. Enrolling by invitation
    Normal Chinese Lifespan Brain Charts Initiative (NCLBCI)
    Phase
    Not given
    Started
    2023-12
    Registry
    NCT06643858

    Age 6 years to 90 years (registered criteria)

    Led by Beijing Tiantan HospitalBeijing

  1691. Enrolling by invitation
    Screening of Small Non-coding RNAs as an Auxiliary Diagnostic Biomarker for Gastric Cancer
    Phase
    Not given
    Started
    2023-12
    Registry
    NCT06776835

    Age 18 years to 85 years (registered criteria)

    Led by Affiliated Hospital of Nantong UniversityNantong

  1692. Enrolling by invitation
    Prolonged Extubation in Gastric Cancer With OSA
    Phase
    Not given
    Started
    2023-01
    Registry
    NCT07362706

    Age 18 years to 85 years (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  1693. Enrolling by invitation
    Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma
    Phase
    N/A
    Started
    2022-07
    Registry
    NCT06048926

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  1694. Enrolling by invitation
    Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma
    Phase
    Phase 1/Phase 2
    Started
    2022-06
    Registry
    NCT06303583

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  1695. Enrolling by invitation
    Phase I Clinical Study of Haplo-HSCT Combined With Hypoxic 3D-Cultured Umbilical Cord MSC for the Treatment of SAA
    Phase
    Phase 1/Phase 2
    Started
    2022-08
    Registry
    NCT07299123

    Age 6 years to 60 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  1696. Enrolling by invitation
    A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients
    Phase
    Phase 2
    Started
    2021-12
    Registry
    NCT05441475

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan

  1697. Enrolling by invitation
    The Efficacy of Sequential RT After Triple Therapy for uHCC
    Phase
    Not given
    Started
    2020-11
    Registry
    NCT07052448

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Provincial HospitalFuzhou

  1698. Enrolling by invitation
    AI-Based Fine Morphological Subtyping of Myeloma Single Cells for Predicting FISH Abnormalities
    Phase
    Not given
    Started
    2018-08
    Registry
    NCT07410403

    Age not stated (registered criteria)

    Led by Zhongnan Hospital of Wuhan UniversityWuhan

  1699. Enrolling by invitation
    Autologous Stem Cell Transplantation for Patients With AL Amyloidosis
    Phase
    Not given
    Started
    2010-07
    Registry
    NCT04210791

    Age 18 years to 75 years (registered criteria)

    Led by Jinling HospitalNanjing

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.